NZ747422B2 - Activin-actrii antagonists and uses for treating bone and other disorders - Google Patents

Abstract

Provided herein are methods for the treatment of bone disorders that are associated with kidney disease, in particular chronic kidney disease-mineral and bone disorder (CKD-MBD), wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification. ovided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

Description

ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS This ation is a onal application divided out of New Zealand patent ation no. 707477 and claims priority to U.S. Provisional Patent Application No. ,898, filed November 2, 2012, and to U.S. Provisional Patent Application No. 61/740,665, filed December 21, 2012, the disclosures of each of which are herein incorporated by reference in their entireties. 1. INTRODUCTION Provided herein are methods for the treatment of bone ers that are associated with kidney disease, such as chronic kidney disease-mineral and bone disorder ("CKD-MBD"), wherein the methods comprise administration of n-ActRII inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRII inhibitors to a subject in need of the treatment. Also ed herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification. 2. BACKGROUND Bone growth and mineralization are dependent on the activities of two cell types, osteoclasts and osteoblasts, although chondrocytes and cells of the vasculature also participate in critical aspects of these processes. Developmentally, bone formation occurs through two mechanisms, endochondral ossification and intramembranous ossification, with the former sible for longitudinal bone formation and the later sible for the formation of topologically flat bones, such as the bones of the skull. ondral ossification requires the sequential ion and degradation of cartilaginous structures in the growth plates that serve as templates for the formation of osteoblasts, osteoclasts, the vasculature and subsequent mineralization. During intramembranous cation, bone is formed directly in the connective tissues. Both processes require the infiltration of osteoblasts and subsequent matrix deposition.

Chronic kidney disease is associated with a progressive deterioration in mineral homeostasis, with a disruption of normal serum and tissue concentrations of phosphorus and calcium, and changes in circulating hormones, such as parathyroid hormone, 25-hydroxyvitamin D, l,25-dihydroxyvitamin D, other vitamin D metabolites, ast growth factor-23, and growth e. See, Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney Disease: Improving Global Outcomes ) CKD-MBD Work Group, In: Kidney Int Suppl. (2009) 76 (Suppl ll3):Sl-l30, page S3. The mineral and hormone homeostasis that is disrupted in chronic kidney disease is critical for l bone formation during growth (bone modeling) and bone structure and fianction during adulthood (bone remodeling). As a result, bone abnormalities are found in patients with chronic kidney disease. In addition, similarly due to the disruption in mineral and endocrine functions, extraskeletal calcification may be found in patients with chronic kidney disease. These syndromes are termed chronic kidney disease- related mineral and bone disorders ("CDK-MBD").

Bone undergoes continuous turnover. Bone turnover is the s of resorption ed by replacement of bone. Osteoblasts and lasts are the cells necessary for bone turnover. Low turnover and adynamic bone diseases are characterized by reduced or absent resorption and replacement of bone. CKD-MBD can be characterized by low turnover or adynamic bone. (Chronic Kidney Disease-Mineral and Bone er (CKD-MBD), Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, In: Kidney Int Suppl. (2009) 76 (Suppl ll3):Sl-l30, page S34).

Increased calcium levels in the vasculature can lead to vascular cation, a condition characterized by increased vessel stiffening. Patients with vascular calcification have an increased risk of myocardial infarction, and ar calcification is particularly prevalent in patients suffering from kidney disease, e.g., CKD-MBD. See, e.g., Shanahan et al., 2011, Circ.

Res. 109:697-71 1.

Two d type II receptors, ActRIIA and ActRIIB, have been identified as the type II receptors for activins (Mathews and Vale, 1991, Cell 65:973-982; Attisano et al., 1992, Cell 68: 97-108). Besides activins, ActRIIA and ActRIIB can biochemically interact with several other TGF-beta family proteins, including BMP7, Nodal, GDF8, and GDFll hita et al., 1995, J. Cell Biol. 130:217-226; Lee and McPherron, 2001, Proc. Natl. Acad. Sci. 98:9306-9311; Yeo and Whitman, 2001, Mol. Cell 7: 949-957; Oh et al., 2002, Genes Dev. 16:2749-54). ALK4 is the primary type I or for activins, particularly for activin A, and ALK—7 may serve as a or for activins as well, particularly for activin B.

SUMMARY In certain embodiments, provided herein are methods for ng an adynamic bone disorder in a subject, wherein the method comprises administering a therapeutically effective amount of an ActRII inhibitor to a subject in need of treatment of the adynamic bone disorder. Further provided herein are methods for ng CKD-MBD in a subject, wherein the method comprises administering a therapeutically effective amount of an ActRII inhibitor to a subject in need of ent of the CKD-MBD.

In a particular ment, provided herein is the use of an ActRII tor, in the manufacture of a medicament for treating chronic kidney e-mineral and bone disorder (CKD-MBD) in a subject.

In certain embodiments the CKD-MBD is an adynamic bone disorder form of CKD-MBD. In certain more specific ments, the ic bone disorder is characterized by absence of tetracycline incorporation into lized bone.

In certain embodiments, the CKD-MBD is a low bone turnover form of CKDMBD.

In a more specific embodiment, the low bone turnover form of CKD-MBD is osteomalacia. In certain embodiments, the CKD-MBD is characterized by hyperphosphatemia.

In certain embodiments, the ActRII inhibitor that can be used with the methods or uses provided herein is a polypeptide comprising an amino acid ce selected from the group consisting of: 90% identical to SEQ ID NO:2; 95% identical to SEQ ID NO:2; 98% identical to SEQ ID NO:2; SEQ ID NO:2; 90% identical to SEQ ID NO:3; 95% cal to SEQ ID NO:3; 98% identical to SEQ ID NO:3; SEQ ID NO:3; 90% identical to SEQ ID NO:7; 95% identical to SEQ ID NO:7; 98% identical to SEQ ID NO:7; SEQ ID NO:7; 90% identical to SEQ ID NO:12; 95% identical to SEQ ID NO:12; 98% identical to SEQ ID NO:12; SEQ ID NO:12; 90% identical to SEQ ID NO:17; 95% identical to SEQ ID NO:17; 98% identical to SEQ ID NO:17; SEQ ID NO:17; 90% identical to SEQ ID NO:20; 95% identical to SEQ ID NO:20; 98% identical to SEQ ID NO:20; SEQ ID NO:20; 90% identical to SEQ ID NO:21; 95% identical to SEQ ID NO:21; 98% identical to SEQ ID NO:21; and SEQ ID NO:21. In a more specific embodiment, the ActRII inhibitor is a polypeptide comprising the amino acid sequence of SEQ ID NO:7.

In a specific embodiment, the ActRII inhibitor that can be used with the methods or uses ed herein is an ActRIIA inhibitor, wherein the A inhibitor comprises or consists of a polypeptide selected from the group consisting of: a. a polypeptide at least 90% identical to SEQ ID NO:2; b. a polypeptide at least 95% identical to SEQ ID NO:2; c. a polypeptide at least 98% identical to SEQ ID NO:2; d. SEQ ID NO:2; e. a polypeptide at least 90% identical to SEQ ID NO:3; f. a polypeptide at least 95% identical to SEQ ID NO:3; g. a polypeptide at least 98% identical to SEQ ID NO:3; h. SEQ ID NO:3; i. a polypeptide at least 90% identical to SEQ ID NO:7; j. a polypeptide at least 95% identical to SEQ ID NO:7; k. a polypeptide at least 98% identical to SEQ ID NO:7; l. SEQ ID NO:7; m. a polypeptide at least 90% identical to SEQ ID NO:12; n. a polypeptide at least 95% identical to SEQ ID NO:12; o. a ptide at least 98% identical to SEQ ID NO:12; and p. SEQ ID NO:12. In a specific embodiment, the A inhibitor is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:7.

In another specific embodiment, the ActRII inhibitor that can be used with the methods or uses provided herein is an ActRIIB inhibitor, wherein the ActRIIB inhibitor comprises or consists of a polypeptide selected from the group consisting of: a. a polypeptide at least 90% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; b. a polypeptide at least 95% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; c. a polypeptide at least 98% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, , 31, 32, 33, 36, 37, 42, or 43; d. SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; e. a polypeptide 90% identical to SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47; f. a polypeptide 95% identical to SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47; g. a polypeptide 98% identical to SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47; and h. SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47.

In a specific embodiment, the ActRIIB tor is a polypeptide sing or consisting of SEQ ID NO:23. In another specific embodiment, the ActRIIB inhibitor is a polypeptide comprising or ting of SEQ ID NO:25.

In another ic embodiment the ActRII inhibitor is a polypeptide comprising: (i) a fragment of the extracellular domain of B, wherein the nt consists of the sequence of amino acid 25 to 131 of SEQ ID NO:28 and wherein the fragment carries the L79D amino acid substitution; (ii) a linker; and (iii) an Fc of an IgG1.

In another ic embodiment, an ActRIIA inhibitor and an ActRIIB inhibitor can be used in the methods or uses provided herein (e.g., a composition comprising an ActRIIA inhibitor and an B inhibitor can be used; or an ActRIIA tor and an ActRIIB inhibitor can both be administered, separately, to a subject being treated in accordance with the methods described herein), wherein the ActRIIA inhibitor comprises or consists of a polypeptide selected from the group consisting of: a. a polypeptide at least 90% identical to SEQ ID NO:2; b. a polypeptide at least 95% identical to SEQ ID NO:2; c. a polypeptide at least 98% identical to SEQ ID NO:2; d. SEQ ID NO:2; e. a polypeptide at least 90% identical to SEQ ID NO:3; f. a polypeptide at least 95% identical to SEQ ID NO:3; g. a ptide at least 98% identical to SEQ ID NO:3; h. SEQ ID NO:3; i. a ptide at least 90% identical to SEQ ID NO:7; j. a polypeptide at least 95% identical to SEQ ID NO:7; k. a ptide at least 98% cal to SEQ ID NO:7; l. SEQ ID NO:7; m. a polypeptide at least 90% identical to SEQ ID NO:12; n. a polypeptide at least 95% identical to SEQ ID NO:12; o. a polypeptide at least 98% identical to SEQ ID NO:12; and p. SEQ ID NO:12; and wherein the B inhibitor comprises or consists of a polypeptide selected from the group consisting of: a. a polypeptide at least 90% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; b. a polypeptide at least 95% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; c. a polypeptide at least 98% identical to SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; d. SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43; e. a polypeptide 90% identical to SEQ ID NO:20, 21, 24, , 34, 35, 38, 39, 40, 41, 44, 46, or 47; f. a polypeptide 95% identical to SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47; g. a polypeptide 98% identical to SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47; and h. SEQ ID NO:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, or 47. In a specific embodiment, the ActRIIA inhibitor is a polypeptide comprising or ting of SEQ ID NO:7 and the ActRIIB inhibitor is a polypeptide comprising or consisting of SEQ ID NO:23. In another specific embodiment, the ActRIIA inhibitor is a polypeptide comprising or consisting of SEQ ID NO:7 and the ActRIIB inhibitor is a polypeptide comprising or consisting of SEQ ID NO:25.

In certain ments, the t to be treated with the methods or uses provided herein is less than 18 years old. In certain ments, the subject to be d with the methods or uses provided herein has end stage renal disease. In certain embodiments, the subject to be treated with the methods or uses provided herein undergoes dialysis. In certain embodiments, the treating to increases the height of the subject.

In n ments of the methods and uses provided herein the subject has c kidney disease, in particular chronic kidney disease that has reached stage 3, stage 4, stage 5, or stage 5D. In certain embodiments the chronic kidney disease is end stage kidney disease. In certain ments of the methods and uses provided herein the subject has end stage renal disease. In certain embodiments of the methods and uses provided herein, the ActRII inhibitor is administered parenterally.

These and other embodiments are bed in further detail below. Certain embodiments are described herein for completeness, but may form the subject of the parent application NZ 707477 Thus in certain embodiments, described herein are methods for treating or preventing hyperphosphatemia, secondary hyperparathyroidism (due to increase in orus), extraskeletal calcification, e.g., vascular calcification, and adynamic bone disorder, e.g. adynamic bone disorder characterized by hyperphosphatemia, in a subject, wherein the method comprises administering a therapeutically effective amount of an ActRII inhibitor to a subject in need of treatment of hyperphosphatemia, ary arathyroidism (due to increase in phosphorus), extraskeletal calcification, e.g., vascular ication, and adynamic bone.

BRIEF DESCRIPTION OF THE FIGURES Figure 1: Mouse body weight following partial nephrectomy.

Figure 2: Changes in BMD by DEXA Scan following partial nephrectomy in mice.

Figure 3: The murine counterpart of SEQ ID NO 7 ("mActRIIA-Fc") hematocrit changes following partial nephrectomy in mice.

Figure 4: MicroCT 3D image of representative bones following partial nephrectomy in mice.

Figure 5: mActRIIA-Fc treatment Increases Hematocrit.

Figure 6: mActRIIA-Fc increases Bone Mineral y.

Figure 7: Representative microCT Scans of Femurs.

Figure 8: mActRIIA-Fc increases Cortical Thickness of the Femur Mid-Shaft.

Figure 9: mActRIIA-Fc Increases Trabecular Bone .

Figure 10: mActRIIA-Fc Increases Trabecular Thickness in the Distal Femur.

Figure ll: mActRIIA-Fc causes a reduction in the levels of aortic calcium in a CKD mouse model.

. DETAILED PTION . 1 OVERVIEW Provided herein, in one aspect, is a method for the treatment of Chronic Kidney Disease-Mineral and Bone ers (CKD-MBD) wherein the method comprises administering an inhibitor of ActRII to a patient in need of treatment. The inhibitor of ActRII can be an inhibitor of ActRIIA and / or ActRIIB.

CKD-MBD can be sed as a systemic disorder of mineral and bone lism due to chronic kidney disease and manifested by either one or a ation of (l) abnormalities of calcium; phosphorus; calcium x phosphorus product; alkaline phosphatases (total or bone specific); bicarbonate; parathyroid hormone ("PTH"); 1-84 PTH, lPTH/7-84 PTH ratio; osteocalcin; osteoprotegrin; tartrate-resistant acid phosphatase isoform 5b ("TRAP-5b"); pyridinoline and deoxypyridinoline; procollagen type 1 amino-terminal extension es; C- al crosslinks; C-terminal crosslinks of collagen; fibroblast growth factor 23 ("FGF23"); Fetulin-A; or vitamin D lism; (2) abnormalities of bone er, mineralization, volume, linear growth, or strength; and (3) ar or other soft tissue calcification. See Nickolas, 2008, Kidney International 74:721-731; and Moe et al., 2006, Kidney International 69: 1945-1953.

Guidelines for the diagnosis of CKD-MBD can be found, e.g., in KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD), Kidney Disease: Improving Global es (KDIGO) CKD-MBD Work Group, In: Kidney Int Suppl. (2009) 76 (Suppl ll3):Sl-l30.

In certain embodiments, provided herein are methods for the treatment of low bone turnover forms of CKD-MBD wherein the method comprises administering an tor of ActRII to a patient in need of treatment. In certain embodiments, provided herein are methods for the treatment of CKD-MBD characterized by hyperphosphatemia and / or hypercalcemia. In certain embodiments, provided herein are methods for the treatment of CKD-MBD terized by extraskeletal calcification, such as, but not limited to atherosclerotic calcification.

In certain embodiments, provided herein are methods for the treatment of CKD- MBD, wherein the chronic kidney e has d stage 3, stage 4, stage 5, or stage 5D. In a specific embodiment, the kidney disease is end stage kidney disease. In certain embodiments, provided herein are methods for the treatment of CKD-MBD characterized by a glomerular ion rate of less than in/l .73m2 in adults or less than 89 ml/min/l .73m2 in pediatric ts. See, Moe et al., 2006, Kidney International 69: 1945-1953. In certain embodiments, provided herein are methods for the treatment in adults of CKD-MBD characterized by a glomerular filtration rate of less than 50ml/min/l .73m2, 40ml/min/l .73m2, 30ml/min/l .73m2, 20ml/min/ l .73m2, or less than lOml/min/ l .73m2. In certain embodiments, provided herein are methods for the treatment in pediatric patients of CKD-MBD characterized by a glomerular filtration rate of less than in/l .73m2, 70ml/min/l .73m2, in/l .73m2, 50ml/min/l .73m2, in/l .73m2, 30ml/min/l .73m2, 20ml/min/l .73m2, or less than 10ml/min/l .73m2.

Without being bound by theory, a glomerular filtration rate of less than 60 /l .73m2 in adult patients and less than 89 /l .73m2 in pediatric ts results in detectable abnormalities in calcium levels, phosphorus levels, PTH levels, and vitamin D metabolism; and abnormal levels of these markers result in bone disease.

In certain embodiments, provided herein are methods for the treatment of a bone pathology associated with chronic kidney disease, z'.e., CKD-MBD. See Moe et al., 2006, Kidney International 69: 1945-1953. In certain embodiments, the CKD-MBD is low-tumover CKD-MBD. Low-tumover CKD-MBD can be diagnosed by the histological features set forth in Table 1 below. See National Kidney Foundation, Kidney Disease Outcomes y Initiative Guidelines at the website of the National Kidney Foundation.

Table l. Histological Features of Low-Turnover CKD-MBD Feature Adynamic Osteomalacia Bone Formation Trabecular bone volume , low Variable Low, normal or high Osteoid volume , low High-very high Osteoid seam thickness Normal, low High-very high Number of osteoblasts Low Low Bone formation rate Low-very low Low-very low Mineralization lag time Normal ged Bone Resorption Eroded bone perimeter , low Variable Often low, may be high Number of osteoclasts Low Low, may be normal or high Marrow fibrosis Absent Absent In a specific embodiment, provided herein is a method for treating extraskeletal calcification in a t, wherein said method comprises administering a therapeutically effective amount of an ActRII inhibitor to the subject. In another specific embodiment, provided herein is a method for preventing extraskeletal calcification in a subject, wherein said method comprises administering a therapeutically effective amount of an ActRII inhibitor to the subject.

In specific embodiments, the extraskeletal cation treated or ted in a subject by the methods described herein is vascular cation, i.e., the accumulation of calcium salts in the vasculature of the subject, e. g., cation of arteries of the t.

In certain embodiments, the methods of of treatment or prevention of extraskeletal calcification, e.g., vascular calcification, provided herein are performed on a subject that is at risk of suffering from extraskeletal calcification, e.g., vascular calcification (i.e., the at risk subject is administered an ActRII inhibitor in accordance with the methods described herein). In a specific embodiment, the subject at risk of suffering from extraskeletal calcification, e.g., vascular calcification, has hypercholesterolemia. In another specific embodiment, the t at risk of suffering from extraskeletal calcification, e.g., vascular calcification, has hypertension. In another specific embodiment, the subject at risk of suffering from extraskeletal calcification, e.g., vascular calcification, has es. In another specific embodiment, the subject at risk of ing from extraskeletal cation, e. g., vascular calcification, has renal disease (e.g., end- stage renal disease). In another specific embodiment, the subject at risk of suffering from extraskeletal calcification, e.g., ar calcification, has chronic kidney disease. In another specific embodiment, the subject at risk of suffering from extraskeletal calcification, e.g., ar calcification, has increased oxidative stress, e.g., an imbalance between oxidant production and antioxidant activity in the vasculature. In another specific embodiment, the subject at risk of suffering from extraskeletal calcification, e.g., vascular calcification, has a calcification inhibitor deficiency (e.g., a ncy in one or more of fetuin-A, matrix gla protein (MGP), and osteoprotegerin (OPG)).

In certain embodiments, the subjects ing from vascular calcification treated in accordance with the s described herein have Media calcification (also known as Monckeberg’s sclerosis or media calcinosis). Media calcification is characterized by diffiase mineral deposits within the arterial tunica media. In a specific embodiment, the ts ing from media calcification are elderly. In a specific embodiment, the subjects suffering from media calcification have a disorder that causes the Media calcification, e.g., es, renal disease (e.g., CKD).

In certain embodiments, the subjects suffering from vascular calcification treated in accordance with the s described herein have Intima calcification. Intima calcification is associated with atherosclerosis and progresses as sclerotic plaques progress.

In certain embodiments, a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification, has increased levels of FGF23, a hormone produced by osteocytes in response to decreased mechanical loading, decreases in bone formation and to excess phosphorus in the exchangable pool (see, e. g., Hruska and Mathew, 2011, es in Chronic Kidney Disease 98-104), relative to FGF23 levels in subjects that are not suffering from, or not at risk of suffering from, a form of CKD- MBD and/or keletal calcification, e. g., ar calcification. Levels of FGF23 can be detected using methods known in the art, e. g., ELISA, using samples from the subjects, e. g, blood, serum. In a specific embodiment, the level of FGF23 (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification, is about 5%, 10%, 15%, 20%, 25%, 30%, %, 40%, 45%, 50%, or greater than 50%, greater than the level of FGF23 (e.g., the level detectable in the serum) in a subject not suffering from, or not at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification. In another specific embodiment, the level of FGF23 (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification, is about 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 50-75%, or 75-100%, greater than the level of FGF23 (e.g., the level detectable in the serum) in a subject not suffering from, or not at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification.

In certain embodiments, levels of FGF23 in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification, can be used to monitor the effectiveness of a method described herein, e.g., a method of ng a form of CKD-MBD and/or a method of treating extraskeletal calcification (e. g., vascular cation), wherein such methods se stration of a therapeutically ive amount of an ActRII inhibitor described herein. In a specific embodiment, a subject d in accordance with one or more of the methods described herein has a decreased level of FGF23 (e.g., as detected in the serum of the subject) as compared to the level of FGF23 detected in the subject prior to being treated with a method described . In another specific embodiment, the level of FGF23 (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification, treated with a method described herein is sed by about 5%, 10%, %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or greater than 50%, relative to the level of FGF23 (e. g., the level detectable in the serum) detected in the subject prior to treatment with a method described herein. In another specific embodiment, the level of FGF23 (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of D and/or extraskeletal cation, e.g., vascular calcification, is decreased by about 5-10%, 10- %, 20-30%, 30-40%, 40-50%, , 50-75%, or 75-100%, relative to the level of FGF23 (e. g., the level detectable in the serum) detected in the subject prior to treatment with a method described herein.

In a specific embodiment, provided herein is a method of treating a form of CKD- MBD and/or keletal calcification, e. g., vascular calcification, comprising: (i) administering an ActRII inhibitor to an individual having a form of CKD-MBD and/or keletal calcification, e.g., vascular calcification; (ii) determining an amount of FGF23 in a tissue sample (e. g., serum) of said individual after the adminstration of the ActRII inhibitor; and (iii) if the amount of FGF23 in said tissue sample is decreased by no more than about 5%, 10%, 15%, 20%, or 25%, or by about 5-10%, 10-20%, 20-30%, as ed to the amount of FGF23 determined in a sample of the same tissue type from said individual (e. g., a different sample of serum from the same individual) prior to stration of the ActRII inhibitor, repeating the administration of the ActRII inhibitor. In certain embodiments, if the amount of FGF23 is not decreased following administration of the ActRII inhibitor, the dose of the ActRII inhibitor stered can be increased. In certain embodiments, if the amount of FGF23 is not decreased following administration of the ActRII inhibitor, the frequency of administration of the ActRII inhibitor administered can be increased.

In certain embodiments, a subject suffering from, or at risk of suffering from, a form of D and/or extraskeletal cation, e.g., vascular cation, has increased levels of sclerostin, a protein increased in subjects suffering from, or at risk of suffering from, CKD- MBD (see, e.g., Graciolli et al., 2010, J Am Soc Nephrol 21 :774A), relative to sclerostin levels in subjects that are not suffering from, or not at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification. Levels of sclerostin can be detected using methods known in the art, e. g., ELISA, using samples from the subjects, e. g, blood, serum. In a specific embodiment, the level of sclerostin (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal cation, e.g., vascular calcification, is about 5%, 10%, 15%, 20%, 25%, 30%, %, 40%, 45%, 50%, or greater than 50%, r than the level of sclerostin (e. g., the level detectable in the serum) in a t not suffering from, or not at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification. In r specific embodiment, the level of stin (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification, is about 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 50-75%, or 75-100%, greater than the level of sclerostin (e.g., the level detectable in the serum) in a subject not suffering from, or not at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification.

In certain embodiments, levels of sclerostin in a subject ing from, or at risk of suffering from, a form of CKD-MBD and/or extraskeletal calcification, e. g., vascular calcification, can be used to monitor the effectiveness of a method described herein, e.g., a method of treating a form of CKD-MBD and/or a method of treating extraskeletal cation (e. g., vascular calcification), wherein such methods comprise administration of a therapeutically effective amount of an ActRII inhibitor described herein. In a specific embodiment, a subject treated in ance with one or more of the methods described herein has a decreased level of sclerostin (e. g., as detected in the serum of the subject) as compared to the level of sclerostin detected in the subject prior to being treated with a method described herein. In another specific embodiment, the level of sclerostin (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD-MBD and/or keletal calcification, e.g., vascular calcification, treated with a method described herein is sed by about 5%, 10%, %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or r than 50%, relative to the level of sclerostin (e.g., the level detectable in the serum) detected in the subject prior to treatment with a method described herein. In another specific embodiment, the level of sclerostin (e.g., the level detectable in the serum) in a subject suffering from, or at risk of suffering from, a form of CKD- MBD and/or extraskeletal cation, e. g., vascular cation, is decreased by about 5-10%, -20%, 20-30%, 30-40%, , 50-60%, 50-75%, or 75-100%, relative to the level of sclerostin (e.g., the level detectable in the serum) detected in the subject prior to treatment with a method described herein.

In a specific ment, provided herein is a method of treating a form of CKD- MBD and/or extraskeletal calcification, e. g., vascular calcification, comprising: (i) administering an ActRII inhibitor to an individual having a form of CKD-MBD and/or extraskeletal calcification, e.g., ar calcification; (ii) determining an amount of sclerostin in a tissue sample (e.g., serum) of said individual after the adminstration of the ActRII tor; and (iii) if the amount of sclerostin in said tissue sample is decreased by no more than about 5%, 10%, 15%, %, or 25%, or by about 5-10%, 10-20%, 20-30%, as compared to the amount of sclerostin determined in a sample of the same tissue from said individual (e.g., a different sample of serum from the same individual) prior to administration of the ActRII inhibitor, repeating the administration of the ActRII inhibitor. In certain embodiments, if the amount of sclerostin is not decreased following administration of the ActRII inhibitor, the dose of the ActRII inhibitor administered can be increased. In certain embodiments, if the amount of sclerostin is not decreased ing stration of the ActRII inhibitor, the frequency of administration of the ActRII inhibitor administered can be increased.

In certain embodiments, the subject suffering from vascular calcification d in accordance with the methods described herein is less than 18 years old. In a specific ment, the subject suffering from vascular calcification d in accordance with the methods described herein is less than 13 years old. In r specific ment, the subject ing from vascular calcification treated in accordance with the methods described herein is less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, or less than 5 years old. In r specific embodiment, the subject suffering from vascular calcification treated in accordance with the methods described herein is 1-3 years old, 3-5 years old, 5-7 years old, 7-9 years old, 9-11 years old, 11-13 years old, 13-15 years old, 15-20 years old, 20-25 years old, 25-30 years old, or greater than 30 years old. In another specific embodiment, the subject suffering from vascular calcification treated in accordance with the methods described herein is 30-35 years old, 35-40 years old, 40-45 years old, 45-50 years old, 50-55 years old, 55-60 years old, or r than 60 years old. In another specific embodiment, the subject suffering from vascular calcification treated in accordance with the methods described herein is 60-65 years old, 65-70 years old, 70-75 years old, 75-80 years old, or greater than 80 years old.

In certain embodiments, the subject suffering from ar calcification treated in accordance with the methods described herein has end stage renal disease. In certain embodiments, the subject suffering from vascular calcification treated in accordance with the methods described herein undergoes dialysis.

In certain embodiments, the effectiveness of treatment or prevention of extraskeletal calcification, e.g., vascular calcification, is assessed using one or more assays known to those of skill in the art. Exemplary assays are bed in n 5.3(a)(iv). In accordance with such embodiments, one of skill in the art will tand that a subject being treated with an ActRII inhibitor as described herein may have their treatment regimen adjusted based on the outcome of the assays. For example, a subject being d by a method described herein that displays increases in levels of calcium, e. g., vascular calcium (e. g., arterial calcium) may be administered an increased dose of ActRII inhibitor, or a may be administered an ActRII inhibitor more frequently (i.e., the time between dose administrations may be decreased). Conversely, a subject being treated by a method described herein that displays decreases in levels of calcium, e. g., vascular calcium (e. g., arterial calcium) may be administered a decreased dose of ActRII inhibitor, or a may be stered an ActRII inhibitor less frequently (i.e., the time between dose administrations may be increased).

In n embodiments, the s ed herein result in the improvement of the symptoms of one or more of the following: hyperphosphatemia, secondary hyperparathyroidism (due to increase in phosphorus), and extraskeletal calcification, e.g., vascular calcification. Any method known to the skilled artisan to determine the degree of these symptoms can be used with the methods provided herein. In specific embodiments, the methods bed herein result in the improvement of one or more symptoms of vascular calcification. Exemplary symptoms include, without limitation, increases in the levels of vascular (e.g., arterial) calcium, increased apoptosis of vascular smooth muscle cells, loss of arterial elasticity, an increase in PWV (pulse wave velocity), development of left ventricular hypertrophy, decrease in coronary artery perfusion, and myocardial ischaemia.

In certain embodiments, the methods bed herein result in a decrease in the levels of vascular calcium, e.g., arterial calcium, in a subject by at least 5%, 10%, 15%, 20%, %, 30%, 35%, 40%, 45% or 50%. In certain ments, the methods described herein result in a decrease in the levels of vascular calcium, e.g., arterial calcium, in a t by 5%- %, 10%-15%, 15%-20%, 20%-25%, 25%-30%, 30%-35%, 35%-40%, 40%-45%, or 45%- 50%.

In a specific embodiment, provided herein is a method of reducing the levels of ar calcium in a subject, comprising: (i) stering an ActRII inhibitor to a subject in need of reduction vascular calcium levels (e. g., a subject having a form of CKD-MBD and/or extraskeletal calcification, e.g., vascular calcification); (ii) determining an amount of vascular calcium in a tissue sample (e.g., serum) of said subject after the adminstration of the ActRII inhibitor; and (iii) if the amount of vascular calcium in said tissue sample is sed by no more than about 5%, 10%, 15%, 20%, or 25%, or by about 5-10%, 10-20%, 20-30%, as compared to the amount of vascular calcium ined in a sample of the same tissue from said subject (e.g., a different sample of serum fiom the same individual) prior to administration of the ActRII inhibitor, repeating the administration of the ActRII inhibitor. In certain embodiments, if the amount of vascular calcium is not decreased following administration of the ActRII inhibitor, the dose of the ActRII inhibitor administered can be sed. In certain embodiments, if the amount of vascular calcium is not decreased following administration of the ActRII inhibitor, the frequency of administration of the ActRII inhibitor administered can be increased.

In certain embodiments, the methods described herein result in a decrease in the progression of the Agatston score of a subject having or at risk of developing vascular calcification. In a c embodiment, the methods described herein result in a 5%, 10%, 15%, %, 25%, 30%, or greater than 30% decrease in the Agatston score of a subject having or at risk of developing vascular calcification as compared to the Agatston score of the subject prior to administration of an ActRII inhibitor in accordance with the methods described herein (see, e.g., Section 5.3(a)(iv)). In another specific embodiment, the methods described herein result in a %-10%, 10%-15%, 15%-20%, 20%-25%, 25%-30%, 30%-35%, 35%-40%, 40%-45%, or 45%- 50% decrease in the Agatston score of a subject having or at risk of developing vascular cation as compared to the Agatston score of the subject prior to administration of an ActRII inhibitor in accordance with the methods described herein (see, e.g., n 5.3(a)(iv)).

In another c embodiment, the methods bed herein result in a decrease in the levels of calcium in the vasculature of a subject, e. g., a decrease in the levels of calcium in one or more es of the t, e. g., a subject having or at risk of developing vascular calcification. In r specific embodiment, the methods described herein result in a decrease in the levels of phosphorus in the vasculature of a subject, e. g., a decrease in the levels of phosphorus in one or more arteries of the subject, e.g., a subject having or at risk of ping vascular calcification.

In certain embodiments, provided herein are methods for the treatment of low turnover bone disorders. Low bone turnover can be diagnosed using the tests set forth in Section .3(a) below. mical markers of bone er include: serum or urine collagen cross- links (N-telopeptide or C-telopeptide), bone-specific alkaline phosphatase, serum osteocalcin and/or propeptide type 1 collagen, 25 hydroxyvitamin D, and yroid hormone ("PTH"). In a c embodiment, the low turnover bone er is adynamic bone disorder. In certain embodiments, a patient to be treated with the methods provided herein has a reduction in bone- tumover of at least 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or of 100%. In certain ments, a patient to be treated with the methods provided herein has a reduction in bone-tumover of at most 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or of 100%. In certain embodiments, a patient to be treated with the methods provided herein has a reduction in bone-tumover of at between 10% and 25%, 20% and 35%, 30% and 45%, 40% and 55%, 50% and 65%, 60% and 75%, 70% and 85%, 80% and 95%, 90% and 100%. In certain embodiments, the reduction in bone turnover is compared to ical data of the same patient. In other embodiments, the reduction in bone turnover is compared to the average bone turnover in a population without bone disorders. The tion without bone disorders can be of the same age and / or same sex as the patient.

In a specific embodiment, provided herein is a method of treating a low turnover bone disorder, e. g., adynamic bone er, comprising: (i) administering an ActRII inhibitor to a subject having a low turnover bone disorder; (ii) determining the level of bone-tumover in said subject after the adminstration of the ActRII inhibitor (e.g., by using one or more of the tests set forth in Section 5.3(a) below and/or by measuring one or more biochemical markers of bone turnover); and (iii) if the level of bone turnover in the subject is sed by no more than about %, 10%, 15%, 20%, or 25%, or by about 5-10%, 10-20%, 20-30%, as compared to the level of bone turnover in the subject prior to administration of the ActRII inhibitor, repeating the administration of the ActRII inhibitor. In certain embodiments, if the level of bone turnover is not decreased following administration of the ActRII tor, the dose of the ActRII inhibitor administered can be increased. In certain ments, if the level of bone turnover is not sed following administration of the ActRII tor, the frequency of administration of the ActRII inhibitor administered can be increased. .2 INHIBITORS OF ACTRII (a) INHIBITORS OF ACTRIIA As used herein, the term "ActRIIA" refers to a family of activin receptor type IIa (ActRIIA) proteins from any species and ts d from such ActRIIA proteins by mutagenesis or other modification. Reference to ActRIIA herein is understood to be a reference to any one of the currently identified forms. Members of the ActRIIA family are generally transmembrane proteins, composed of a -binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted /threonine kinase activity.

ActRIIA inhibitors to be used in the compositions and methods described herein include, without limitation, activin-binding soluble ActRIIA ptides; antibodies that bind to activin (particularly the activin A or B subunits, also referred to as BA or BB) and disrupt ActRIIA binding; antibodies that bind to ActRIIA and t activin binding; non-antibody proteins ed for activin or ActRIIA binding (see e.g., WO/2002/088l7l, WO/2006/055689, WO/2002/032925, WO/2005/037989, US 2003/0133939, and US 2005/0238646, each ofwhich is incorporated herein by reference in its entirety, for examples of such proteins and methods for design and selection of same); and randomized peptides selected for n or ActRIIA binding, which can be conjugated to an EC domain.

In certain embodiments, two or more different proteins (or other moieties) with n or ActRIIA binding activity, especially activin binders that block the type I (e.g., a soluble type I activin receptor) and type II (e.g., a soluble type II activin receptor) binding sites, respectively, may be linked together to create a bifilnctional or lnctional binding molecule that inhibits ActRIIA and thus can be used in the compositions and methods described herein. In certain ments, Activin-ActRIIA signaling axis antagonists that inhibit ActRIIA include nucleic acid rs, small les and other agents are used in the compositions and methods described herein include. (i) ActRIIA Inhibitors Comprising ActRIIA ptides The term "ActRIIA polypeptide" includes polypeptides sing any naturally occurring polypeptide of an ActRIIA family member as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity. For example, ActRIIA polypeptides include polypeptides derived from the sequence of any known ActRIIA having a sequence at least about 80% identical to the sequence of an ActRIIA polypeptide, and ally at least 85%, 90%, 95%, 97%, 98%, 99% or greater identity. For example, an ActRIIA polypeptide may bind to and inhibit the fianction of an ActRIIA protein and/or activin. An ActRIIB polypeptide may be selected for its ability to promote bone growth and bone mineralization. Examples of ActRIIA polypeptides include human A precursor polypeptide (SEQ ID NO: 1) and soluble human ActRIIA ptides (e.g., SEQ ID NOs: 2, 3, 7 and 12). With respect to the ActRIIA sor polypeptide whose amino acid sequence is depicted at SEQ ID NO:l, the signal peptide of the human ActRIIA precursor polypeptide d at amino acid positions I to 20; the extracellular domain is located at amino acid positions 21 to 135 and the N—linked glycosylation sites of the human ActRIIA precursor polypeptide (SEQ ID NO: 1) are located at amino acid positions 43 and 56 of SEQ ID NO: 1.

The nucleic acid sequence encoding the human B sor polypeptide of SEQ ID NO:1 is disclosed as SEQ ID NO:4 (nucleotides 164-1705 of Genbank entry NM_OOl6l6). The nucleic acid sequence encoding the soluble human ActRIIA polypeptide of SEQ ID NO:2 is disclosed as SEQ ID NO:5. See Table 6 for a ption of the sequences.

In specific embodiments, the ActRIIA polypeptides used in the itions and methods described herein are e ActRIIA polypeptides. An extracellular domain of an ActRIIA protein can bind to n and is generally soluble, and thus can be termed a soluble, activin-binding ActRIIA ptide. Thus, as used herein, the term "soluble ActRIIA polypeptide" generally refers to polypeptides comprising an ellular domain of an ActRIIA protein, including any naturally occurring extracellular domain of an ActRIIA protein as well as any variants thereof (including s, fragments and peptidomimetic forms). Soluble ActRIIA polypeptides can bind to activin; however, the wild type ActRIIA protein does not exhibit significant selectivity in binding to n versus GDF8/ l 1. Native or altered ActRIIA proteins may be given added specificity for activin by coupling them with a second, activin-selective binding agent. Examples of soluble, activin-binding ActRIIA polypeptides include the soluble polypeptides rated in SEQ ID NOs: 2, 3, 7, 12 and 13. Other examples of soluble, activin- binding ActRIIA polypeptides se a signal sequence in addition to the extracellular domain of an ActRIIA protein, for example, the honey bee mellitin leader sequence (SEQ ID NO: 8), the tissue plasminogen activator (TPA) leader (SEQ ID NO: 9) or the native ActRIIA leader (SEQ ID NO: 10). The ActRIIA-hFc ptide illustrated in SEQ ID NO: 13 uses a TPA leader.

In certain embodiments, the inhibitors of ActRIIA used in the compositions and s described herein comprise a conjugate/fusion protein comprising an activin-binding domain ofActRIIA linked to an Fc portion of an antibody. In certain embodiments, the activin- binding domain is linked to an Fc portion of an dy via a linker, e.g., a peptide linker.

Optionally, the Fc domain has one or more mutations at residues such as Asp-265, lysine 322, and Asn-434. In certain cases, the mutant Fc domain having one or more of these mutations (e. g., an Asp-265 mutation) has a reduced ability to bind to the Fcy receptor relative to a wild- type Fc domain. In other cases, the mutant Fc domain having one or more of these mutations (e.g., an Asn-434 mutation) has an increased ability to bind to the MHC class 1- related Fc- receptor (FcRN) relative to a wild-type Fc domain. Exemplary fusion proteins comprising a soluble extracellular domain of ActRIIA fused to an Fc domain are set forth in SEQ ID NOs: 6, 7, 12, and 13.

In a specific embodiment, the A inhibitors used in the compositions and methods described herein comprise the extracellular domain of ActRIIA, or a portion thereof, linked to an Fc portion of an antibody, wherein said ActRIIA inhibitor comprises an amino acid sequence that is at least 75% identical to an amino acid sequence selected from SEQ ID NOs: 7, 12, and 13. In another specific ment, the ActRIIA inhibitors used in the compositions and methods described herein se the ellular domain of ActRIIA, or a portion thereof, linked to an Fc portion of an antibody, n said ActRIIA inhibitor comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence ed from SEQ ID NOs: 7, 12, and 13.

In certain embodiments, the inhibitors of ActRIIA used in the itions and methods described herein comprise a truncated form of an extracellular domain of A. The truncation can be at the carboxy terminus and/or the amino terminus of the ActRIIA polypeptide.

In certain embodiments, the truncation can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long relative to the mature ActRIIB polypeptide extracellular domain. In certain ments, the truncation can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 N-terminal amino acids of the mature ActRIIA polypeptide extracellular domain. In certain embodiments, the truncation can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 C-terminal amino acids of the mature A polypeptide extracellular domain. For example, truncated forms of ActRIIA include polypeptides with amino acids 20-119; 20-128; ; 20-130; 20-131; 20- 132; 20-133; 20-134; 20-131; 21-131; 22-131; 23-131; 24-131; and 25-131, wherein the amino acid ons refer to the amino acid positions in SEQ ID NO:1.

In n embodiments, the inhibitors of ActRIIA used in the compositions and methods described herein comprise an extracellular domain of ActRIIA with one or more amino acid substitutions. In certain embodiments, the inhibitors of ActRIIA used in the compositions and methods described herein comprise a truncated form of an ActRIIA ellular domain that also carries an amino acid substitution.

In a specific embodiment, the ActRIIA inhibitor to be used in the compositions and methods described herein is a fusion protein between the extracellular domain of the human ActRIIA receptor and the Fc portion of IgGl. In another specific embodiment, the ActRIIA inhibitor to be used in the compositions and methods described herein is a fusion protein between a ted extracellular domain of the human ActRIIA receptor and the Fc portion of IgGl. In another specific embodiment, the ActRIIA inhibitor to be used in the compositions and methods described herein is a fusion protein between a ted extracellular domain of the human ActRIIA receptor and the Fc portion of IgGl wherein the truncated extracellular domain of the human ActRIIA receptor possesses one or more amino acid substitutions.

Functionally active fragments of A polypeptides can be obtained, for example, by screening polypeptides recombinantly produced from the corresponding fragment of the nucleic acid encoding an ActRIIA polypeptide. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional eld solid phase f-Moc or t-Boc chemistry. The nts can be ed (recombinantly or by al synthesis) and tested to identify those yl nts that can filnction as antagonists (inhibitors) of ActRIIA protein or signaling mediated by activin.

In addition, functionally active variants of ActRIIA polypeptides can be obtained, for e, by screening libraries of modified polypeptides recombinantly produced from the corresponding mutagenized nucleic acids encoding an ActRIIA polypeptide. The variants can be produced and tested to fy those that can function as antagonists (inhibitors) of ActRIIA protein or signaling mediated by activin. In certain embodiments, a filnctional variant of the ActRIIA polypeptides comprises an amino acid sequence that is at least 75% cal to an amino acid sequence selected from SEQ ID NOs: 2 or 3. In certain cases, the functional variant has an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to an amino acid ce selected from SEQ ID NOs: 2 or 3.

Functional variants may be generated, for example, by modifying the structure of an A polypeptide for such purposes as ing therapeutic efficacy, or stability (e.g., ex vivo shelf life and resistance to lytic degradation in vivo). Such modified ActRIIA polypeptides when selected to retain activin binding, can be considered functional equivalents of the naturally-occurring ActRIIA polypeptides. Modified ActRIIA polypeptides can also be produced, for instance, by amino acid substitution, deletion, or addition. For instance, it is reasonable to expect that an isolated replacement of a e with an isoleucine or valine, an aspartate with a glutamate, a ine with a serine, or a r replacement of an amino acid with a structurally related amino acid (e.g., vative mutations) will not have a major effect on the biological actiVity of the resulting le. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Whether a change in the amino acid ce of an ActRIIA polypeptide results in a functional homolog can be readily determined by assessing the ability of the t A polypeptide to produce a response in cells in a fashion similar to the wild-type ActRIIA polypeptide.

In certain embodiments, the ActRIIA inhibitor to be used in the compositions and methods described herein may se an ActRIIA polypeptide having one or more ic mutations that can alter the glycosylation of the polypeptide. Such mutations may introduce or eliminate one or more glycosylation sites, such as O-linked or N—linked glycosylation sites.

Asparagine-linked glycosylation recognition sites generally se a tripeptide sequence, asparagine-X-threonine (or asparagines-X-serine) (where "X" is any amino acid) which is specifically recognized by appropriate cellular glycosylation enzymes. The alteration may also be made by the addition of, or tution by, one or more serine or threonine residues to the sequence of the wild-type ActRIIA polypeptide (for ed glycosylation sites). A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non- glycosylation at the modif1edtripeptide sequence. r means of increasing the number of carbohydrate moieties on an A polypeptide is by chemical or enzymatic coupling of glycosides to the ActRIIA polypeptide. Depending on the coupling mode used, the sugar(s) may be attached to (a) ne and histidine; (b) free carboxyl groups; (c) free sulfhydryl groups such as those of cysteine; (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline; (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan; or (f) the amide group of glutamine. These methods are described in WO 87/05330 published Sep. 11, 1987, and in Aplin and Wriston (1981) CRC Crit. ReV. Biochem., pp. 259-306, incorporated by reference herein. l of one or more carbohydrate moieties present on an ActRIIA polypeptide may be accomplished chemically and/or enzymatically. Chemical deglycosylation may involve, for example, exposure of the ActRIIA polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the g sugar (N—acetylglucosamine or N—acetylgalactosamine), while leaving the amino acid ce intact. Chemical deglycosylation is further described by Hakimuddin et al. (1987) Arch. Biochem. Biophys. 259:52 and by Edge et al. (1981) Anal.

Biochem. 118: 13 1. Enzymatic cleavage of carbohydrate moieties on ActRIIA polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al. (1987) Meth. Enzymol. 138350. The sequence of an ActRIIA polypeptide may be adjusted, as appropriate, depending on the type of expression system used, as mammalian, yeast, insect and plant cells may all introduce differing glycosylation patterns that can be affected by the amino acid sequence of the peptide. In l, ActRIIA proteins for use in humans can be expressed in a mammalian cell line that es proper glycosylation, such as HEK293 or CHO cell lines, although other sion systems, such as other mammalian expression cell lines, yeast cell lines with engineered glycosylation s and insect cells, are expected to be useful as well.

Further provided herein are methods of generating mutants, particularly sets of combinatorial mutants of an ActRIIA polypeptide, as well as truncation mutants; pools of combinatorial mutants are especially useful for identifying fianctional variant sequences. The purpose of screening such combinatorial libraries may be to generate, for example, ActRIIA polypeptide variants which can act as either agonists or antagonist, or alternatively, which possess novel activities all er. A variety of screening assays are provided below, and such assays may be used to te variants. For example, an ActRIIA polypeptide variant may be screened for ability to bind to an ActRIIA ligand, to prevent g of an ActRIIA ligand to an ActRIIA polypeptide or to interfere with signaling caused by an ActRIIA ligand.

Combinatorially-derived variants can be generated which have a selective or lly increased potency relative to a naturally occurring ActRIIA polypeptide. Likewise, mutagenesis can give rise to ts which have intracellular ives dramatically different than the corresponding a wild-type ActRIIA ptide. For example, the altered protein can be rendered either more stable or less stable to proteolytic degradation or other cellular processes which result in destruction of, or otherwise inactivation of a native ActRIIA polypeptide. Such variants, and the genes which encode them, can be utilized to alter ActRIIA polypeptide levels by modulating the half-life of the ActRIIA polypeptides. For ce, a short half-life can give rise to more transient biological effects and can allow tighter control of inant ActRIIA polypeptide levels within the patient. In an Fc fusion protein, mutations may be made in the linker (if any) and/or the Fc portion to alter the half-life of the protein.

A atorial library may be produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of potential ActRIIA polypeptide sequences. For instance, a e of synthetic ucleotides can be enzymatically d into gene sequences such that the degenerate set of potential ActRIIA polypeptide nucleotide sequences are expressible as individual ptides, or alternatively, as a set of larger fusion proteins (e. g., for phage display).

There are many ways by which the library of potential homologs can be ted from a degenerate oligonucleotide sequence. Chemical sis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be d into an riate vector for expression. The synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, S A (1983) Tetrahedron 39:3; Itakura et al., (1981) Recombinant DNA, Proc. 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp 273-289; Itakura et al., (1984) Annu. Rev. Biochem. 53:323; Itakura et al., (1984) Science 198: 1056; Ike et al., (1983) c Acid Res. 11:477). Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al., (1990) Science 249:386-390; Roberts et al., (1992) PNAS USA 89:2429-2433; Devlin et al., (1990) Science 249: 404-406; Cwirla et al., (1990) PNAS USA 87: 6378-6382; as well as US. Pat. Nos. ,223,409, 5,198,346, and 5,096,815).

Alternatively, other forms of mutagenesis can be utilized to generate a combinatorial library. For example, A polypeptide variants can be generated and isolated from a library by screening using, for example, e scanning mutagenesis and the like (Ruf et al., (1994) Biochemistry 33:1565-1572; Wang et al., (1994) J. Biol. Chem. 269:3095-3099; Balint et al., (1993) Gene 137: 109-1 18; Grodberg et al., (1993) Eur. J. Biochem. 21 8 :5 97-60 1; Nagashima et al., (1993) J. Biol. Chem. 268:2888-2892; Lowman et al., (1991) Biochemistry 30: 10832-10838; and Cunningham et al., (1989) Science 244: 1081-1085), by linker scanning mutagenesis (Gustin et al., (1993) gy 193:653-660; Brown et al., (1992) Mol. Cell Biol. 12:2644-2652; McKnight et al., (1982) Science 232:316); by saturation mutagenesis (Meyers et al., (1986) Science 232:613); by PCR mutagenesis (Leung et al., (1989) Method Cell Mol Biol 9); or by random mutagenesis, including chemical mutagenesis, etc. (Miller et al., (1992) A Short Course in Bacterial Genetics, CSHL Press, Cold Spring Harbor, N.Y.; and r et al., (1994) Strategies in Mol Biol 7:32-34). Linker scanning mutagenesis, particularly in a atorial setting, is an attractive method for identifying truncated (bioactive) forms of ActRIIA polypeptides.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations and truncations, and, for that matter, for screening cDNA libraries for gene products having a certain property. Such techniques will be generally ble for rapid screening of the gene libraries generated by the atorial mutagenesis of ActRIIA polypeptides. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable sion vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector ng the gene whose t was detected. Preferred assays include n g assays and activin-mediated cell signaling assays.

In certain embodiments, ActRIIA polypeptides used in the inhibitors of the methods and compositions described herein may further comprise post-translational modifications in addition to any that are naturally present in the A polypeptides. Such modifications may include, but are not limited to, acetylation, ylation, glycosylation, phosphorylation, lipidation, and acylation. As a result, the d ActRIIA polypeptides may contain non- amino acid elements, such as polyethylene s, lipids, poly- or mono-saccharide, and phosphates. Effects of such non-amino acid elements on the filnctionality of a ActRIIA polypeptide may be tested by any method known to the skilled artisan. When an ActRIIA polypeptide is produced in cells by cleaving a t form of the ActRIIA polypeptide, post- translational processing may also be important for correct folding and/or function of the n.

Different cells (such as CHO, HeLa, MDCK, 293, W138, 3 or HEK293) have specific cellular machinery and teristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the ActRIIA polypeptides.

In certain aspects, functional variants or modified forms of the ActRIIA polypeptides used in the inhibitors of the methods and compositions described herein include fusion proteins having at least a portion of the ActRIIA polypeptides and one or more fusion domains. Well known examples of such fusion domains include, but are not limited to, polyhistidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, n G, an immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), or human serum albumin. A ‘l domain may be selected so as to confer a desired property. For example, some fusion domains are particularly useful for ion of the filSlOI‘l proteins by affinity chromatography. For the purpose of affinity purification, relevant matrices for affinity tography, such as glutathione-, amylase-, and nickel- or cobalt-conjugated resins are used. Many of such matrices are available in "kit" form, such as the Pharmacia GST purification system and the QIAexpress.TM. system (Qiagen) useful with (HIS6) filSlOI‘l partners. As another example, a fusion domain may be selected so as to facilitate detection of the ActRIIA polypeptides.

Examples of such detection domains e the various fluorescent proteins (e.g., GFP) as well as "epitope tags," which are usually short peptide sequences for which a specific antibody is available. Well known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus hemagglutinin (HA), and c-myc tags. In some cases, the filsion domains have a protease ge site, such as for Factor Xa or Thrombin, which allows the relevant protease to partially digest the ‘l proteins and thereby liberate the recombinant proteins therefrom. The liberated proteins can then be isolated from the filSlOI‘l domain by uent chromatographic separation. In n red embodiments, an ActRIIA polypeptide is fused with a domain that stabilizes the ActRIIA polypeptide in vivo (a "stabilizer" domain). By "stabilizing" is meant anything that increases serum half life, regardless of whether this is because of decreased destruction, decreased clearance by the kidney, or other pharmacokinetic effect. Fusions with the Fc portion of an immunoglobulin are known to confer desirable pharmacokinetic ties on a wide range of proteins. Likewise, fusions to human serum albumin can confer desirable properties. Other types of fusion domains that may be selected include multimerizing (e.g., dimerizing, erizing) domains and fianctional domains (that confer an additional biological function, such as further stimulation of bone growth or muscle growth, as desired).

It is tood that different elements of the filSlOI‘l proteins may be arranged in any manner that is consistent with the desired onality. For example, an ActRIIA ptide may be placed C-terminal to a heterologous domain, or, alternatively, a heterologous domain may be placed C-terminal to an ActRIIA polypeptide. The ActRIIA polypeptide domain and the heterologous domain need not be adjacent in a fusion protein, and additional domains or amino acid sequences may be included C- or inal to either domain or between the domains.

In n embodiments, the ActRIIA polypeptides used in the inhibitors of the methods and compositions described herein may contain one or more modifications that are capable of stabilizing the ActRIIA polypeptides. For example, such modifications may enhance the in Vitro half life of the A polypeptides, enhance circulatory half life of the ActRIIA polypeptides or reduce proteolytic degradation of the ActRIIA polypeptides. Such stabilizing modifications may include, but are not limited to, fusion ns (including, for example, fusion ns comprising an ActRIIA polypeptide and a stabilizer domain), modifications of a glycosylation site (including, for example, addition of a glycosylation site to an ActRIIA polypeptide), and modifications of carbohydrate moiety (including, for example, removal of carbohydrate moieties from an ActRIIA polypeptide). In the case of fusion proteins, an ActRIIA polypeptide is fused to a stabilizer domain such as an IgG molecule (e. g., an Fc domain). As used , the term "stabilizer domain" not only refers to a fusion domain (e.g., PC) as in the case of fusion proteins, but also includes nonproteinaceous modifications such as a ydrate moiety, or nonproteinaceous polymer, such as polyethylene glycol.

In certain embodiments, isolated and/or purified forms of ActRIIA polypeptides, which are isolated fiom, or otherwise ntially free of, other proteins can be used with the methods and compositions described herein. ActRIIA polypeptides can generally be produced by sion from recombinant nucleic acids.

In certain aspects, the ActRIIA polypeptides used in the compositions and methods described herein are generated using isolated and/or recombinant nucleic acids encoding any of the ActRIIA ptides (e.g., soluble ActRIIA polypeptides), including fragments, onal variants and fusion ns disclosed herein. For example, SEQ ID NO: 4 s the naturally occurring human ActRIIA precursor polypeptide, while SEQ ID NO: 5 encodes the processed extracellular domain of ActRIIA. Such nucleic acids may be single-stranded or double stranded.

Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for example, in methods for making ActRIIA ptides or as direct therapeutic agents (e.g., in a gene therapy approach).

In certain aspects, nucleic acids encoding ActRIIA polypeptides may include nucleic acids that are ts of SEQ ID NO: 4 or 5. t nucleotide ces e sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants.

In certain embodiments, ed or recombinant nucleic acid sequences encoding A polypeptides may be least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 4 or 5. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NO: 4 or 5, and variants of SEQ ID NO: 4 or 5 may be used in the production of A ptides suitable for use in the methods and compositions described herein. In fiarther embodiments, such nucleic acid sequences can be isolated, recombinant, and/or fused to a heterologous nucleotide sequence, or be from a DNA library.

In other embodiments, nucleic acids used in the production of ActRIIA polypeptides suitable for use in the s and compositions described herein may include nucleotide sequences that hybridize under highly stringent conditions to the nucleotide sequence designated in SEQ ID NO: 4 or 5, complement sequence of SEQ ID NO: 4 or 5, or fragments thereof. One of ordinary skill in the art will understand that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one can perform the hybridization at 6.0 times sodium chloride/sodium citrate (SSC) at about 45 degree Celsius, followed by a wash of 2.0 times SSC at 50 degree Celsius. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 times SSC at 50 degree Celsius to a high stringency of about 0.2 times SSC at 50 degree Celsius. In addition, the temperature in the wash step can be increased from low ency conditions at room temperature, about 22 degree Celsius, to high stringency conditions at about 65 degree s. Both temperature and salt may be varied, or ature or salt concentration may be held constant while the other variable is changed. In one embodiment, nucleic acids which hybridize under low stringency conditions of 6 times SSC at room temperature followed by a wash at 2 times SSC at room temperature can be used with the s and compositions described herein.

Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NOs: 4 or 5 due to degeneracy in the genetic code also can be used in the production of ActRIIA polypeptides suitable for use in the methods and compositions described herein. For example, a number of amino acids are designated by more than one triplet. Codons that y the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" mutations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these ions in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular n may exist among individuals of a given species due to natural allelic variation.

In certain embodiments, the recombinant nucleic acids may be operably linked to one or more regulatory nucleotide sequences in an expression uct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. lly, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter ces, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, ational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible ers as known in the art are contemplated herein. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an e, such as a plasmid, or the expression uct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the ion of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain s, the a nucleic acid used in the production of ActRIIA polypeptides suitable for use in the methods and itions described herein can be provided in an expression vector comprising a nucleotide sequence encoding an A polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the ActRIIA polypeptide. Accordingly, the term regulatory sequence es ers, enhancers, and other expression control elements. Exemplary regulatory sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, Calif (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding an ActRIIA polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac system, the trp system, the TAC or TRC system, T7 er Whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the l regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid atase, e.g., PhoS, the promoters of the yeast u-mating factors, the polyhedron er of the baculovirus system and other sequences known to l the expression of genes of prokaryotic or eukaryotic cells or their viruses, and s combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be sed. Moreover, the vectors copy number, the ability to control that copy number and the expression of any other protein encoded by the , such as antibiotic markers, should also be considered.

A recombinant nucleic acid used in the production of ActRIIA ptides suitable for use in the methods and compositions described herein can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of a recombinant ActRIIA ptide include ds and other vectors. For instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as E. coli.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are sed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, ka2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug ance selection in both prokaryotic and eukaryotic cells. Alternatively, tives of viruses such as the bovine papilloma virus (BPV-l), or n-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene y delivery systems. The s methods employed in the preparation of the plasmids and in transformation of host organisms are well known in the art.

For other suitable expression systems for both yotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning A Laboratory Manual, 3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 2001). In some instances, it may be desirable to express the recombinant polypeptides by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL- derived vectors (such as pVLl392, pVLl393 and pVL94l), pAcUW-derived vectors (such as ), and pBlueBac-derived vectors (such as the B-gal containing pBlueBac III).

Vectors can be designed for production of the t ActRIIA polypeptides in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and o vectors (Promega, Madison, Wis). As will be apparent, the subject gene constructs can be used to cause expression of the subject ActRIIA polypeptides in cells propagated in culture, e.g., to produce proteins, including fusion ns or t proteins, for purification.

Host cells transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 4 or 5) for one or more of the subject ActRIIA polypeptides can be used in the production of ActRIIA polypeptides suitable for use in the methods and compositions bed herein. The host cell may be any prokaryotic or eukaryotic cell. For e, an ActRIIA polypeptide provided herein may be expressed in bacterial cells such as E. coli, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other le host cells are known to those skilled in the art.

Accordingly, provided herein are s of producing the ActRIIA ptides.

For example, a host cell transfected with an expression vector encoding an ActRIIA polypeptide can be cultured under appropriate conditions to allow expression of the ActRIIA polypeptide to occur. The A polypeptide may be secreted and isolated from a mixture of cells and medium containing the ActRIIA polypeptide. Alternatively, the ActRIIA polypeptide may be retained cytoplasmically or in a membrane fraction and the cells ted, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The subject ActRIIA ptides can be isolated from cell e medium, host cells, or both, using techniques known in the art for ing proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, immunoaffinity purification with antibodies specific for particular epitopes of the ActRIIA ptides and y purification with an agent that binds to a domain filsed to the ActRIIA polypeptide (e.g., a protein A column may be used to purify an ActRIIA-Fc filsion).

In a preferred embodiment, the ActRIIA ptide is a fusion protein ning a domain which tates its purification. In one embodiment, purification is achieved by a series of column chromatography steps, including, for example, three or more of the following, in any order: protein A chromatography, Q sepharose chromatography, phenylsepharose chromatography, size exclusion chromatography, and cation exchange tography. The purification could be completed with viral filtration and buffer exchange. As demonstrated herein, ActRIIA-hFc protein was purified to a purity of >98% as determined by size exclusion chromatography and >95% as determined by SDS PAGE. This level of purity was sufficient to achieve desirable effects on bone in mice and an acceptable safety profile in mice, rats and non- human primates.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N—terminus of the desired portion of a recombinant ActRIIA polypeptide, can allow purification of the expressed fusion protein by affinity chromatography using a Ni2+ metal resin. The ation leader sequence can then be uently removed by treatment with enterokinase to provide the purified ActRIIA polypeptide (e.g., see Hochuli et al., (1987) J. Chromatography 41 1 : 177; and Janknecht et al., PNAS USA 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA nts coding for different polypeptide sequences is performed in accordance with tional techniques, employing blunt-ended or stagger-ended termini for ligation, ction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase ent to avoid undesirable joining, and enzymatic ligation.

In another ment, the fusion gene can be synthesized by conventional techniques including automated DNA sizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in lar Biology, eds. Ausubel et al., John Wiley & Sons: 1992).

ActRIIA-Fc fusion protein can be expressed in stably transfected KX Bl 1 cells from a pAID4 vector (SV40 ori/enhancer, CMV promoter), using a tissue plasminogen leader sequence of SEQ ID NO:9. The Fc portion is a human IgG1 Fc sequence, as shown in SEQ ID NO:7. In certain embodiments, upon expression, the protein ned has, on average, between about 1.5 and 2.5 moles of sialic acid per molecule of ActRIIA-Fc fusion protein.

In certain ments, the long serum half-life of an ActRIIA-Fc fusion can be 25- 32 days in human ts. Additionally, the CH0 cell expressed material can have a higher affinity for activin B ligand than that reported for an ActRIIA-hFc fusion protein expressed in human 293 cells (del Re et al., J Biol Chem. 2004 Dec l7;279(51):53126-35). Additionally, without being bound by theory, the use of the TPA leader sequence provided greater production than other leader sequences and, unlike ActRIIA-Fc expressed with a native leader, may provide a highly pure N—terminal sequence. Use of the native leader sequence may result in two major species of ActRIIA-Fc, each having a different N—terminal sequence. (b) INHIBITORS OF ACTRIIB As used , the term "ActRIIB" refers to a family of activin receptor type IIB (ActRIIB) proteins from any s and variants d from such ActRIIB ns by mutagenesis or other modification. Reference to ActRIIB herein is tood to be a reference to any one of the currently identified forms of the receptor. Members of the ActRIIB family are generally transmembrane ns, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine kinase ty.

ActRIIB inhibitors to be used in the compositions and methods described herein include, without limitation, n-binding soluble ActRIIB polypeptides; antibodies that bind to activin (particularly the activin A or B subunits, also referred to as BA or BB) and disrupt ActRIIB binding; antibodies that bind to ActRIIB and disrupt n binding; non-antibody ns selected for activin or ActRIIB binding; and randomized peptides selected for activin or ActRIIB binding, which can be conjugated to an Fc domain.

In certain embodiments, two or more different proteins (or other moieties) with activin or ActRIIB binding activity, especially activin binders that block the type I (e.g., a soluble type I activin receptor) and type II (e.g., a e type II activin receptor) binding sites, respectively, may be linked together to create a bifilnctional or lnctional binding molecule that inhibits ActRIIB and thus can be used in the compositions and methods described herein include. In certain embodiments, Activin-ActRIIB signaling axis antagonists that t ActRIIB include nucleic acid aptamers, small molecules and other agents are used in the compositions and methods described herein include. (i) ActRIIB Inhibitors Comprising ActRIIB ptides As used herein, the term "ActRIIB polypeptide" refers to polypeptides comprising any naturally occurring polypeptide of an ActRIIB family member as well as any variants thereof (including mutants, nts, fusions, and peptidomimetic forms) that retain a useful ty.

For example, ActRIIB polypeptides include polypeptides derived from the sequence of any known ActRIIB receptor having a ce at least about 80% identical to the sequence of an ActRIIB polypeptide, and optionally at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater ty. For example, an ActRIIB polypeptide may bind to and inhibit the function of an ActRIIB protein and/or n. An example of an ActRIIB polypeptide es the human ActRIIB precursor polypeptide (SEQ ID NO:l6 or SEQ ID NO:28). With respect to the ActRIIB precursor polypeptide whose amino acid sequence is depicted as SEQ ID NO: 16 or SEQ ID NO:28 (i.e., the human ActRIIB precursor polypeptide), the signal peptide of the ActRIIB precursor ptide is located at amino acids 1 to 18; the extracellular domain is located at amino acids 19 to 134 and the potential N—linked glycosylation sites are located at amino acid positions 42 and 65. The nucleic acid sequence encoding the human ActRIIB precursor polypeptide of SEQ ID NO:l6 is sed as SEQ ID NO: 19 (SEQ ID NO: 19 provides an alanine at the codon corresponding to amino acid position 64, but could be readily ed by one of skill in the art using methods known in the art to provide an arginine at the codon corresponding to amino acid position 64 instead). See Table 6 for a description of the sequences.

The numbering of amino acids for all of the ActRIIB-related ptides described herein is based on the amino acid numbering for SEQ ID NO: 16 and SEQ ID NO:28 (which only differ in the amino acid expressed at position 64), unless specifically designated otherwise. For example, if an ActRIIB polypeptide is described as having a tution/mutation at amino acid position 79, then it is to be understood that position 79 refers to the 79th amino acid in SEQ ID NO: 16 or SEQ ID NO:28, from which the ActRIIB polypeptide is derived. Likewise, if an ActRIIB polypeptide is described as having an alanine or an arginine at amino acid position 64, then it is to be understood that position 64 refers to the 64th amino acid in SEQ ID NO:16 or SEQ ID NO:28, from which the ActRIIB polypeptide is derived.

In certain embodiments, the tors of ActRIIB used in the compositions and methods described herein comprise polypeptides comprising an activin-binding domain of ActRIIB. In some embodiments, the activin-binding domains of B comprise the ellular domain of ActRIIB, or a portion thereof. In c embodiments, the extracellular domain or portion thereof of ActRIIB is e. Illustrative modified forms of ActRIIB polypeptides are disclosed in US. Patent Application Publication Nos. 05308 and 20100068215, the disclosures of which are incorporated herein by reference in their entireties.

In c embodiments, the ActRIIB ptides used in the compositions and methods bed herein are soluble ActRIIB polypeptides. The term "soluble ActRIIB polypeptide" generally refers to polypeptides comprising an extracellular domain of an ActRIIB n, including any naturally occurring extracellular domain of an ActRIIB protein as well as any variants thereof (including mutants, fragments and peptidomimetic forms). Soluble ActRIIB polypeptides can bind to activin; however, the wild type ActRIIB protein does not exhibit significant selectivity in binding to activin versus GDF8/ l 1. In certain embodiments, altered forms of B with different binding properties can be used in the methods provided herein.

Such altered forms are disclosed, e. g., in ational patent application publication Nos. WO 2006/012627 and , the disclosures ofwhich are incorporated herein by reference in their entireties. Native or altered ActRIIB proteins may be given added specificity for activin by coupling them with a second, activin-selective binding agent. Exemplary soluble ActRIIB polypeptides include the extracellular domain of a human ActRIIB polypeptide (e.g., SEQ ID NOs: 17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43).

An Fc fusion protein having the ActRIIB ellular sequence disclosed by Hilden et al. (Blood, 1994, 83(8):2l63-70), which has an alanine at the position corresponding to amino acid 64 of the B precursor amino acid sequence, i.e., SEQ ID NO: 16 (herein referred to as "A64"), has been demonstrated to possess a relatively low affinity for activin and GDF-l 1.

By contrast, an EC fusion protein with an arginine at position 64 of the ActRIIB sor amino acid sequence n referred to as "R64") has an affinity for activin and GDF-ll in the low nanomolar to high picomolar range (see, e.g., US. Patent Application ation No. 20100068215, the disclosure of which is herein incorporated in its entirety). An ActRIIB precursor amino acid sequence with an arginine at position 64 is presented in SEQ ID NO:28.

As such, in certain embodiments, the ActRIIB polypeptides used in ance with the compositions and s described herein may se either (i) an alanine at the on corresponding to amino acid 64 of the B precursor amino acid sequence, i.e., SEQ ID NO: 16; or (ii) an ne at position 64 of the ActRIIB precursor amino acid sequence, i.e., SEQ ID NO: 28. In other embodiments, the ActRIIB polypeptides used in accordance with the compositions and s described herein may comprise an amino acid that is not alanine or arginine at the position corresponding to amino acid 64 of the ActRIIB precursor amino acid sequence, i.e., SEQ ID NO: 16 or SEQ ID NO:28.

It has been shown that a deletion of the e knot at the C-terminus of the extracellular domain of ActRIIB reduces the affinity of the receptor for activin (see, e.g., Attisano et al., Cell, 1992, 68(1):97-108). An ActRIIB-Fc fusion protein containing amino acids -119 of SEQ ID NO: 28 (i.e., SEQ ID NO:32), "ActRIIB(20-119)-Fc" has reduced binding to GDF-ll and activin relative to an B-Fc fusion protein containing amino acids 20-134 of SEQ ID NO: 28 (i.e., SEQ ID , "ActRIIB(20-134)-Fc", which includes the proline knot region and the complete juxtamembrane domain. However, an ActRIIB-Fc fusion protein containing amino acids 20-129 of SEQ ID NO: 28, "ActRIIB(20-129)—Fc" retains similar but somewhat reduced activity relative to the non-truncated extracellular domain of ActRIIB, even though the proline knot region is disrupted. Thus, B polypeptides comprising extracellular domains that stop at amino acid 134, 133, 132, 131, 130 and 129 of SEQ ID NO: 28 (or SEQ ID NO: 16) are all expected to be active, but constructs stopping at amino acid 134 or 133 may be most active. Similarly, mutations at any of residues 129-134 are not expected to alter ligand binding affinity by large margins, as indicated by the fact that mutations of P129 and P130 of SEQ ID NO: 28 do not substantially decrease ligand g. Therefore, the B polypeptides used in accordance with the methods and compositions described herein may end as early as amino acid 109 (i.e., the final cysteine) of SEQ ID NO:28 (or SEQ ID NO:16), however, forms ending at or between amino acid positions 109 and 119 of SEQ ID NO:28 (or SEQ ID NO:16) are expected to have reduced ligand binding ability.

Amino acid 29 of SEQ ID NO: 16 and SEQ ID NO:28 represents the initial cysteine in the ActRIIB precursor sequence. It is expected that an ActRIIB polypeptide beginning at amino acid 29 of the N—terminus of SEQ ID NO:16 or SEQ ID NO:28, or before these amino acid positions, will retain ligand binding activity. An alanine to asparagine mutation at position 24 of SEQ ID NO: 16 or SEQ ID NO:28 introduces an N—linked glycosylation sequence Without substantially affecting ligand binding. This confirms that mutations in the region between the signal cleavage peptide and the cysteine cross-linked region, corresponding to amino acids 20-29 of SEQ ID NO:l6 or SEQ ID NO:28, are well tolerated. In particular, ActRIIB polypeptides beginning at amino acid position 20, 21, 22, 23 and 24 of SEQ ID NO: 16 or SEQ ID NO:28 Will retain actiVity, and B polypeptides beginning at amino acid positions 25, 26, 27, 28 and 29 of SEQ ID NO:l6 or SEQ ID NO:28 are also expected to retain actiVity. An B polypeptide beginning at amino acid position 22, 23, 24 or 25 of SEQ ID NO: 16 or SEQ ID NO:28 Will have the most ty.

Taken together, the active portions (i.e., ActRIIB polypeptides) of the B precursor protein (i.e., SEQ ID NO: 16 or SEQ ID NO:28) to be used in accordance with the methods and compositions described herein will generally comprise amino acids 29-109 of SEQ ID NO: 16 or SEQ ID NO:28, and such ActRIIB polypeptides may, for example, begin at a residue ponding to any one of amino acids 19-29 of SEQ ID NO:16 or SEQ ID N028 and end at a position corresponding to any one of amino acids 109-134 of SEQ ID NO: 16 or SEQ ID NO:28. Specific examples of B polypeptides encompassed herein include those that begin at an amino acid position from 19-29, 20-29 or 21-29 of SEQ ID NO:l6 or SEQ ID N028 and end at an amino acid position from 119-134, 119-133 or 129-134, 129-133 of SEQ ID NO: 16 or SEQ ID NO:28. Other specific examples of ActRIIB polypeptides encompassed herein include those that begin at an amino acid position from 20-24 (or 21-24, or 22-25) of SEQ ID NO:l6 or SEQ ID N028 and end at an amino acid position from 109-134 (or 109-133), 119- 134 (or 119-133) or 129-134 (or 129-133) of SEQ ID NO:l6 or SEQ ID NO:28. t ActRIIB polypeptides g Within these ranges are also contemplated, particularly those having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity or sequence homology to the corresponding n of SEQ ID NO: 16 or SEQ ID NO:28.

In n embodiments, the inhibitors of B used in the compositions and methods described herein comprise a truncated form of an extracellular domain of ActRIIB. The truncation can be at the carboxy terminus and/or the amino terminus of the ActRIIB polypeptide.

In certain embodiments, the truncation can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, l4, l5, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long relative to the mature ActRIIB polypeptide extracellular domain. In certain ments, the tion can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 N—terminal amino acids ofthe mature ActRIIB polypeptide extracellular domain. In n embodiments, the truncation can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 C-terminal amino acids of the mature B polypeptide extracellular domain. For e, truncated forms of ActRIIB include polypeptides with amino acids 20-119; 20-128; 20-129; 20-130; 20-131; 20- 132; 20-133; 20-134; 20-131; 21-131; 22-131; ; 24-131; and 25-131, wherein the amino acid positions refer to the amino acid positions in SEQ ID NO: 16 or SEQ ID NO:28.

Additional exemplary truncated forms of ActRIIB include (i) ptides beginning at amino acids at any of amino acids 21-29 of SEQ ID NO: 16 or SEQ ID NO:28 (optionally beginning at 22-25 of SEQ ID NO: 16 or SEQ ID N028) and ending at any of amino acids 109- 134 of SEQ ID NO: 16 or SEQ ID NO:28; (ii) polypeptides beginning at any of amino acids 20- 29 of SEQ ID NO:16 or SEQ ID NO:28 (optionally beginning at 22-25 of SEQ ID NO:16 or SEQ ID N028) and ending at any of amino acids 109-133 of SEQ ID NO:16 or SEQ ID NO:28; (iii) polypeptides beginning at any of amino acids 20-24 of SEQ ID NO: 16 or SEQ ID NO:28 (optionally beginning at 22-25 of SEQ ID NO:16 or SEQ ID NO:28) and ending at any of amino acids 109-133 of SEQ ID NO: 16 or SEQ ID NO:28; (iV) polypeptides beginning at any of amino acids 21-24 of SEQ ID NO:16 or SEQ ID NO:28 and ending at any of amino acids 109-134 of SEQ ID NO: 16 or SEQ ID NO:28; (V) polypeptides beginning at any of amino acids 20-24 of SEQ ID NO:16 or SEQ ID NO:28 and ending at any of amino acids 118-133 of SEQ ID NO:16 or SEQ ID NO:28; (Vi) polypeptides beginning at any of amino acids 21-24 of SEQ ID NO: 16 or SEQ ID NO:28 and ending at any of amino acids 118-134 of SEQ ID NO:16 or SEQ ID NO:28; (Vii) polypeptides beginning at any of amino acids 20-24 of SEQ ID NO: 16 or SEQ ID N028 and ending at any of amino acids 128-133 of SEQ ID NO:16 or SEQ ID NO:28; (Viii) polypeptides beginning at any of amino acids 20-24 of SEQ ID NO: 16 or SEQ ID NO:28 and ending at any of amino acids 128-133 of SEQ ID NO:16 or SEQ ID NO:28; (ix) polypeptides beginning at any of amino acids 21-29 of SEQ ID NO: 16 or SEQ ID NO:28 and ending at any of amino acids 118-134 of SEQ ID NO: 16 or SEQ ID NO:28; (x) polypeptides beginning at any of amino acids 20-29 of SEQ ID NO:16 or SEQ ID NO:28 and ending at any of amino acids 118- 133 of SEQ ID NO: 16 or SEQ ID NO:28; (xi) polypeptides beginning at any of amino acids 21- 29 of SEQ ID NO:16 or SEQ ID NO:28 and ending at any of amino acids 128-134 of SEQ ID NO: 16 or SEQ ID N028; and (xii) polypeptides beginning at any of amino acids 20-29 of SEQ ID NO:16 or SEQ ID NO:28 and ending at any of amino acids 128-133 of SEQ ID NO:16 or SEQ ID NO:28. In a specific embodiment, an ActRIIB ptides comprises, consists essentially of, or consists of, an amino acid sequence beginning at amino acid position 25 of SEQ ID NO:16 or SEQ ID NO:28 and ending at amino acid position 131 of SEQ ID NO:16 or SEQ ID NO:28. In another c embodiment, an ActRIIB polypeptide consists of, or consists essentially of, the amino acid sequence of SEQ ID NO:17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43.

Any of the ActRIIB polypeptides used in the compositions and s described herein may be produced as a homodimer. Any of the B polypeptides used in the compositions and methods described herein may be formulated as a fusion protein having a heterologous portion that comprises a constant region from an IgG heavy chain, such as an Fc domain. Any of the ActRIIB polypeptides used in the compositions and methods described herein may comprise an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 16 or SEQ ID NO:28, ally in combination with one or more onal amino acid substitutions, deletions or insertions relative to SEQ ID NO:16 or SEQ ID NO:28.

In specific embodiments, the inhibitors of B used in the compositions and methods described herein se an extracellular domain of ActRIIB with one or more amino acid substitutions/mutations. Such an amino acid substitution/mutation can be, for example, an exchange from the leucine at amino acid position 79 of SEQ ID NO:16 or SEQ ID NO:28 to an acidic amino acid, such as aspartic acid or glutamic acid. For example, position L79 of SEQ ID NO: 16 or SEQ ID NO:28 may be d in ActRIIB extracellular domain polypeptides to confer altered actiVin-myostatin (GDF-l 1) binding properties. L79A and L79P mutations reduce GDP- 11 binding to a greater extent than actiVin binding. L79E and L79D mutations retain GDF-ll binding, While demonstrating greatly reduced actiVin binding.

In n embodiments, the inhibitors of ActRIIB used in the compositions and methods described herein comprise a truncated form of an ActRIIB extracellular domain that also carries an amino acid tution, e. g., an exchange from the e at amino acid position 79 of SEQ ID NO: 16 or SEQ ID NO:28 to an acidic amino acid, such as aspartic acid or glutamic acid. In a specific embodiment, the truncated form of an extracellular domain of ActRIIB polypeptide that also carries an amino acid substitution used in the compositions and methods described herein is SEQ ID NO:23. Forms of B that are truncated and/or carry one or more amino acid substitutions can be linked to an EC domain of an antibody as discussed above.

] Functionally active fragments of ActRIIB polypeptides can be obtained, for example, by screening polypeptides recombinantly produced from the corresponding fragment of the nucleic acid encoding an ActRIIB polypeptide. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrif1eld solid phase f-Moc or t-Boc chemistry. The fragments can be produced binantly or by chemical synthesis) and tested to fy those yl fragments that can fianction as antagonists itors) of ActRIIB protein or signaling mediated by activin.

In addition, functionally active variants of ActRIIB polypeptides can be obtained, for example, by screening libraries of modified polypeptides recombinantly produced from the corresponding nized nucleic acids encoding an B polypeptide. The variants can be produced and tested to fy those that can function as antagonists (inhibitors) of ActRIIB n or ing mediated by activin. In certain embodiments, a fianctional variant of the ActRIIB polypeptides comprises an amino acid sequence that is at least 75% identical to an amino acid sequence selected from SEQ ID NO:l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43. In certain embodiments, the functional variant has an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from SEQ ID NO:l7, l8,23,26,27,29, 30, 31, 32, 33, 36, 37,42, and 43.

Functional variants may be generated, for example, by modifying the structure of an B ptide for such purposes as enhancing therapeutic efficacy, or stability (e.g., ex vivo shelf life and resistance to proteolytic degradation in vivo). Such modif1ed ActRIIB polypeptides when selected to retain activin binding, are considered functional equivalents of the naturally-occurring ActRIIB polypeptides. d ActRIIB ptides can also be produced, for instance, by amino acid substitution, deletion, or addition. For instance, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (e.g., conservative mutations) will not have a major effect on the biological activity of the resulting le. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Whether a change in the amino acid sequence of an B polypeptide results in a functional homolog can be readily determined by assessing the ability of the variant ActRIIB polypeptide to produce a response in cells in a fashion similar to the wild-type ActRIIB polypeptide.

ActRIIB polypeptide mutants, particularly sets of combinatorial mutants of an B polypeptide, as well as truncation mutants; pools of combinatorial mutants are especially useful for fying functional variant sequences can be used in the methods and compositions described herein. The purpose of screening such combinatorial ies may be to generate, for example, ActRIIB polypeptide variants which can act as either agonists or antagonist, or atively, which s novel activities all together.

It has been demonstrated that the ligand binding pocket of ActRIIB is defined by residues Y3l, N33, N35, L38 through T41, E47, E50, Q53 through K55, L57, H58, Y60, S62, K74, W78 h N83, Y85, R87, A92, and E94 through F101 of SEQ ID NO:l6 or SEQ ID NO:28. At these positions, it is expected that conservative mutations will be tolerated, although a K74A mutation is well-tolerated, as are R40A, K55A, F82A and mutations at position L79.

R40 is a K in Xenopus, indicating that basic amino acids at this on will be ted. Q53 is R in bovine ActRIIB and K in Xenopus ActRIIB, and therefore amino acids including R, K, Q, N and H will be tolerated at this position. Thus, a general formula for an ActRIIB polypeptide for use in the methods and compositions described herein is one that comprises amino acids 29- 109 of SEQ ID NO: 16 or SEQ ID NO:28, but optionally beginning at an amino acid position ranging from 20-24 or 22-25 of SEQ ID NO: 16 or SEQ ID NO:28 and ending at an amino acid position ranging from 129-134 of SEQ ID NO:16 or SEQ ID NO:28, and comprising no more than 1, 2, 5, or 15 conservative amino acid changes in the ligand binding pocket, and zero, one or more non-conservative alterations at amino acid positions 40, 53, 55, 74, 79 and/or 82 of SEQ ID NO: 16 or SEQ ID NO:28 in the ligand binding pocket. Such an ActRIIB ptide may retain greater than 80%, 90%, 95% or 99% sequence identity or sequence homology to the sequence of amino acids 29-109 of SEQ ID NO: 16 or SEQ ID NO:28. Sites outside the binding pocket, at which variability may be particularly well tolerated, include the amino and carboxy termini of the extracellular domain of ActRIIB, and positions 42-46 and 65-73. An asparagine to e alteration at on 65 of SEQ ID NO: 16 or SEQ ID NO:28 (N65A) actually improves ligand binding in the A64 background, and is thus ed to have no detrimental effect on ligand binding in the R64 background. This change ly eliminates ylation at N65 in the A64 background, thus demonstrating that a significant change in this region is likely to be tolerated. While an R64A change is poorly tolerated, R64K is well-tolerated, and thus another basic residue, such as H may be tolerated at position 64.

] As a specific example of an ActRIIB polypeptide with a mutation in the ligand binding domain, the positively-charged amino acid residue Asp (D80) of the ligand-binding domain of ActRIIB can be mutated to a different amino acid residue such that the variant ActRIIB ptide preferentially binds to GDF8, but not activin. In a specific embodiment, the D80 residue is changed to an amino acid residue selected from the group consisting of: an uncharged amino acid residue, a negative amino acid residue, and a hydrophobic amino acid residue. As a fiarther specific example, the hydrophobic e L79 can be altered to the acidic amino acids aspartic acid or glutamic acid to greatly reduce activin binding while retaining GDFll binding. As will be ized by one of skill in the art, most of the described mutations, variants or modifications may be made at the nucleic acid level or, in some cases, by post translational modification or chemical synthesis. Such techniques are well known in the art.

In specific embodiments, the inhibitors of ActRIIB used in the compositions and methods described herein comprise a conjugate/fusion protein comprising an ellular domain (e.g., an activin-binding domain) of an ActRIIB receptor linked to an Fc portion of an antibody. Such conjugate/fusion ns may comprise any of the ActRIIB polypeptides disclosed herein (e.g., any of SEQ ID NOs:l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, or 43), any ActRIIB polypeptides known in the art, or any ActRIIB polypeptides generated using s known in the art and/or provided herein.

In n embodiments, the extracellular domain is linked to an Fc portion of an antibody via a linker, e.g., a peptide linker. Exemplary linkers e short polypeptide sequences such as 2-10, 2-5, 2-4, 2-3 amino acid es (e. g., glycine residues), such as, for example, a Gly-Gly-Gly linker. In a specific embodiment, the linker comprises the amino acid sequence Gly-Gly-Gly (GGG). In another specific embodiment, the linker ses the amino acid sequence Thr-Gly-Gly-Gly (TGGG). ally, the Fc domain has one or more mutations at residues such as 5, lysine 322, and Asn-434. In certain cases, the mutant Fc domain having one or more of these mutations (e.g., an Asp-265 mutation) has a reduced ability to bind to the Fcy receptor relative to a wild-type Fc domain. In other cases, the mutant Fc domain having one or more of these mutations (e.g., an Asn-434 on) has an increased ability to bind to the MHC class 1- related Fc-receptor (FCRN) relative to a wild-type Fc .

Exemplary fusion proteins comprising a soluble extracellular domain of B fused to an EC domain are set forth in SEQ ID NOs:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, and 47.

In a specific embodiment, the ActRIIB inhibitors used in the compositions and methods described herein comprise the extracellular domain of ActRIIB, or a portion thereof, linked to an Fc portion of an antibody, wherein said ActRIIB inhibitor comprises an amino acid sequence that is at least 75% identical to an amino acid sequence selected from SEQ ID NOs:20, 21, 24, 25, 34, 35, 38, 39, 40, 41, 44, 46, and 47. In r specific ment, the ActRIIB inhibitors used in the compositions and methods described herein comprise the extracellular domain of ActRIIB, or a portion thereof, linked to an Fc portion of an antibody, n said B inhibitor comprises an amino acid ce that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from SEQ ID NOs:20, 21, 24, , 34, 35, 38, 39, 40, 41, 44, 46, and 47.

In a specific embodiment, the ActRIIB inhibitor to be used in the compositions and methods described herein is a fusion protein between the extracellular domain of the human B receptor and the Fc portion of IgG1. In another specific embodiment, the ActRIIB inhibitor to be used in the compositions and methods described herein is a fusion protein between a truncated extracellular domain of the human ActRIIB receptor and the Fc portion of IgG1. In another specific embodiment, the ActRIIB inhibitor to be used in the compositions and methods described herein is a fusion protein between a truncated extracellular domain of the human ActRIIB receptor and the Fc portion of IgG1 wherein the truncated extracellular domain of the human ActRIIB receptor possesses an amino acid substitution at the amino acid position corresponding to amino acid 79 of SEQ ID NO: 16 or SEQ ID NO:28. In one embodiment, the amino acid substitution at the amino acid position corresponding to amino acid 79 of SEQ ID NO: 16 or SEQ ID NO:28 is substitution of Leucine for Aspartic Acid (i.e., an L79D mutation).

In a specific embodiment, the ActRIIB inhibitor to be used in the compositions and methods described herein is SEQ ID NO:24 or 25, which represents a fusion protein n the ellular domain of the human B receptor and the Fc n of IgG1, wherein said ActRIIB extracellular domain comprises amino acids 25-131 of SEQ ID NO:28 with an L79D mutation. The nucleic acid ce ng the ActRIIB-Fc fusion protein of SEQ ID NO:24 is presented in SEQ ID NO:45.

In another specific embodiment, the ActRIIB inhibitor to be used in the compositions and methods described herein is SEQ ID NO:34 or 35, which represents a fusion protein between the extracellular domain of the human ActRIIB receptor and the Fc portion of IgG1 n said ActRIIB ellular domain comprises amino acids 25-131 of SEQ ID NO: 16 with an L79D mutation.

Asparagine-linked glycosylation recognition sites generally comprise a tripeptide sequence, asparagine-X-threonine (or asparagine-X-serine) (where "X" is any amino acid) which is specifically recognized by appropriate cellular glycosylation enzymes. The tion may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the wild-type ActRIIB polypeptide (for O-linked ylation sites). A variety of amino acid substitutions or deletions at one or both of the first or third amino acid ons of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence. Another means of increasing the number of carbohydrate moieties on an ActRIIB polypeptide is by chemical or enzymatic coupling of glycosides to the ActRIIB polypeptide. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine; (b) free carboxyl groups; (c) free sulfhydryl groups such as those of cysteine; (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline; (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan; or (f) the amide group of glutamine. These methods are bed in International Patent Application No. WO 87/05330 published Sep. 11, 1987, and in Aplin and Wriston (1981) CRC Crit. Rev. Biochem., pp. 25 9-3 06, incorporated by reference herein. Removal of one or more carbohydrate moieties present on an ActRIIB ptide may be accomplished chemically and/or enzymatically. Chemical deglycosylation may involve, for example, exposure of the ActRIIB polypeptide to the nd trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N—acetylglucosamine or ylgalactosamine), while leaving the amino acid sequence intact.

Chemical deglycosylation is further described by Hakimuddin et al. (1987) Arch. Biochem.

Biophys. 259:52 and by Edge et al. (1981) Anal. Biochem. 118: 13 1. Enzymatic cleavage of ydrate es on ActRIIB polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al. (1987) Meth. Enzymol. 138350. The sequence of an ActRIIB polypeptide may be adjusted, as appropriate, depending on the type of expression system used, as mammalian, yeast, insect and plant cells may all introduce differing glycosylation patterns that can be ed by the amino acid ce of the peptide. In general, ActRIIB ns for use in humans will be expressed in a mammalian cell line that provides proper glycosylation, such as HEK293 or CHO cell lines, although other sion systems, such as other ian expression cell lines, yeast cell lines with engineered glycosylation enzymes and insect cells, are expected to be useful as well.

In specific embodiments, d ActRIIB polypeptides comprising the addition of a further N-linked glycosylation site /T) that increases the serum half-life of an ActRIIB-Fc fusion protein, relative to the ActRIIB(R64)—Fc form can be used in the methods and compositions described herein. In a specific embodiment, introduction of an asparagine at position 24 of SEQ ID NO: 16 or SEQ ID NO:28 (A24N) results in the on of an NXT sequence that confers a longer ife. Other NX(T/S) sequences can be found at 42-44 (NQS) and 65-67 (NSS), although the latter may not be efficiently glycosylated with the R at position 64 (i.e., in R64 polypeptides). T sequences may be generally introduced at positions outside the ligand binding pocket of ActRIIB, which is detailed above. Particularly suitable sites for the introduction of dogenous N-X-S/T sequences include amino acids 20-29, 20-24, 22-25, 109-134, 120-134 or 129-134 of SEQ ID NO:l6 or SEQ ID NO:28. N-X-S/T ces may also be introduced into the linker between the ActRIIB sequence and the PC or other fusion component. Such a site may be introduced with minimal effort by introducing an N in the correct position with respect to a pre-existing S or T, or by ucing an S or T at a position corresponding to a pre-existing N. Thus, desirable alterations that would create an N-linked glycosylation site are: A24N, R64N, S67N (possibly combined with an N65A alteration), ElO6N, Rl 12N, GlZON, E123N, P129N, Al32N, R112S and R112T (with all amino acid positions corresponding to the positions they can be found in SEQ ID NO:l6 or SEQ ID NO:28).

Any S that is predicted to be glycosylated may be altered to a T without creating an immunogenic site, because of the protection afforded by the glycosylation. Likewise, any T that is predicted to be glycosylated may be altered to an S. Thus the alterations S67T and S44T are encompassed . Likewise, in an A24N variant, an S26T alteration may be used.

Accordingly, an ActRIIB polypeptide may e one or more additional, non-endogenous N- linked glycosylation sus sequences.

A variety of screening assays may be used to te B polypeptide variants.

For e, an ActRIIB polypeptide variant may be screened for ability to bind to an ActRIIB ligand, to prevent binding of an ActRIIB ligand to an ActRIIB polypeptide or to interfere with signaling caused by an ActRIIB ligand. The activity of an ActRIIB polypeptide or its variants may also be tested in a cell-based or in vivo assay. atorially-derived variants can be generated which have a selective or generally increased potency relative to a naturally occurring ActRIIB polypeptide. Likewise, mutagenesis can give rise to variants which have intracellular half-lives dramatically different than the corresponding wild-type ActRIIB polypeptide. For example, the altered protein can be rendered either more stable or less stable to proteolytic degradation or other ar processes which result in destruction of, or otherwise inactivation of a native ActRIIB ptide. Such variants, and the genes which encode them, can be utilized to alter ActRIIB polypeptide levels by modulating the half-life of the ActRIIB ptides. For instance, a short ife can give rise to more transient ical effects and can allow tighter control of recombinant ActRIIB polypeptide levels within the patient. In an Fc fusion protein, mutations may be made in the linker (if any) and/or the Fc n to alter the half-life of the protein.

A combinatorial library may be produced by way of a rate library of genes encoding a library of polypeptides which each e at least a portion of potential ActRIIB polypeptide sequences. For instance, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential ActRIIB polypeptide nucleotide sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e. g., for phage display).

There are many ways by which the library of potential homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be ligated into an appropriate vector for expression. The synthesis of degenerate ucleotides is well known in the art (see for example, Narang, S A (1983) Tetrahedron 39:3; Itakura et al., (1981) Recombinant DNA, Proc. 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, dam: Elsevier pp 273-289; Itakura et al., (1984) Annu. Rev. Biochem. 53:323; Itakura et al., (1984) Science 198: 1056; Ike et al., (1983) Nucleic Acid Res. 11:477). Such ques have been employed in the directed evolution of other proteins (see, for example, Scott et al., (1990) Science 249:386-390; Roberts et al., (1992) PNAS USA 89:2429-2433; Devlin et al., (1990) Science 249: 6; Cwirla et al., (1990) PNAS USA 87: 6378-6382; as well as US. Pat. Nos. ,223,409, 5,198,346, and 5,096,815).

Alternatively, other forms of mutagenesis can be utilized to generate a combinatorial library. For example, ActRIIB polypeptide variants can be generated and isolated from a library by screening using, for e, e scanning mutagenesis and the like (Ruf et al., (1994) Biochemistry 33:1565-1572; Wang et al., (1994) J. Biol. Chem. 269:3095-3099; Balint et al., (1993) Gene 137: 109-1 18; rg et al., (1993) Eur. J. Biochem. 21 8 :5 97-60 1; Nagashima et al., (1993) J. Biol. Chem. 268:2888-2892; Lowman et al., (1991) Biochemistry 30: 10832-10838; and gham et al., (1989) Science 244: 1081-1085), by linker ng mutagenesis (Gustin et al., (1993) Virology 193:653-660; Brown et al., (1992) Mol. Cell Biol. 4-2652; McKnight et al., (1982) Science 232:316); by saturation mutagenesis (Meyers et al., (1986) Science 3); by PCR mutagenesis (Leung et al., (1989) Method Cell Mol Biol 1:11-19); or by random mutagenesis, including chemical mutagenesis, etc. r et al., (1992) A Short Course in Bacterial Genetics, CSHL Press, Cold Spring Harbor, N.Y.; and Greener et al., (1994) Strategies in Mol Biol 7:32-34). Linker scanning mutagenesis, particularly in a combinatorial setting, is an attractive method for identifying truncated (bioactive) forms of ActRIIB polypeptides.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations and truncations, and, for that matter, for screening cDNA libraries for gene products having a certain property. Such ques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of ActRIIB polypeptides. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting y of vectors, and sing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose t was detected. Preferred assays include activin binding assays and activin-mediated cell signaling assays.

In certain ments, ActRIIB ptides used in the methods and compositions described herein may further comprise post-translational ations in addition to any that are naturally present in the ActRIIB polypeptides. Such modifications include, but are not limited to, acetylation, ylation, glycosylation, phosphorylation, lipidation, and acylation. As a , the modified ActRIIB polypeptides may contain non-amino acid elements, such as polyethylene glycols, lipids, poly- or mono-saccharide, and phosphates. Effects of such nonamino acid elements on the functionality of a ActRIIB polypeptide may be tested by any method known to the skilled artisan. When an ActRIIB polypeptide is produced in cells by ng a nascent form of the ActRIIB polypeptide, post-translational sing may also be important for t folding and/or filnction of the protein. Different cells (such as CHO, HeLa, MDCK, 293, W138, NIH-3T3 or HEK293) have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the ActRIIB polypeptides.

In certain aspects, functional variants or modified forms of the B polypeptides include fusion proteins having at least a portion of the ActRIIB polypeptides and one or more fusion s. Well known examples of such fusion domains include, but are not limited to, stidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, an immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), or human serum albumin. A fusion domain may be ed so as to confer a desired property. For example, some fusion domains are particularly useful for isolation of the fusion proteins by affinity chromatography. For the purpose of affinity purification, relevant matrices for affinity chromatography, such as glutathione-, e-, and nickel- or cobalt-conjugated resins are used. Many of such matrices are available in "kit" form, such as the Pharmacia GST ation system and the QIAexpressTM system (Qiagen) useful with (HIS6) fusion partners. As another example, a fusion domain may be selected so as to facilitate detection of the ActRIIB polypeptides. Examples of such detection domains e the various fluorescent proteins (e.g., GFP) as well as "epitope tags," which are usually short peptide sequences for which a specific antibody is available. Well known epitope tags for which specific monoclonal antibodies are readily available e FLAG, influenza virus hemagglutinin (HA), and c-myc tags. In some cases, the fusion domains have a protease ge site, such as for Factor Xa or Thrombin, which allows the relevant protease to partially digest the fusion proteins and thereby liberate the inant proteins therefrom. The liberated proteins can then be isolated from the filSlOI‘l domain by subsequent chromatographic separation. In certain preferred embodiments, an ActRIIB polypeptide is fused with a domain that izes the ActRIIB ptide in Vivo (a "stabilizer" domain). By "stabilizing" is meant anything that increases serum half life, less of whether this is because of decreased destruction, decreased clearance by the kidney, or other pharmacokinetic effect. Fusions with the Fc portion of an immunoglobulin are known to confer desirable pharmacokinetic properties on a wide range of ns. Likewise, fusions to human serum albumin can confer ble properties. Other types of fusion domains that may be selected include multimerizing (e.g., dimerizing, tetramerizing) domains and filnctional domains (that confer an additional biological function, such as further stimulation of bone growth or muscle growth, as desired).

It is understood that different elements of the filSlOI‘l proteins may be arranged in any manner that is consistent with the desired functionality. For example, an ActRIIB polypeptide may be placed inal to a heterologous domain, or, alternatively, a heterologous domain may be placed C-terminal to an ActRIIB polypeptide. The ActRIIB polypeptide domain and the heterologous domain need not be adjacent in a fusion protein, and additional domains or amino acid sequences may be included C- or N—terminal to either domain or between the domains.

In certain embodiments, the ActRIIB polypeptides used in the methods and compositions described herein contain one or more modifications that are capable of stabilizing the ActRIIB polypeptides. For example, such modifications enhance the in Vitro half life of the B polypeptides, enhance circulatory half life of the ActRIIB polypeptides or reduce lytic degradation of the B ptides. Such stabilizing modifications e, but are not limited to, filSlOI‘l proteins (including, for example, fusion proteins comprising an ActRIIB polypeptide and a stabilizer domain), modifications of a glycosylation site (including, for e, addition of a glycosylation site to an ActRIIB ptide), and modifications of carbohydrate moiety ding, for example, removal of carbohydrate moieties from an ActRIIB polypeptide). In the case of fusion proteins, an ActRIIB polypeptide is fused to a stabilizer domain such as an IgG molecule (e. g., an Fc domain). As used , the term "stabilizer domain" not only refers to a fusion domain (e.g., PC) as in the case of fusion proteins, but also includes teinaceous modifications such as a carbohydrate moiety, or nonproteinaceous polymer, such as polyethylene glycol.

In certain embodiments, the methods and compositions bed herein use isolated or purified ActRIIB polypeptides, i.e., ActRIIB polypeptides which are isolated from, or otherwise ntially free of, other proteins can be used with the methods and itions described herein. ActRIIB ptides will generally be produced by expression from recombinant nucleic acids.

In certain aspects, the ActRIIB polypeptides used in the methods and compositions bed herein are encoded by isolated and/or recombinant nucleic acids, including nts, functional variants and fusion proteins sed herein. For example, SEQ ID NO: 19 encodes the naturally occurring human ActRIIB precursor polypeptide. The subject nucleic acids may be single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for e, in methods for making B polypeptides or as direct therapeutic agents (e. g., in a gene therapy approach).

In certain aspects, the nucleic acids that can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described herein are r understood to include nucleic acids that are variants of SEQ ID NO: 19 as well as variants of those nucleic acid sequences that encode soluble ActRIIB polypeptides (e. g., nucleic acids that encode SEQ ID NOs: l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43). Variant nucleotide sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants.

In certain ments, the isolated or recombinant c acid sequences that can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described herein are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e.g., nucleic acids that encode SEQ ID NOs: l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37,42, and 43).

One of ordinary skill in the art will appreciate that nucleic acid ces complementary to SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e. g., nucleic acids that encode SEQ ID NOs: l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37,42, and 43), and variants of SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e.g., nucleic acids that encode SEQ ID NOs: l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43) can be used with the methods and itions described herein. In further embodiments, the nucleic acid sequences can be ed, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids that can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described herein include nucleotide sequences that hybridize under highly stringent conditions to the nucleotide sequence ated in SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e.g., nucleic acids that encode SEQ ID NOs: 17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43), complement sequence of SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e.g., nucleic acids that encode SEQ ID NOs: 17, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43), or fragments thereof. One ofordinary skill in the art will understand that riate stringency conditions which promote DNA hybridization can be varied. For example, one can perform the hybridization at 6.0 times sodium chloride/sodium citrate (SSC) at about 45 degree Celsius, followed by a wash of 2.0 times SSC at 50 degree Celsius. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 times SSC at 50 degree s to a high ency of about 0.2 times SSC at 50 degree Celsius. In on, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 degree Celsius, to high stringency conditions at about 65 degree s. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, nucleic acids which hybridize under low ency conditions of 6 times SSC at room temperature followed by a wash at 2 times SSC at room temperature can be used with the methods and compositions bed herein.

] Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NO: 19 or those nucleic acid sequences that encode soluble ActRIIB polypeptides (e.g., nucleic acids that encode SEQ ID NOs: 17, 18,23,26,27,29, 30, 31, 32, 33, 36, 37,42, and 43) due to degeneracy in the genetic code can also be used to produce ActRIIB polypeptides le for use in the methods and compositions described herein. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" mutations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence rphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among ian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic ion. Any and all such tide variations and resulting amino acid polymorphisms can be used with the methods and compositions described herein.

In n embodiments, the recombinant nucleic acids that can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described herein may be operably linked to one or more regulatory nucleotide sequences in an sion construct.

Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and le regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and ation sequences, ational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible ers as known in the art can be used with the methods and compositions described herein. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain aspects, the nucleic acids that can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described herein are provided in an expression vector comprising a nucleotide sequence ng an B ptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the ActRIIB polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, and other sion control ts. Exemplary regulatory sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology, ic Press, San Diego, Calif. (1990). For ce, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding an ActRIIB polypeptide. Such useful expression l sequences, include, for example, the early and late promoters of SV40, tet er, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac , the trp system, the TAC or TRC , T7 promoter Whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., PhoS, the promoters of the yeast u-mating s, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such s as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the y to control that copy number and the expression of any other n encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of a recombinant ActRIIB polypeptide include plasmids and other vectors. For instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, derived ds and rived plasmids for expression in prokaryotic cells, such as E. coli.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, ka2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors le for transfection of eukaryotic cells. Some of these vectors are ed with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. atively, derivatives of viruses such as the bovine papilloma virus (BPV-l), or Epstein-Barr virus , pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy ry systems. The s methods employed in the preparation of the plasmids and in transformation of host organisms are well known in the art.

For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular g A Laboratory Manual, 3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 2001). In some instances, it may be desirable to express the recombinant polypeptides by the use of a baculovirus sion system. es of such baculovirus sion systems include pVL- derived vectors (such as pVLl392, pVLl393 and pVL94l), pAcUW-derived vectors (such as pAcUWl), and pBlueBac-derived vectors (such as the B-gal containing pBlueBac 111).

In one embodiment, a vector can be designed for production of the ActRIIB polypeptides used in the methods and compositions described herein in CHO cells, such as a cript vector (Stratagene, La Jolla, Calif), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and pCI-neo vectors (Promega, Madison, Wis). As will be apparent, the subject gene constructs can be used to cause expression of the t ActRIIB polypeptides in cells propagated in culture, e.g., to produce ns, including fusion proteins or variant proteins, for purification.

Host cells transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 19 or those c acid sequences that encode soluble ActRIIB polypeptides (e. g., nucleic acids that encode SEQ ID NOs: l7, 18, 23, 26, 27, 29, 30, 31, 32, 33, 36, 37, 42, and 43)) for one or more of the subject B polypeptides can be used to produce ActRIIB polypeptides suitable for use in the methods and compositions described . The host cell may be any prokaryotic or eukaryotic cell. For e, an ActRIIB ptide may be sed in bacterial cells such as E. coli, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, provided herein are methods of producing the ActRIIB polypeptides used in the methods and compositions described . For example, a host cell transfected with an expression vector encoding an ActRIIB polypeptide can be cultured under appropriate conditions to allow expression of the ActRIIB polypeptide to occur. The ActRIIB polypeptide may be secreted and isolated from a mixture of cells and medium containing the ActRIIB polypeptide. Alternatively, the ActRIIB polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein ed. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art.

The subject ActRIIB ptides can be isolated from cell culture medium, host cells, or both, using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, immunoaffinity purification with antibodies specific for particular epitopes of the ActRIIB polypeptides and affinity purification with an agent that binds to a domain fused to the ActRIIB ptide (e.g., a protein A column may be used to purify an ActRIIB-Fc filsion). In a preferred embodiment, the ActRIIB polypeptide is a fusion protein containing a domain which facilitates its purification.

In a preferred ment, ation is ed by a series of column chromatography steps, including, for example, three or more of the following, in any order: protein A chromatography, Q ose chromatography, phenylsepharose chromatography, size exclusion chromatography, and cation exchange chromatography. The purification could be completed with viral filtration and buffer exchange. As demonstrated herein, ActRIIB -hFc protein was purified to a purity of >98% as determined by size exclusion chromatography and >95% as determined by SDS PAGE.

This level of purity was sufficient to achieve desirable effects on bone in mice and an acceptable safety profile in mice, rats and non-human primates.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a His)/enterokinase cleavage site sequence at the N—terminus of the desired portion of the recombinant ActRIIB polypeptide, can allow ation of the expressed filsion protein by affinity chromatography using a Ni2+ metal resin. The purification leader sequence can then be uently removed by treatment with kinase to provide the purified ActRIIB polypeptide (e.g., see i et al., (1987) J. Chromatography 41 l : 177; and Janknecht et al., PNAS USA 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with tional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.

In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene nts can be carried out using anchor primers which give rise to complementary ngs between two consecutive gene fragments which can uently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons: 1992).

ActRIIB -Fc fusion protein can be expressed in stably transfected CHO-DUKX Bl 1 cells from a pAID4 vector (SV40 ori/enhancer, CMV promoter), using a tissue plasminogen leader sequence of SEQ ID NO:8. The Fc n can comprise a human IgGl Fc ce, as shown in SEQ ID NO:7. In certain embodiments, upon expression, the protein contained has, on average, between about 1.5 and 2.5 moles of sialic acid per molecule of ActRIIB-Fc fusion protein.

In certain embodiments, the long serum half-life of an ActRIIB-Fc fusion can be 25- 32 days in human ts. Additionally, the CH0 cell expressed al can have a higher affinity for activin B ligand than that reported for an ActRIIB-hFc fusion protein sed in human 293 cells (del Re et al., J Biol Chem. 2004 Dec l7;279(51):53l26-35). Additionally, without being bound by theory, the use of the TPA leader sequence provided greater production than other leader sequences and, unlike ActRIIB-Fc expressed with a native , may provide a highly pure N—terminal sequence. Use of the native leader sequence may result in two major species of ActRIIB-Fc, each having a different N—terminal sequence. (ii) Other ActRII Receptor Inhibitors In certain embodiments, the inhibitors of ActRII receptors used in the compositions and methods described herein are c acid compounds. es of categories of nucleic acid compounds that inhibit ActRII receptors include antisense nucleic acids, siRNA or RNAi constructs and tic c acid constructs.

A nucleic acid compound may be single- or double-stranded. A -stranded compound may also include regions of overhang or non-complementarity, where one or the other of the strands is single-stranded. A single-stranded compound may include s of self-complementarity, meaning that the compound may form a so-called "hairpin" or "stem-loop" structure, with a region of double helical structure.

In certain ments, the nucleic acid compounds that inhibit ActRII receptors may comprise a nucleotide sequence that is complementary to a region consisting of no more than 1000, no more than 500, no more than 250, no more than 100 or no more than 50, 35, 30, , 22, 20 or 18 nucleotides of the full-length ActRII receptor nucleic acid sequence or activin nucleic acid sequence (e.g., the nucleic acid sequence of an activin A or n B subunit, also referred to as BA or BB). In specific ments, the region of complementarity will be at least 8 nucleotides, and optionally at least 10 or at least 15 nucleotides, and optionally between 15 and nucleotides. A region of complementarity may fall within an intron, a coding sequence or a noncoding sequence of the target transcript, such as the coding sequence portion. Generally, a nucleic acid compound that inhibits an ActRII receptor will have a length of about 8 to about 500 nucleotides or base pairs in length, and optionally the length will be about 14 to about 50 nucleotides. A nucleic acid compound that inhibits an ActRII receptor may be a DNA (particularly for use as an antisense), an RNA, or an RNA:DNA hybrid. Any one strand may include a mixture ofDNA and RNA, as well as modified forms that cannot readily be classified as either DNA or RNA. Likewise, a double stranded nucleic acid compound may be DNA:DNA, DNA:RNA, or A, and any one strand may also include a mixture ofDNA and RNA, as well as modified forms that cannot readily be classified as either DNA or RNA.

The nucleic acid compounds that inhibit an ActRII receptor may include any of a variety of modifications, including one or modifications to the ne (the sugar-phosphate portion in a natural c acid, including cleotide linkages) or the base portion (the purine or dine portion of a natural nucleic acid). In certain embodiments, an antisense nucleic acid nd will have a length of about 15 to about 30 nucleotides and will often contain one or more modifications to improve certain characteristics, such as stability in the serum, stability in a cell, or stability in a place where the nd is likely to be delivered, such as, e.g., the stomach in the case of orally red nds and the lung for inhaled compounds. In the case of an RNAi construct, the strand complementary to the target transcript will generally be RNA or modifications thereof. The other strand may be RNA, DNA, or any other variation. The duplex portion of double stranded or single ed "hairpin" RNAi construct may, in certain embodiments, have a length of 18 to 40 nucleotides in length and optionally about 21 to 23 nucleotides in length, so long as it serves as a Dicer substrate.

Catalytic or enzymatic nucleic acids may be mes or DNA enzymes and may also contain modified forms. In certain embodiments, nucleic acid compounds that inhibit ActRII receptors may inhibit expression of their target by about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more under physiological conditions and at a concentration where a nonsense or sense control has little or no effect. Concentrations for testing the effect of nucleic acid compounds include 1, 5, 10 micromolar, or more.

In other embodiments, the inhibitors of ActRII receptors used in the compositions and s described herein are antibodies. Such antibodies include dies that bind to n (particularly the activin A or B subunits, also referred to as BA or BB) and disrupt ActRII receptor binding; and antibodies that bind to ActRII receptor polypeptides (e.g., a soluble ActRIIA or soluble ActRIIB ptide) and disrupt activin binding.

By using immunogens derived from an ActRII receptor polypeptide or an activin polypeptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (see, for e, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a r or rabbit can be immunized with an immunogenic form of the ActRII receptor polypeptide, an antigenic fragment which is e of eliciting an antibody response, or a fusion protein. Techniques for conferring immunogenicity on a protein or e e conjugation to carriers or other techniques well known in the art. An immunogenic portion of an ActRII receptor or activin polypeptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by ion of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization of an animal with an antigenic preparation of an ActRII receptor polypeptide, antisera can be obtained and, if desired, onal antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with alizing cells such as myeloma cells to yield hybridoma cells.

Such techniques are well known in the art, and include, for example, the hybridoma technique (originally developed by Kohler and in, (1975) Nature, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) logy Today, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with an ActRII receptor polypeptide and monoclonal antibodies isolated from a culture comprising such oma cells.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a subject polypeptide. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)2 nts can be generated by treating antibody with pepsin. The resulting F(ab)2 fragment can be treated to reduce disulfide bridges to produce Fab fragments. An antibody is filrther intended to include ific, single-chain, chimeric, humanized and fillly human molecules having affinity for an ActRII receptor or activin polypeptide conferred by at least one CDR region of the antibody. An antibody may r comprise a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent nd, enzyme or enzyme co-factor).

In n embodiments, the antibody is a recombinant antibody, which term encompasses any antibody generated in part by ques of molecular biology, including CDR- grafted or chimeric antibodies, human or other antibodies assembled from library-selected antibody domains, single chain antibodies and single domain antibodies (e.g., human VH proteins or camelid VHH proteins). In certain embodiments, an antibody can be a monoclonal antibody, and in certain embodiments. For example, a method for generating a monoclonal dy that binds specifically to an ActRII or polypeptide or activin polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the antigen polypeptide effective to stimulate a detectable immune response, obtaining antibodyproducing cells (e. g., cells from the spleen) from the mouse and fusing the antibody-producing cells with a cells to obtain antibody-producing hybridomas, and testing the antibody- producing hybridomas to identify a oma that produces a monoclonal antibody that binds specifically to the antigen. Once ed, a hybridoma can be propagated in a cell culture, optionally in culture conditions where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the antigen. The monoclonal antibody may be purified from the cell culture.

] The adjective "specifically reactive wit " as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective n the antigen of interest (e.g., an ActRII receptor polypeptide) and other antigens that are not of interest that the dy is useful for, at m, detecting the presence of the antigen of interest in a particular type of biological sample. In certain methods employing the antibody, such as therapeutic ations, a higher degree of specificity in binding may be desirable.

Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively n the desired antigens and cross-reacting polypeptides. One characteristic that influences the specificity of an dy:antigen interaction is the affinity of the antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, lly preferred dies will have an affinity (a dissociation constant) of about 10-6, 10-7, 10-8, 10-9 or less. Given the extraordinarily tight binding n activin and an ActRII receptor, it is expected that a lizing anti-activin or anti-ActRII receptor antibody would generally have a dissociation constant of 10-10 or less.

In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties of the antibody obtained. For example, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are ble for g interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, e plasmon resonance binding assays (e.g., the Biacore.TM. binding assay, Biacore AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN ational, Inc., Gaithersburg, Md.), n blots, immunoprecipitation assays, and immunohistochemistry.

In certain embodiments, ActRII receptor inhibitors to be used in the compositions and s described herein include alternative forms of activin, particularly those with alterations in the type I receptor binding domain can bind to type II receptors and fail to form an active ternary complex. In certain embodiments, nucleic acids, such as antisense molecules, siRNAs or ribozymes that inhibit activin A, B, C or E, or, particularly, ActRII receptor expression, can be used in the compositions and methods bed herein.

In other embodiments, the inhibitors of ActRII receptors used in the compositions and methods described herein are non-antibody proteins with ActRII receptor antagonist activity, including inhibin (i.e., inhibin alpha subunit), follistatin (e. g., follistatin-288 and tatin-315), Cerberus, follistatin related protein ("FSRP"), endoglin, activin C, alpha(2)-macroglobulin, and an M108A (methionine to alanine change at position 108) mutant activin A.

] In a specific embodiment, the ActRII receptor tor to be used in the compositions and methods described herein is a follistatin polypeptide that antagonizes activin bioactivity and/or binds to activin. The term "follistatin polypeptide" includes polypeptides comprising any naturally occurring polypeptide of follistatin as well as any variants thereof ding mutants, fragments, qulOI‘lS, and peptidomimetic forms) that retain a useful ty, and further includes any filnctional monomer or er of follistatin. Variants of follistatin polypeptides that retain activin binding properties can be identified based on previous studies involving follistatin and activin interactions. For example, W02008/030367, which is included by reference herein in its entirety, discloses specific follistatin domains ("FSDs") that are shown to be important for activin binding. Follistatin polypeptides include polypeptides derived from the sequence of any known follistatin having a ce at least about 80% identical to the sequence of a follistatin polypeptide, and optionally at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater identity.

Examples of follistatin ptides include the mature follistatin polypeptide or shorter isoforms or other variants of the human follistatin precursor polypeptide as described, for example, in W02005/025601, which is ed by reference herein in its entirety.

In a specific embodiment, the ActRII receptor inhibitor to be used in the compositions and methods described herein is a follistatin-like related gene (FLRG) that antagonizes activin bioactivity and/or binds to activin. The term "FLRG polypeptide" includes polypeptides comprising any naturally occurring polypeptide of FLRG as well as any variants thereof ding mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity.

Variants of FLRG polypeptides that retain activin binding ties can be identified using e methods to assay FLRG and activin interactions. See, for example, US. Pat. No. 6,537,966, which is included by reference herein in its entirety. FLRG polypeptides include polypeptides derived from the sequence of any known FLRG having a sequence at least about 80% identical to the sequence of an FLRG polypeptide, and ally at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater identity.

In n ments, functional variants or modified forms of the follistatin ptides and FLRG polypeptides include fusion ns having at least a portion of the follistatin polypeptides or FLRG polypeptides and one or more fusion domains, such as, for example, domains that facilitate isolation, detection, stabilization or multimerization of the polypeptide. Suitable fusion domains are discussed in detail above with reference to the ActRIIA and ActRIIB polypeptides. In one ment, an ActRII receptor tor is a fusion protein comprising an activin binding portion of a follistatin ptide filsed to an Fc domain.

In another embodiment, an ActRII receptor inhibitor is a fusion protein comprising an activin binding portion of an FLRG polypeptide fused to an Fc domain. .3 ASSAYS (a) DIAGNOSTIC ASSAYS (i) BONE ER Various ating markers of bone turnover can be used to diagnose bone disorders, such as low bone er. Circulating markers of bone turnover are markers of bone formation such as bone specific alkaline phosphatase (bAP), osteocalcin, lagen type I C-terminal propeptide (PICP) and insulin-like growth -1 ), some being markers of bone resorption such as pyridinoline, deoxypyridinoline, tartrate-resistant acid phosphatase , TRAP type 5b, pyridinoline, deoxypyridinoline and procollagen type I C-terminal ptide (ICTP), serum or urine collagen cross-links (N-telopeptide or C-telopeptide), and 25 hydroxyvitamin D. Assays to measure the entire parathyroid hormone (PTH) molecule can also be used. The skilled artisan is aware of imaging methods allowing the assessment of bone mineral density (BMD). See, e. g., Tilman B. Drueke and Sharon M. Moe, Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment, Nephrol Dial lant (2004) 19: 534—536; Okuno S, Inaba M., Biochemical markers of bone turnover. New aspect. Dialysis and bone metabolic marker, Clin Calcium. 2009 Aug;l9(8): 1084-91; Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, Cantor T, Malluche HH, The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients, Clin Nephrol. 2009 Jul;72(l):5-l4; Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G., Bone histomorphometry and mical markers of bone turnover in patients with chronic kidney disease Stages 3 — 5, Clin Nephrol. 2008 Oct;70(4):296- 305; Driieke TB., Is parathyroid e measurement useful for the diagnosis of renal bone disease?, Kidney Int. 2008 Mar;73(6):674-6; Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y., Utility of serum tartrate-resistant acid phosphatase Sb) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction., Clin Endocrinol (OXf). 2008 Aug;69(2):l89-96. Epub 2008 Jan 23. See also, Paul D. , Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease, 2009.

Another marker for monitoring bone tion in CKD patients with mild renal dysfunction is serum concentration of type I collagen N-telopeptide (S-NTX). See, e. g., Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, Okada N, Imai E, Horio M, Ito T., Serum NTX is a cal marker for assessing antiresorptive therapy for glucocorticoid treated patients with c kidney disease, Bone. 2006 Nov;39(5):1067-72. Epub 2006 Jun 16.

Quantitative computed tomography (QCT) can also be used to determine bone turnover. (ii) ADYNAMIC BONE DISORDER MODEL A mouse model for ic bone disease in a renal setting is to use a mouse nephrectomy model, such as the 5/6 nephrectomy model used in Sections 6.2 and 6.3, wherein the mice are fed a low phosphate diet.

In another mouse model, mice are subjected to electrocautery of one kidney and ctomy of the other kidney. The mice are fed low-phosphate chow supplemented with calcitriol. See, e.g., Lund et al., 2004, J Am Soc Nephrol 15:349-369. (iii) TETRACYCLINE LABELING OF BONE A diagnostic test that can be used to determine the type of bone disease associated with CKD is iliac crest bone biopsy with double tetracycline labeling and bone histomorphometric analysis. See, e.g., National Kidney Foundation: NKF KDOQI Guidelines. (iv) VASCULAR CALCIFICATION ] Non-contrast computed tomography (CT) for imaging the extent of coronary artery calcification (CAC) and contrast CT for noninvasive coronary angiography (CTA) are developments lly used to se obstructive coronary disease. Radionuclide stress testing, ry artery calcium scanning, and noninvasive coronary angiography for diagnostic and prognostic cardiac assessment can also be used. See: Berman DS, Shaw LJ, Hachamovitch R, Friedman JD, Polk DM, Hayes SW, Thomson LE, Germano G, Wong ND, Kang X, Rozanski A., Comparative use of radionuclide stress g, coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and stic c assessment, Semin Nucl Med. 2007 Jan;37(l):2-l6.

Coronary calcium screening results from asymptomatic patients can be used as a comparison. For example, calcium screening results obtained prior to the onset of kidney disease can be used as a comparison when vascular calcification is related to the kidney disease.

Possible methods of detecting and quantifying coronary artery calcification (CAC) include, but are not limited to, X-ray computed aphy and myocardial perfusion single photon emission computed aphy (SPECT). Moser KW, O'Keefe JH Jr, Bateman TM, McGhie 1A., Coronary calcium screening in asymptomatic ts as a guide to risk factor modification and stress myocardial perfusion imaging, J Nucl Cardiol. 2003 c;lO(6):590- 8. Multi-detector ed tomography (MDCT) also can be used to detect ar calcification (see, e.g., Burrill et al., 2007, Postgrad. Med. J. 83(985):698-704).

Another diagnostic method for vascular cation is fluorine 18 fiuorodeoxyglucose (FDG) uptake in the thoracic aortic wall at combined positron emission tomography (PET)/computed tomography (CT). See: i M, Cohade C, to Y, Wahl RL., Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis, ogy. 2003 Dec;229(3):83 l-7. Epub 2003 Oct 30.

In even another embodiment, ultrafast CT can be used to detect the presence of atherosclerotic coronary disease. See, e. g., Breen JF, Sheedy PF 2nd, Schwartz RS, Stanson AW, Kaufmann RB, Moll PP, Rumberger JA, Coronary artery calcification detected with ultrafast CT as an indication of coronary artery disease, Radiology. 1992 Nov;l85(2):435-9.

Electron-beam computed tomography scanning can also be used to diagnose coronary artery disease. See: Schmermund A, Baumgart D, Sack S, Mohlenkamp S, Gronemeyer D, Seibel R, Erbel R., ment of coronary calcification by electron-beam computed tomography in symptomatic patients with normal, abnormal or equivocal se stress test, Eur Heart J. 2000 Oct;2l(20): 1674-82.

Another test for vascular calcification regards the plaque composition in plexogenic and thromboembolic pulmonary hypertension. c thromboembolic pulmonary hypertension is associated with atherosclerotic plaques with glycophorin-rich pultaceous cores, and plexogenic ary hypertension with fibrous plaques. Thromboembolic material plays a critical role in the formation of pultaceous cores, of which erythrocyte membrane derived glycophorin is a major component. Thereby, chronic thromboembolic and plexogenic pulmonary hypertension (primary and secondary (Eisenmenger me)) are investigated.

See: Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, Vigano M, Tavazzi L, Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core ion, Heart. 2002 Aug;88(2): 177-82.

Agatston scoring, a calcium scoring system based on density measurements of deposited calcium plaques, can be used to quantify ar calcification. In this system, levels of ar calcification can be measured by detector computed tomography (MDCT) and attenuations in the rate of progression in the Agatston score can be assessed (see, e. g., Sharma et al., 2010, Vasc. Health Risk Manag. 6:603-611). r, vascular calcification can be assessed using the methods described in o et al., 2004, l. Dial. Transplant 19:1480-1488.

Another assay for use in quantifying vascular calcification in a subject is the lesion- specific calcium score, which comprises a method of calcium measurement that results from a CT test for coronary artery calcification. This method is described by, e. g., Akram and Voros, 2008, Int. J. cardiovac. Imaging -749. (v) KIDNEY DISEASE Glomerular filtration rate can be determined by any method known to the skilled artisan to determine kidney disease. See website of the National Kidney Foundation.

(Vi) SECONDARY PARATHYROIDISM ary hyperparathyroidism occurs when the parathyroid glands produce too much parathyroid hormone (PTH) because of too low calcium levels or increased phosphorus levels. Calcium, phosphorus, and PTH levels can be determined from blood samples. (vii) HYPERPHOSPHATEMIA Abnormally elevated levels of phosphate in the blood can be determined by any method known to the d artisan. (b) Screening Assays s ActRII polypeptide variants, or soluble ActRII polypeptide ts, may be tested for their ability to inhibit ActRII. In addition, compounds can be tested for their ability to inhibit ActRII. Once inhibitors of ActRII activity are confirmed, these compounds can be used with the methods provided herein. ActRII can be ActRIIA or ActRIIB. The assays below are described for ActRIIA but can be performed analogously for ActRIIB.

For example, the effect of an ActRIIA polypeptide variant on the expression of genes involved in bone production or bone destruction may be assessed. This may, as needed, be performed in the presence of one or more recombinant ActRIIA ligand ns (e.g., activin), and cells may be transfected so as to produce an ActRIIA polypeptide and/or variants thereof, and optionally, an ActRIIA ligand. Likewise, an ActRIIA polypeptide may be administered to a mouse or other animal, and one or more bone properties, such as density or volume may be assessed. The g rate for bone fractures may also be evaluated. nergy x-ray absorptiometry (DEXA) is a well-established, vasive, quantitative technique for assessing bone y in an . In humans central DEXA systems may be used to evaluate bone density in the spine and pelvis. These are the best predictors of overall bone density. eral DEXA systems may be used to evaluate bone y in peripheral bones, including, for example, the bones of the hand, wrist, ankle and foot. Traditional x-ray imaging systems, including CAT scans, may be used to evaluate bone growth and fracture healing. In addition, bone density can be measured using quantitative computed tomography (qCT). The mechanical strength of bone may also be evaluated.

In certain s, provided herein is the use of ActRIIA polypeptides (e.g., soluble A polypeptides) and activin polypeptides to identify compounds (agents) which are agonist or antagonists of the activin-ActRIIA signaling pathway. Compounds identified through this screening can be tested to assess their ability to modulate bone growth or mineralization in vitro. Optionally, these compounds can further be tested in animal models to assess their ability to modulate tissue growth in vivo.

There are numerous approaches to screening for therapeutic agents for modulating tissue growth by targeting activin and ActRIIA polypeptides. In certain embodiments, high- throughput screening of compounds can be carried out to identify agents that perturb activin or ActRIIA-mediated effects on bone. In certain embodiments, the assay is carried out to screen and identify nds that specifically inhibit or reduce binding of an A polypeptide to activin. Alternatively, the assay can be used to identify compounds that enhance binding of an ActRIIA polypeptide to n. In a further embodiment, the compounds can be identified by their ability to interact with an activin or ActRIIA polypeptide.

A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described herein will nevertheless be comprehended by one of ordinary skill in the art. As described herein, the test compounds (agents) used herein may be created by any atorial chemical method. Alternatively, the subject compounds may be naturally occurring biomolecules synthesized in vivo or in Vitro. Compounds (agents) to be tested for their ability to act as tors of tissue growth can be produced, for example, by bacteria, yeast, plants or other organisms (e.g., natural products), ed chemically (e.g., small les, including peptidomimetics), or produced recombinantly. Test compounds contemplated herein include non-peptidyl organic molecules, peptides, ptides, peptidomimetics, sugars, hormones, and nucleic acid molecules. In a specific embodiment, the test agent is a small organic molecule haVing a molecular weight of less than about 2,000 s.

The test compounds can be provided as single, discrete entities, or provided in libraries of greater complexity, such as made by combinatorial chemistry. These libraries can comprise, for example, alcohols, alkyl halides, amines, amides, esters, des, ethers and other classes of organic nds. Presentation of test nds to the test system can be in either an isolated form or as mixtures of compounds, especially in initial screening steps.

Optionally, the compounds may be derivatized with other compounds and have derivatizing groups that facilitate isolation of the compounds. Non-limiting examples of derivatizing groups include biotin, fluorescein, digoxygenin, green fluorescent protein, isotopes, polyhistidine, magnetic beads, glutathione S transferase (GST), photoactivatible crosslinkers or any combinations thereof.

In many drug screening programs which test ies of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of nds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or urified proteins, are often red as "primary" screens in that they can be generated to permit rapid development and relatively easy ion of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity or bioavailability of the test compound can be generally ignored in the in Vitro system, the assay d being focused primarily on the effect of the drug on the molecular target as may be st in an alteration of g affinity between an ActRIIA polypeptide and actiVin.

Merely to illustrate, in an exemplary screening assay, the nd of interest is contacted with an isolated and purified A polypeptide which is ordinarily capable of binding to activin. To the mixture of the compound and ActRIIA polypeptide is then added a composition containing an ActRIIA ligand. ion and fication of ActRIIA/activin complexes provides a means for determining the compounds efficacy at inhibiting (or potentiating) complex formation between the ActRIIA polypeptide and activin. The efficacy of the nd can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. For example, in a control assay, isolated and d activin is added to a composition containing the ActRIIA polypeptide, and the formation of ActRIIA/activin complex is quantitated in the absence of the test compound. It will be understood that, in general, the order in which the reactants may be admixed can be varied, and can be admixed simultaneously. Moreover, in place of d proteins, cellular extracts and lysates may be used to render a suitable ree assay system.

Complex formation between the ActRIIA polypeptide and n may be detected by a variety of techniques. For instance, modulation of the formation of complexes can be quantitated using, for example, detectably labeled proteins such as radiolabeled (e.g., 32P, 358, 14C or 3H), cently labeled (e. g., FITC), or enzymatically labeled ActRIIA polypeptide or activin, by immunoassay, or by chromatographic detection.

In certain embodiments, plated herein is the use of fluorescence polarization assays and fluorescence resonance energy transfer (FRET) assays in measuring, either directly or indirectly, the degree of interaction between an ActRIIA polypeptide and its binding protein.

Further, other modes of detection, such as those based on optical waveguides (PCT Publication WO 96/26432 and US. Pat. No. 5,677,196), surface plasmon resonance (SPR), surface charge s, and surface force sensors, are compatible with many embodiments described herein. er, an interaction trap assay, also known as the "two hybrid assay," can be used for identifying agents that disrupt or iate interaction between an ActRIIA polypeptide and its binding protein. See for example, US. Pat. No. 5,283,317; Zervos et al. (1993) Cell -232; Madura et al. (1993) J Biol Chem 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; and Iwabuchi et al. (1993) Oncogene 8: 1693-1696). In a specific ment, contemplated herein is the use of reverse two hybrid systems to identify compounds (e.g., small molecules or peptides) that dissociate ctions between an ActRIIA ptide and its binding protein. See for example, Vidal and Legrain, (l 999) Nucleic Acids Res 27:919-29; Vidal and Legrain, (1999) Trends Biotechnol -81; and US. Pat. Nos. ,525,490; 5,955,280; and 5,965,368.

In certain embodiments, the subject compounds are identified by their ability to interact with an ActRIIA or activin ptide. The interaction between the compound and the ActRIIA or activin polypeptide may be covalent or non-covalent. For e, such interaction can be identified at the protein level using in vitro biochemical methods, including photo- crosslinking, radiolabeled ligand binding, and y chromatography (Jakoby W B et al., 1974, Methods in Enzymology 46: 1). In certain cases, the compounds may be screened in a mechanism based assay, such as an assay to detect compounds which bind to an activin or ActRIIA polypeptide. This may include a solid phase or fluid phase binding event.

Alternatively, the gene encoding an activin or ActRIIA polypeptide can be transfected with a reporter system (e.g., B-galactosidase, luciferase, or green fluorescent protein) into a cell and screened t the library preferably by a high throughput screening or with individual members of the library. Other mechanism based binding assays may be used, for example, binding assays which detect changes in free energy. Binding assays can be performed with the target fixed to a well, bead or chip or ed by an immobilized antibody or resolved by capillary electrophoresis. The bound compounds may be detected usually using colorimetric or fluorescence or e plasmon resonance.

In certain aspects, provided herein are methods and agents for ting (stimulating or inhibiting) bone formation and sing bone mass. Therefore, any compound identified can be tested in whole cells or tissues, in vitro or in vivo, to confirm their ability to te bone growth or mineralization. Various s known in the art can be utilized for this purpose. In particular, the compounds can be tested for their ability to increase bone turnover.

For example, the effect of the ActRIIA or activin polypeptides or test compounds on bone or cartilage growth can be determined by measuring induction of Msx2 or differentiation of osteoprogenitor cells into osteoblasts in cell based assays (see, e. g., Daluiski et al., Nat Genet. 2001, 27(1):84-8; Hino et al., Front Biosci. 2004, 9: 1520-9). Another example of cell-based assays includes analyzing the osteogenic activity of the subject ActRIIA or activin polypeptides and test compounds in hymal progenitor and osteoblastic cells. To illustrate, recombinant adenoviruses expressing an activin or ActRIIA polypeptide can be constructed to infect pluripotent mesenchymal progenitor C3H10Tl/2 cells, preosteoblastic C2Cl2 cells, and osteoblastic TE-85 cells. Osteogenic activity is then determined by measuring the induction of alkaline phosphatase, osteocalcin, and matrix mineralization (see, e.g., Cheng et al., J bone Joint Surg Am. 2003, 85-A(8): 1544-52).

Also provided herein are in viva assays to measure bone or cartilage growth. For example, Namkung-Matthai et al., Bone, 28:80-86 (2001) discloses a rat orotic model in which bone repair during the early period after fracture is studied. Kubo et al., Steroid Biochemistry & Molecular Biology, 68: 197-202 (1999) also discloses a rat osteoporotic model in which bone repair during the late period after fracture is studied. Andersson et al., J. Endocrinol. 170:529-537 describe a mouse osteoporosis model in which mice are ovariectomized, which causes the mice to lose ntial bone mineral content and bone l density, with the trabecular bone losing roughly 50% of bone mineral density. Bone density could be increased in the ovariectomized mice by administration of factors such as parathyroid hormone. In certain aspects, re healing assays that are known in the art can be used. These assays include fracture technique, histological analysis, and biomechanical analysis, which are described in, for e, US. Pat. No. 750, which is incorporated by reference in its entirety for its disclosure of experimental protocols for causing as well as measuring the extent of fractures, and the repair process. .4 DOSE ] Provided herein are methods for the treatment of D and / or low turnover bone e, wherein the methods comprise administering to a patient in need of treatment a therapeutically effective amount of an inhibitor of ActRII (see Section 5.2). In n embodiments, an ActRII inhibitor is an inhibitor of ActRIIA as set forth in Section 5.2(a). In other embodiments, an ActRII tor is an inhibitor of ActRIIB as set forth in Section 5.2(b).

In certain embodiments, an ActRII inhibitor is a combination of an ActRIIA inhibitor and an ActRIIB inhibitor.

In certain embodiments, a therapeutically effective amount of an ActRII inhibitor is sufficient to ameliorate one symptom of CKD-MBD. In certain embodiments, a therapeutically ive amount of an ActRII inhibitor is ent to prevent at least one symptom of CKD- MBD from worsening.

In certain embodiments, a therapeutically effective amount of an ActRII inhibitor improves or stabilizes kidney on. Kidney function can be measured by glomerular filtration rate. See, e. g., Section 5.4(a)(iv). In certain embodiments, a therapeutically effective amount of an ActRII inhibitor is a daily dose that is sufficient to stabilize the glomerular filtration rate of a CKD-MBD patient for the duration of treatment with ActRII inhibitor and for at least 3 months, 6 months, 9 months, or 12 months. In certain embodiments, a therapeutically effective amount of an ActRIIA inhibitor is a daily dose that is ent to increase the glomerular filtration rate by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or at least 50%.

In certain embodiments, a therapeutically effective amount of an ActRII inhibitor increases the red blood cell level and / or hemoglobin levels in the t.

] In certain embodiments, a therapeutically effective amount of an ActRII inhibitor is effective to (a) increase red blood cell and / or obin levels in the patient; (b) improvement in bone quality and / or bone mineral density in the patient; and (c) e kidney filnction in the t.

] In certain embodiments, a therapeutically effective amount of an ActRII inhibitor is ive to (a) increase red blood cell and / or hemoglobin levels in the patient; (b) increase the bone turnover in the patient; and (c) e kidney function in the patient.

In certain embodiments, the ActRII inhibitor is dosed at intervals and amounts sufficient to achieve serum concentrations of 0.2 microgram/kg or greater, and serum levels of 1 microgram/kg or 2 microgram/kg or greater are desirable for achieving significant effects on bone density and strength. Dosing regimens may be designed to reach serum concentrations of between 0.2 and 15 microgram/kg, and optionally between 1 and 5 microgram/kg. In humans, serum levels of 0.2 microgram/kg may be achieved with a single dose of 0.1 mg/kg or greater and serum levels of 1 microgram/kg may be achieved with a single dose of 0.3 mg/kg or greater.

The observed serum half-life of the le is between about 20 and 30 days, substantially longer than most Fc fusion proteins, and thus a sustained effective serum level may be achieved, for example, by dosing with 0.2-0.4 mg/kg on a weekly or biweekly basis, or higher doses may be used with longer intervals between s. For example, doses of 1-3 mg/kg might be used on a monthly or bimonthly basis, and the effect on bone may be sufficiently durable that dosing is necessary only once every 3, 4, 5, 6, 9, 12 or more months. .5 PHARMACEUTICAL COMPOSITIONS In certain embodiments, activin-ActRII antagonists (e.g., ActRII polypeptides) are formulated with a pharmaceutically able carrier for use with the methods described herein.

For example, an ActRII ptide can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human or nary medicine.

ActRII can be ActRIIA or ActRHB.

In certain embodiments, the eutic methods described herein include administering the composition systemically, or locally as an implant or . When administered, the eutic compositions used herein can be in a pyrogen-free, physiologically acceptable form. Therapeutically useful agents other than the ActRIIA antagonists which may also optionally be included in the composition as described above, may be administered simultaneously or sequentially with the subject compounds (e.g., ActRH polypeptides, such as ActRIIA and / or ActRHB ptides (see Section 5.2)).

Typically, ActRIIA antagonists will be stered parenterally. ceutical itions suitable for parenteral administration may se one or more ActRII polypeptides in ation with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile inj ectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or ning agents. Examples of suitable aqueous and eous carriers which may be employed in the pharmaceutical compositions used in the methods described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

Further, the composition may be encapsulated or injected in a form for delivery to a target tissue site (e. g., bone). In certain embodiments, compositions used in the methods described herein may include a matrix capable of delivering one or more therapeutic nds (e. g., ActRIIA polypeptides) to a target tissue site (e.g., bone), providing a structure for the developing tissue and optimally capable of being resorbed into the body. For example, the matrix may provide slow release of the ActRIIA polypeptides. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix al is based on biocompatibility, biodegradability, mechanical ties, cosmetic appearance and interface properties. The particular application of the subject compositions will define the appropriate formulation. ial matrices for the compositions may be biodegradable and chemically defined m sulfate, tricalciumphosphate, hydroxyapatite, ctic acid and polyanhydrides. Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen.

Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are non-biodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and ciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

] In certain embodiments, the compositions used in the methods described herein can be stered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an s or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each ning a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

In solid dosage forms for oral stration (capsules, s, pills, dragees, powders, es, and the like), one or more therapeutic nds used in the methods described herein may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, e, mannitol, and/or silicic acid; (2) binders, such as, for example, ymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) egrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution ing agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) g agents, such as, for example, cetyl alcohol and glycerol earate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid hylene glycols, sodium lauryl sulfate, and mixtures f; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid itions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

Liquid dosage forms for oral administration include pharmaceutically acceptable ons, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl ate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- ne glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, , and sesame oils), glycerol, tetrahydrofuryl l, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

Suspensions, in addition to the active compounds, may n suspending agents such as lated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, rystalline cellulose, aluminum metahydroxide, bentonite, gar and tragacanth, and mixtures thereof.

The compositions used in the methods described herein may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal , for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to e isotonic agents, such as , sodium chloride, and the like into the compositions. In addition, prolonged absorption of the inj ectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

It is understood that the dosage regimen will be determined by the attending physician considering various factors which modify the action of the t nds used in the methods described herein (e.g., ActRII polypeptides, such as ActRIIA and / or ActRIIB polypeptides (see Section 5.2)). The various factors include, but are not limited to, amount of bone weight desired to be formed, the degree of bone density loss, the site of bone damage, the condition of the damaged bone, the t's age, sex, and diet, the severity of any disease that may be contributing to bone loss, time of administration, and other clinical s. Optionally, the dosage may vary with the type of matrix used in the reconstitution and the types of compounds in the composition. The addition of other known growth factors to the final composition, may also affect the dosage. Progress can be monitored by ic assessment of bone growth and/or repair, for e, X-rays (including DEXA), histomorphometric determinations, and tetracycline labeling.

In certain embodiments, the methods described herein se gene therapy for the in vivo tion of ActRII polypeptides. Such therapy would achieve its therapeutic effect by introduction of the ActRII polynucleotide sequences into cells or tissues having the disorders as listed above. ry of ActRII polynucleotide sequences can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Preferred for therapeutic delivery of ActRII cleotide sequences is the use of targeted liposomes. The ActRII polypeptides can be ActRIIA and / or ActRIIB polypeptides (see Section 5.2)). s viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of iral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by ing, for example, a sugar, a glycolipid, or a protein. red targeting is accomplished by using an antibody. Those of skill in the art will recognize that specific polynucleotide sequences can be ed into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the ActRIIA polynucleotide. In a preferred embodiment, the vector is targeted to bone or cartilage.

Alternatively, tissue culture cells can be ly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium ate transfection.

These cells are then transfected with the vector plasmid containing the genes of st. The resulting cells e the retroviral vector into the e medium.

Another targeted delivery system for ActRIIA polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed es, and liposomes. One colloidal system that can be used is a liposome.

Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a ically active form (see e. g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mannino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome tion include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Illustrative olipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and lle-specificity and is known in the art.

In certain embodiments, the ActRIIA inhibitor is substantially pure in a pharmaceutical ition. Specifically, at most 20%, 10%, 5%, 2.5%, 1%, 0.1%, or at most 0.05% of the compounds in the pharmaceutical ition are compounds other than the ActRII inhibitor and the pharmaceutical acceptable carrier. 6. EXAMPLES 6.1 Example 1 (a) ActRIIA-Fc Fusion Proteins A soluble ActRIIA fusion protein that has the extracellular domain of human ActRIIA fiJsed to a human or mouse Fc domain with a minimal linker is described. The constructs are referred to as ActRIIA-hFc and mActRIIA-Fc, respectively. ActRIIA-hFc is provided as SEQ ID NO:7. mActRIIA-Fc is the murine counterpart to SEQ ID NO:7.

The ActRIIA-hFc and mActRIIA-Fc proteins were expressed in CHO cell lines.

Three ent leader sequences were considered: (i) Honey bee mellitin (HBML): SEQ ID NO: 8 (ii) Tissue Plasminogen Activator (TPA): SEQ ID NO: 9 (iii) Native ActRIIA: SEQ ID NO: 10 The selected form s the TPA leader and has the following unprocessed amino acid sequence is set forth in SEQ ID NO: 13. This polypeptide is encoded by SEQ ID NO: 14. (b) ActRIIB-Fc Fusion Proteins Co-crystal structure of an extracellular domain of human ActRIIB fiJsed to a human Fc domain and Activin did not show any role for the final (C-terminal) 15 amino acids (referred to as the "tail" herein) of the extracellular domain in ligand binding. This sequence failed to e on the crystal structure, suggesting that these residues are present in a flexible loop that did not pack mly in the crystal. Thompson et al. EMBO J. 2003 Apr 1 :1555-66.

This ce is also poorly conserved between ActRIIB and ActRIIA. Accordingly, these es were omitted in the basic, or ound, ActRIIB-Fc fusion construct. Additionally, position 64 in the background form is occupied by an alanine, which is generally considered the "wild type" form, although a A64R allele occurs naturally. Thus, the background ActRIIB-Fc fusion has the sequence disclosed as SEQ ID NO:21. singly, the C-terminal tail was found to e n and GDF-ll binding, thus a preferred version of ActRIIB-Fc has a sequence SEQ ID NO:20.

A variety of ActRIIB a variants that may be used according to the methods described herein are described in the International Patent Application published as W02006/012627 (see e.g., pp. 59-60), incorporated herein by reference in its entirety. 6.2 EFFECTS OF mACTRIIA INHIBITION IN A MOUSE MODEL OF C KIDNEY DISEASE This study was designed to study the effects of soluble mouse ActRIIA fused with mouse PC via a minimal linker (SEQ ID NO: 15) on treatment of blood and bone parameters in a mouse model of chronic kidney e and D.

Patients with chronic kidney disease (CKD) can become anemic and also become osteopenic. Mice with partial renal ablation (5/6 nephrectomy) were used as a model of CKD to test the effects of the polypeptide with the amino acid sequence of SEQ ID NO: 15 in this model.

Mice received two surgeries to 1) remove one kidney completely and 2) to ligate 2 of the 3 renal arteries in the ing kidney. Sham operated mice were also included as controls. The sham or 5/6 nephrectomy surgeries were performed at Jackson Laboratories.

After mice were ed they were placed on high fat diet for the duration of the study. Two weeks after the final surgery mice were divided into groups (both SHAM and CKD) and began dosing with vehicle (PBS) or mActRIIA-Fc at 10 mg/kg twice per week for 8 weeks.

Complete blood counts (CBC) were taken periodically during the study to assess for anemia.

Bone mineral y was determined using dual energy X-ray absorptiometry (DEXA, PIXIMus). At the sion of the study necropsies were conducted to collect the long bones of the hind limbs and major organs. The remnant kidney was sent for histology processing and staining with H&E or Trichrome stain. Femurs were scanned by uCT (Scanco) to determine bone microarchitecture.

Mice appeared normal and healthy throughout the study period and put on weight as the study ssed (Figure 1). Bone mineral density increased in all four groups of mice, but mActRIIA-Fc treated mice (SHAM and CKD) had greater increases than either vehicle treated group (Figure 2). mActRIIA-Fc treatment in CKD mice had bone mineral densities that d or exceeded SHAM-VEH treated mice by the end of the study. CKD mice also became anemic by the end of the study (HCT < 40%), but mActRIIA-Fc treatment prevented anemia in the CKD group (HCT > 40%; Figure 3). mActRIIA-Fc treated mice in the SHAM group also showed increases in HCT when compared to VEH controls. Micro CT is of femurs after dissection showed increases in trabecular bone in the mActRIIA-Fc treated mice, but there were no major differences between the SHAM and CKD vehicle treated groups at this time in the disease ssion. At necropsy, no major differences in organ weights were observed, although mActRIIA-Fc treated mice had a slight increase in fat pad weights. Trichrome stained histological sections of the remnant kidney did not indicate widespread fibrosis at this point in the study in the CKD mice. 6.3 mACTRIIA INHIBITION PREVENTS ANEMIA AND BONE LOSS IN A THERAPEUTIC MODEL OF ESTABLISHED KIDNEY E The 5/6 nephrectomy surgery in rodents is a commonly performed mental protocol used to model chronic kidney disease. In this two-phase surgery 2/3 of one kidney and the complete kidney on the contralateral side are removed using aseptic surgical procedures. As a result of the y the animal experiences impaired kidney fianction and exhibits physiologic behavior analogous to humans with chronic kidney disease.

Sham or 5/6 nephrectomy surgery was performed at Jackson Laboratories ing to rd ing procedures. Animals were allowed to recover from surgery and then shipped. Animals were acclimated to laboratory conditions for a minimum of 48 hours prior to the first measurements being made. During this period all s were observed for any signs of clinical abnormalities that would exclude them from study. Animals were assigned a study number on their cage cards and uniquely identified by ear ng.

ActRIIA-mIgGZaFc was diluted using Sterile PBS to a concentration of 2.0 mg/ml.

The dosing concentration: was 2.0 mg/ml. ActRIIA-mIgGZaFc was stored at -65°C :: 15°C, material may be thawed at room temperature, or overnight at 4°C. Thawed protein was kept on wet ice until use.

Thirty C57BL/6 female mice (10 weeks old) underwent a 5/6 nephrectomy surgery in which one kidney is completely removed followed by ligation of 2 of 3 renal veins d in the remaining kidney two weeks later. Sham surgeries were also med on thirty 6 females in which the animals are subject to the same abdominal surgical procedure without removal of the kidneys. After ry from the second surgery s were shipped and allowed to acclimate to laboratory conditions for a minimum of 48 hours. Two months after the second surgery mice were randomly assigned to one of four treatment groups with 15 mice per group (Table 2). Mice were weighed and dosed with either mActRIIA-Fc or PBS twice per week for a total of 8 weeks. udinal measurements of bone mineral density (BMD) and hematological parameters were made at baseline, an interim time point and at the conclusion of the study. At necropsy bones were collected and stored for histological examination or for analysis by microCT scanning.

Table2 Rout 1 15 C57BL/6 Chow PBS Sham volume 8.0. 2 15 C57BL/6 Chow mAcliEHA' Sham 10 mg/kg 8.0. 3 15 C57BL/6 Chow PBS volume 8.0.

Nephr. mActRIIA- 5/6 4 15 C57BL/6 Chow 10 mg/kg 8.0.

FC Nephr_ (a) EXPERIMENTAL PROCEDURES (i) Surgical modification Female C57BL/6 mice aged 10 weeks were given a two-stage surgery to accomplish a hrectomy or the equivalent sham y. (ii) Animal Dosing Dosing in the current study commenced one month after the completion of the 5/6 ctomy surgery. Mice were weighed and stered either PBS or mActRIIA-Fc at 10 mg/kg twice per week by subcutaneous injection. (iii) DXA scanning Longitudinal measurements of BMD were made monthly on anesthetized mice using DXA scanning (Lunar PIXIMus, GE Medical Systems). During DXA scan analysis ofBMD the mouse head was eliminated from the region of interest prevent quantification artifacts associated with the skull. (iv) Blood collection udinal measurements of complete blood counts (HM2, VetScan) were made on blood collected by monthly submandibular ng. At the termination of the study a terminal bleed was performed, blood was collected and divided into either an EDTA containing tube for CBC analysis or into a serum separation tube for serum collection. Serum was frozen at -80° for future analyses. (v) Serum Analyses Frozen serum was defrosted and 100 microliter were analyzed using a Vetscan V82 analyzer (Abaxis, Inc.). A comprehensive stic rotor was used to analyzes the samples for serum albumin (ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), total bilirubin (TBIL), blood urea nitrogen (BUN), total calcium (Ca++), Phosphorus (PHOS), creatinine (CRE), glucose (GLU), sodium (NA+), potassium (K+), total protein (TP) and in (GLOB). (vi) Necropsy At the conclusion of the study mice were euthanized by C02 inhalation. The kidneys and spleens were removed, weighed and stored in 10% formalin. The tibiae and femurs were ted and stored in 70% ethanol. (vii) microCT analysis At the termination of the experiment the left femur and tibia from each mouse were dissected and fixed in 70% ethanol. Bones were scanned using a Scanco microCT T75, Scanco) at 55 kV, 145 microA and a voxel size of 20 microm. Scanned images were reconstructed using the incorporated Scanco software. Trabecular bone volume (BV/TV) and trabecular thickness (Tb.Th) were ed in a 400 microm section of bone which was positioned 200 microm from the distal tip of the femur. Cortical ess was measured in a 200 microm section of bone centered at the ne of the femur. (viii) DATA IS Comparisons between IA-Fc and vehicle treated mice and tissues were performed by Student’s t-Test using Microsoft Excel. Data are expressed as mean :: SEM. (b) Results We investigated the ability of mActRllA-Fc to prevent anemia and bone loss in a mouse model of chronic kidney disease. After 2 months of disease progression following the 5/6 nephrectomy surgery (Day 0), 5/6 nephrectomized mice (CKD) exhibited a significant decrease in hematocrit compared to the sham cohorts (-5.4%, P<0.01). Longitudinal blood sampling and subsequent CBC analysis showed that mActRllA-Fc treated mice in both the CKD and sham cohorts displayed significant increases in hematocrit compared to their VEH d counterparts after 4 and 8 weeks of treatment (Figure 5).

] After 2 months of e progression following the 5/6 nephrectomy surgery (Day 0), 5/6 ctomized mice (CKD) ted a significant decrease in BMD compared to the sham cohorts (-5.4%, P<0.01). Through 6 weeks of treatment the mActRllA-Fc treated sham and CKD cohorts had significantly r BMD compared to their VEH treated counterparts (Figure At the sion of the study the hind limbs were collected and fixed in 70% ethanol. The right femur was microCT scanned (VivaCT 75, Scanco) to quantify cortical and ular bone structure. Figure 7 shows cross-sectional images of femurs from each treatment group. Nephrectomized mice exhibited decreased cortical thickness and no s changes to trabecular bone structure. mActRllA-Fc treated mice exhibited increases in both cortical thickness and trabecular bone volume. Analyses of the femur aft were used to quantify the mean cortical thickness in each cohort (Figure 8). The CKD mice had thinner cortical bones than their sham counterparts in both the VEH (P<0.0l) and mActRllA-Fc (P<0.0l) cohorts. mActRllA-Fc treated mice had a significant increase in cortical thickness in both the sham (+17%, P<0.0l) and CKD (+19.2%, P<0.01) cohorts compared to their tive VEH-treated mice. As evidenced by the sample images in Figure 7, analyses of the distal femur revealed dramatic increases in trabecular bone volume and thickness in mActRllA-Fc treated mice. mActRllA-Fc was able to significantly increase trabecular bone volume (Figure 9) and trabecular thickness (Figure 10) over VEH treated mice in both the sham and CKD cohorts. Measurements of ular bone volume demonstrated at week 8 that mActRllA-Fc treated mice had a cant increase in trabecular bone volume in both the sham (+549%, P<0.001) and CKD (+827%, P<0.001) cohorts compared to their respective eated mice. Measurements of trabecular thickness demonstrated at week 8 that mActRIIA-Fc treated mice had a significant increase in trabecular thickness in the CKD (+62%, P<0.001) cohorts compared to their respective VEH-treated mice.

At terminal ce whole blood was taken from all animals and processed for serum. Serum samples were analyzed using a Vetscan VSZ analyzer s, Inc) using a comprehensive profile rotor. Mean values for the analyates from each group are shown in Table 3. Comparison of the SHAM and CKD vehicle control groups showed increases in blood urea en (BUN) and creatinine (CRE) as expected due to impaired renal filnction. Additionally the ALT and amylase (AMY) were increased in CKD mice due to altered kidney filnction or suggestive of the nephrectomy also altering liver function. Calcium (CA++) and total ne phosphates (ALP) levels also increased as expected due to increased bone turnover. mActRIIA- Fc ent increased ALP levels in both the SHAM and CKD mice due to the bone anabolic properties of the drug. In CKD mice mActRIIA-Fc treatment decreased albumin (ALB), total protein (TP) and CRE levels compared to H controls, but were not different than SHAM mice. These changes are not thought to be relevant to the model or the ent at this point.

Table 3 3‘71;th :13:leIA CKD VEH gfigtRlIA -Fc -Fc 865.45 1 803.38 1 1486.18 1 1418.42 1 39.41 66.06 53.82 36.68 AMY UlL 0.25 1 0.23 1 0.23 1 0.27 1 0.02 0.02 0.01 0.010 TBIL mgldL 27.92 1 29.20 1 52.75 1 51.50 1 1.39 1.26 2.66 2.10 BUN mgldL .181 10.381 11.00 11.331 0.16 0.12 1.13 0.13 CA" mgldL 8.58 1 8.96 1 8.28 1 7.96 1 0.17 0.28 0.36 0.26 PHOS mgldL 0.33 1 0.40 1 0.44 1 0.31 1 0.05 0.05 0.05 0.020 CRE mgldL 198.50 1 260.90 1 223.67 1 260.86 1 6.52 28.79* 13.53 14.98 GLU mgldL 156.50 1 157.60 1 158.58 1 155.64 1 0.77 0.73 2.37 0.34 NA+ mmollL 7651 7851 7981 7771 0.14 0.15 0.14 0.13 K+ mmollL .66 i 5.42 i 5.73 i 5.47 1 0.05 0.057 0.08 0.07u TP gldL 1.79 i 1.67 i 1.73 i 1.97 i 0.08 0.06 0.07 0.06u GLOB gldL *= p<0.05 VS SHAM VEH; ++ = p<0.05 VS CKD VEH (c) CONCLUSIONS Treatment with mActRIIA-Fc was able to prevent anemia and bone loss in a 5/6 nephrectomy model of chronic kidney disease. CKD mice were anemic, had lower BMD and thinner cortical bone structure in the femur when compared to the sham rparts. mActRIIA- Fc treatment of CKD mice increased the hematocrit, BMD and cortical bone structure significantly over the VEH treated mice. rmore, mActRIIA-Fc was able to increase trabecular bone volume and ular thickness in the CKD mice to values greater than the VEH treated mice in both the sham and CKD cohorts. These data demonstrate that blocking Activin or IIA signaling by mActRIIA-Fc administration can prevent anemia and bone loss in the 5/6 nephrectomy model of chronic kidney disease. 6.4 PROPHETIC EXAMPLE-mACTRIIA INHIBITION TO TREAT ADYNAMIC BONE DISEASE IN CDK CONTEXT Mice are subjected to electrocautery of one kidney and nephrectomy of the other kidney. The mice are fed low-phosphate chow supplemented with calcitriol. See, e.g, Lund et al., 2004, J Am Soc Nephrol -369.

This study is designed to study the effects of soluble mouse ActRIIA that is fused with mouse PC via a minimal linker (SEQ ID NO: 15) on ent of blood and bone parameters in a mouse model of adynamic bone disorder.

Mice with ocautery of one kidney and nephrectomy of the other kidney are used as a model of adynamic bone in CKD ) context to test the effects of the polypeptide with the amino acid sequence of SEQ ID NO: 15 in this model. Mice receive two surgeries to 1) remove one kidney completely and 2) ocautery of the other kidney. Sham operated mice are also included as controls. The surgeries can be conducted as described in Lund et al., 2004, J Am Soc Nephrol 15:349-369.

One group of mice is placed on low-phosphate chow supplemented with calcitriol diet. r group of mice is placed on normal chow diet. Two weeks after the final y mice are divided into groups (both SHAM and ADB) and administration begins with vehicle (PBS) or mActRIIA-Fc at 10 mg/kg twice per week for 8 weeks. Complete blood counts (CBC) are taken periodically during the study to assess for anemia.

Bone mineral y is determined using dual energy X-ray absorptiometry (DEXA, PIXIMus). At the conclusion of the study necropsies are conducted to collect the long bones of the hind limbs and major organs. The remnant kidney is sent for histology processing and staining with H&E or Trichrome stain. Femurs are scanned by uCT (Scanco) to determine bone microarchitecture. Quantitative computed tomography (QCT) can also be used to determine bone turnover. 6.5 EFFECTS OF A INHIBITION ON VASCULAR CALCIFICATION This Example demonstrates that inhibiting ACTRIIA is effective in reducing calcium levels in the vasculature of subjects, and thus represents a means for treating ar calcification.

Stage 3 chronic kidney disease (CKD) was induced in 14-week old ldlr'/' mice (C57Bl/6J background; Jackson Laboratory) that were fed high fat diets ("CKD mice"). sity lipoprotein receptor (ldlr) is known to be ed in lipid clearance, and ldlr knockout mice represent a model of atherosclerosis. The ldlr deficient mice that are fed high fat/cholesterol diets develop atherosclerosis, and aortic plaque associated calcification that is stimulated by CKD induced by renal ablation. CKD was induced in the ldlr'/' mice by 5/6 nephrectomy (see above). As described above, the 5/6 nephrectomy ses complete removal of one kidney ed by ligation of 2 of the 3 renal veins in the remaining kidney.

By week 22, vascular calcification is established in the CKD mice, as confirmed by chemical calcification quantitation. Briefly, hearts and aorta from the mice are ted at sacrifice, and all extraneous tissue is removed by blunt dissection under a dissecting cope.

Tissues are desiccated for 20-24 hours at 55°C, weighed and crushed to a powder with a pestle and mortar. m is eluted in 10% formic acid (10:1 V/w) for 24 hours at 4°C. Calcium content of eluate is assayed using a cresolphthalein complexone method (Sigma, St , according to manufacturers instructions, and results are corrected for dry tissue weight.

The CKD mice were d into two experimental groups (i) mActRlIA-Fc treated mice; and (ii) Vehicle mice, which were administered the vehicle portion only of the mActRIIA-Fc composition (i.e., the mice were administered a saline composition without mActRlIA-Fc). mActRlIA-Fc-treated mice (n=5) were administered 10 mg/kg of mActRIIA-Fc twice per week for 6 weeks. CKDVehicle mice (n=6; vehicle=saline) were administered vehicle only on the same days that mActRIIA-Fc was administered to the mActRlIA-Fc-treated mice. Wild-type mice (n=6; C57Bl/6J background) and SHAM mice (n=8; C57Bl/6J ound) were used as negative controls. SHAM mice consisted of ldlr'/' mice that were operated on, but in which CKD was not induced (e.g., nephrectomy was not conducted). All mice were euthanized at week 28 for ment of aortic calcium levels in each of the four treatment groups -Vehicle; mActRIIA-Fc-treated; SHAM; and wild-type).

Table 4, below, provides the aortic calcium levels observed in each mouse used in the study (column 2), as well as the average m levels for each of the SHAM, CKDVehicle, mActRlIA-Fc, and wild-type study groups (column 3). The results are presented in graph form in Figure 11. As demonstrated by the data, a clear reduction in aortic calcium was observed in the mice belonging to the mActRlIA-Fc treated group compared to the vehicle-treated group. In 4 of the 5 CKD mice that were treated with mActRIIA-Fc, levels of aortic calcium were comparable to levels observed in the two ve control groups (wild-type and SHAM mice).

] Elevated vascular (e. g., arterial) calcium levels are known to be associated with vascular calcification (see, e.g., Raggi P et al., Clin J Am Soc Nephrol 2008; 3: 836-843). Thus, the foregoing results indicate that ActRIIA inhibition represents a suitable approach for the treatment and tion of vascular calcification.

Table 4: Aortic Calcium Levels Experimental Group Subject Specific Ca2+ Levels (mg/g) Average Ca2+ mg/g Wild-type (n = 6) 0.25, 0.11, 0.26, 0.36, 0.31, 0.35 Sham (n = 8) 0.28, 0.18, 0.24, 0.16, 0.13, 0.25, 0.26, 0.27 CKDVehicle (n = 6) 0.58, 0.17, 0.51, 0.52 :: 0.28 0.56, 0.31, 0.99 Experimental Group Subject Specific Ca2+ Levels (mg/g) e Ca2+ mg/g mActRllA-Fc (n = 5) 0.83, 0.28, 0.19, 0.29 :: 0.31 0.13, 0.04 6.6 EFFECTS OF ACTRIIA INHIBITION ON AR CALCIFICATION This e describes a study of the the effect of ActRII inhibition on vascular calcification in subjects with chronic kidney disease.

The mouse model of early CKD-MBD described in the preceding examples can be used. In this model, renal ablation is added to c deficiency of the LDL receptor, ldlr, and mice are fed a high fat high cholesterol diet. In stage 3 CKD, the animals have CKD induced stimulation of vascular cation, decreases in bone formation, ed FGF23 levels, hyperphosphatemia, and elevated PTH levels. (a) Materials and Methods Animals and diets: LDL receptor null (LDLR'/_) mice on a C57Bl/6J background or wild type C57Bl/6J mice can be purchased from Jackson Laboratory (Bar Harbor, Maine) and bred in a pathogen-free environment. Animals can be weaned at three weeks to a chow diet having 6.75% calories as fat. At 10 weeks, some animals can be initiated on a high cholesterol (0.15%) diet containing 42% calories as fat (Harlan Teklad, Madison WI, Product No.

TD88137), a diet that has been shown to generate atherosclerosis with vascular calcification in this c background (see, e.g., Towler et al., 1998, J Biol Chem 427-30434). Calcium content in all diets can be 0.6%. Animals can be given access to water ad libitam, and maintained according to local and national animal care guidelines. mActRlIA-Fc can be administered IP (10 mg/kg) twice .

Surgical Procedures: A two-step procedure can be utilized to create CKD as previously described (see, e.g., Davies et al., 2003, J Am Soc Nephrol 14: 1559-1567; and Davies et al., 2005, J Am Soc Nephrol 16:917-928). Briefly, electrocautery can be applied to the right kidney h a 2 cm flank incision at 10 weeks post-natal, followed by left total nephrectomy through a similar incision 2 weeks later. Control animals can receive sham ions in which the appropriate kidney is exposed and mobilized but not treated in any other way. Intraperitoneal esia (xylazine 13 mg/kg and ketamine 87 mg/kg) can be used for all procedures.

Saphenous vein blood samples can be taken at 1 week following the second surgery to assess baseline post-surgical renal function. Animals can be ced under anesthesia at 20 weeks, or 26 weeks depending on the group after blood is taken by intracardiac stab. The heart and aorta can be dissected en bloc.

Tissue Preparation: Resected specimens can be fixed in formalin, and then divided as s: the heart, ascending aorta and aortic arch can be separated from the descending aorta, and bisected sagittally through the aortic outflow tract. The descending aorta can be bisected coronally, approximately halfway along its length. All four pieces can be embedded in the same wax block. Slices (5 um thick) can be cut and stained with xilin and eosin, trichrome, Alizarin Red and von Kossa.

Immanohistochemistry: Tissue sections can be prepared as above, deparaff1nized in xylene, and rehydrated in graded ethanols. Endogenous peroxidase activity can be blocked by incubation in 3% hydrogen peroxide , St Louis MO), and non-specific binding can be blocked with a 10-minute incubation with a etary solution of casein in PBS ("Background SNIPER’, e Medical, Walnut Creek CA). Antigen retrieval can be performed with a 5- minute incubation with citrate buffer (‘Decloaker’ BioCare Medical, Walnut Creek CA) at 1000 C. Sections can be incubated with affinity-purified goat polyclonal antibody against mouse osteocalcin (OC) (Biogenesis Inc, Brentwood NH) overnight, then incubated with biotinylated mouse anti-goat secondary antibody for 10 minutes prior to avidin-conjugated peroxidase staining (all reagents, BioCare Medical, Walnut Creek CA), and counterstained with 0.1% xylin (Sigma).

RT-PCR: RNA can be extracted from tissue samples using the RNAqueous-4PCR kit (Ambion), according to the manufacturer’s ctions. RT-PCR can be performed using the One-step RT-PCR Kit (Qiagen, ia CA) according to manufacturer’s instructions.

Conditions can be: 50°C for 30 min, 95°C for 15 min, then 35-40 cycles of 94°C for 1 min, 60°C for 1 min & 72°C for 1 min, then 72°C for 10 min. Primer specifc to murine osteocalcin and murin GAPDH can be selected.

Chemical cation Qaantitation: Hearts and aorta can be dissected at sacrifice, and all extraneous tissue removed by blunt dissection under a dissecting microscope. Tissues can be desiccated for 20-24 hours at 55°C, d and crushed to a powder with a pestle and mortar. Calcium can be eluted in 10% formic acid (10:1 v/w) for 24 hours at 4°C. Calcium content of eluate can be d using a cresolphthalein complexone method (Sigma, St Louis), according to manufacturers ctions, and results can be ted for dry tissue .

Bone Histomorphometry: Bone formation rate can be determined by double fluorescence labeling. All mice can receive intraperitoneal calcein kg) 7d and 2d before they are ced. Both femurs can be dissected at the time the animals are ced and placed in 70% ethanol. The specimens can be implanted undecalcified in a plastic embedding kit H7000 (Energy Beam Sciences). Bones can be sectioned longitudinally through the frontal plane in 10-um sections with JB-4 microtome (Energy Beam Sciences). Unstained sections can be used for calcein-labeled fluorescence analysis. Slides can be examined at X400 magnification with a Leitz microscope attached to an easure Image Analyzer (Osteometrics, Atlanta GA). Ten contiguous 0.0225-mm2 fields of the distal femur, 150 um proximal to the growth plate, can be examined per animal.

Measurements ofParathyroid Hormone and Serum Chemistry: Blood samples can be obtained at 2 and 8 weeks of CKD by capillary tube aspiration of the saphenous vein, and with a different ure (intracardiac puncture) at the time of sacrifice (12 weeks CKD) and transferred to heparinized tubes. After centrifugation (400X g for 5 minutes), plasma can be removed, aliquoted and frozen at -800C. Intact PTH levels (performed only at sacrifice because of the volume of blood required) can be measured by two-site immunoradiometric assay (IRMA) using a commercially available kit (Immutopics, San Clemente, CA). Blood urea nitrogen (BUN), serum calcium and phosphorus can be measured using standard multichannel analyzer techniques.

Measurements ofFGF23.‘ An FGF23 murine ELISA assay can be purchased from the Kainos company.

] Measurements 0fDKKI and osteocalcin: Commercial ELISA assays for DKKl and undercarboxylated osteocalcin can be used.

Measurements 0f0PG and sRANKL: The ratio of OPG to RANKL can be determined in serum assays. These assays have been shown to correlate well with bone turnover and excess bone tion (see, e. g., Geusens et al., 2006, Arthritis & Rheumatism 54:1772- 17775). The levels of sRANKL in the serum can be ined by a radioimmunoassay (Linco Research, St. Louis MO). Levels of serum OPG can be measured by an ELISA method (OSTEOmedical NL, Marishof, NL). The intra- and interassay coefficients of variation (CV) are less than 10% for both tests, according to the manufacturers. The detection limit for sRANKL is 0.08 pmol/l, and for OPG is 0.14 .

Measurements ers ofBone Turnover: Serum PlNP and osteocalcin can be used as markers of osteoblast activity and tartrate resistant acid phosphatase form 5b (TRACP 5b) (mouseTRAP, IDS Ltd, Bolden, UK) can be used as a marker of osteoclast levels.

Measurements ofMarkers 0finflamati0n: Serum assays for TNF alpha, and c reactive protein can be used to follow the levels of tion and the response to mActRIIA- ] Statistical Analysis: Data can be analyzed for statistical significance (P<.05) using ANOVA. Comparison can be made between animals treated with vehicle (control group) and those treated with IA-Fc. Comparison can also be made between sham-operated mice and CKD mice d with Vehicle and mActRHA-Fc. These analyses can be performed with the SPSS 11.0 statistical package (Needham Heights, MA). (b) Study Parameters Mice used in the study can be placed into one of eight groups as shown in Table 5, below.

Table 5 _LDLRHigh Fat/CKD vehicle treated euth 22 wks LDLR High D RAP-011 treated euth 22 wks _LDLRHigh Fat/CKD vehicle teated euth 28 wks LDLR Hih Fat/CKD RAP-011 treated euth 28 wks F LDLR High Fat/sham operation euth 28 wks 10 G LDLR Hih Fat/sham o oeration euth 20 wks 10 LDLR Hih Fat/CKD euth at 14 weeks One group of animals (Group H in Table 5) can be ced at 14 weeks to measure the baseline vascular calcification and histomorphometry at the time of instituting therapy.

Groups C and E can be used to assess the efficacy of treatment with mActRIIA-Fc compared to vehicle treated groups s B and D) over variable periods of CKD. Groups F and G are age d sham operated high fat fed animals that can be used as the control for the CKD effects.

Group sizes of 10 animals per group after randomization into the treatment groups can be sufficient to obtain statistical significance.

At 16-18 weeks, ular filtration rate (GFR) can be measured by injection of inulin into the mice and measurment of its disappearance. At euthanasia, blood can be drawn by intracardiac stab, and serum DKKl, FGF23, osteocalcin, PTH and calcitriol levels can be determined, along with serum calcium, Pi, blood urea nitrogen (BUN), glucose, and cholesterol levels.

Aortas from the ldlr-/— high fat fed CKD animals can be analyzed. Total aortic calcium levels and von Kossa stained microscopic ns can be obtained. Aortas can be processed to obtain RNA for analysis of aortic gene expression. Aortas can be sed for immunohistochemistry. At 22 weeks in the model of CKD described above, the euthanasia age for groups B and C, vascular cation is ished and adynamic bone disorder is present despite secondary hyperparathyroidism. Between 22 and 28 weeks, vascular cation is progressive and the effects of the presence of parathyroid hormone begin to increase osteoblast surfaces.

The study bed in this example can be used to determine the effects of ActRII inhibition on vascular calcification, bone remodeling rates, and secondary hyperparathyroidism observed in subjects having CKD.

HiUmm>UBUZBMDMmBZ¢meQUMOBmmmwflHflwmmomHflm>4m4flM¢¢4OZ >mmmDMMm>UDBMD%UZHDDQBUOOM>HmHmOmHzmzfiflmUmmmmmmmww HflZflm>flmwflflHzwwmmMmB>mZmBmOB>mmemwmmMmZUZZOmooomw m¢m>mflfl0flmMflUflflmmmmmmwmDOBm>fl>mmwflzmmmmw>Bm40H>H04 HmOflHZHEMZOQQmw>mmeOBmOMDOHmmHM>¢>$MZQQO¢MB>UUmMO QOM¢ZBM4HEUQMZBm>>Z¢MflmDmQmUMmmm4BHQBQD>D>mBOMMm¢U flflOmmflHUdBQZZMQQ>ZMmMHDmEmHflmMEODMflOmHammflwfl mmflflm3fl>fl024wzmHmqmflmmomzH40Mfl>mmflzwmmfiw>00mfimwflmm $DMfl>mMMMME>>>MOZDMQmmEOUHmmmmmflzwmm>mwmflflfio ZB>>B>HDMBBHHZBQmOZOBHmmw>owflmflm4mflmmmzommHBHUQZflZ flmmmMmmmD>ZB> mwmHZMBBflmUmmmmmmmwwomm>OBUZBMDMmBZ¢meHUMOBmmmwflH memwmmMmZUZZOmooomw>mmmDMMm>UDBMD%UZHDDHBUOOM>HEH mmMmB>mZmBmOB>m BBflmUmmmmmmmwwomm>OBUZBMDMmBZ¢meHUm0BmmquH memwmmMmZUZZOmUUUmw>mmmDMMm>UDBMD%UZHDDQBUOOM>HMH UHHUHUUBOBflHHUHEROBOODOBBBOUOOBBOflflflUOfiowfiowflwwwfifl dBHHUHHHBOHUHUflUUflUHU¢¢4040Bflwflfiwwfifivflfiflfiowfiwwflofifi BOBOUUdflOBBOBOOHU¢¢mmmDMMm>UDBmD%UZHDDHBUOOM>HmH HZQBDMmMmmmqm>mmwwqqmmflmommofimfiwwwfimmMmB>mZmBmOB>m >>mwfimzwommmmMBM¢Zm>m>OD>%BZmM>mmDmmm>m>>>ofi>mmBmm QQQBw>OmmmmOUM¢MmHBMMHm>mHflMZm>MommeOZHBDOEQ>BQ>m mODmDQ>mmBBM%ZmeOOmeBm>4HDmmwmwm>qofiqm>OZMBmemm MOmmamamMOmeZEQ4mmZ>mUmm>ZOOOBmmMD>BHmeqmm 4%meH%>>Zm>q4>Z>quZ mm>m>4woqqq>oqumM24mz 40mmUqum>4m4qM¢¢¢UZ MOBmmmOHH mwmHzmzfiflmommmmmmmwwomm>OBOZBmDMm324meHUMOBmmquH memwmmMmzozzwmooomw>mmmDMMm>UDBmD%UZHDDHBUOOM>HmH mm>m>>>ofi>mmfimmHZHBDMmMmmmHm>mmOqumm4mUQQUBEBUUUB HMOZQBDOEQ>BQ>m>>mwfimzwommmmMBM¢Zm>m>OD>%BZmM>mmOm QUBQm>OZMBmemmmmqfiw>OmmmmOOM¢MmHBMmHm>QQ¢MZm>Momw 03mmMD>BQmeqmmmODmmq>mmBBM%ZmeOOme3m>4HDmmwmwm> MUmmamquOmezmqflmmz>momm>ZOO BOZBmDMm324meHUMOBmmmOHH¢m>4woqqq>ooqme24DZ MMm>UDBmD%UZHDDQBUUOM>HmHmwmHzmzfiflmommmmmmmwwomm>w UUUBQmMmB>mZmBmOB>mmemwmmMmZUZZOmooomw>mmmm $32mm>mmmmmm>m>>>ofi>mmfimmHZHBDMmMmmmqm>mmOOflqmm4mU ddMZm>MUM$HMOZQBDOEH>BQ>m>>M%BmzwommmmMBM¢Zm>m>OD> 4HDmmwmwm>flofiflm>OZMBZMMMmmmflfiw>OmmmmOOM¢MmHBMHHm>m Z>m0mm>ZOOOBMmMD>BflmeflmmmODmmfl>mmBBM%ZmeOOme3m> MOmmqmflmMOmezmflflmm Op fluHB mUHUm nofiumfinomwn UmmSM mo mo M®U®®H no mocmsvmm qfluHHHmE QHMEOU mocmsvmm EmmHm A4mev 4HHmu04 Ucm HmQHEMmulz QflmuOMm mflu OQHEM omfllflHHmuofl 4HHmu04 ma 4HHmu04 mo M®U®®H me momMuXm mo QmESQ QmESQ mflu m Mmfimmq hmqom qummv Mmfimmq mSmmHH HOum>flu04 ®>Humz omfllflHHmuofl omfilflHHmuofl moqmsvmm omlflHHmuofl Goflumamfi HMQHEMmu mo QHMEOU OMQQD fluHB mogmsvmm 0mm uoz w m OH HH NH MH monmsvmm U0400BUBUBUUHOUBUUHUHUHOUBUBUOUUflUflUflflUBd¢UUB4®UB4 0040HodfldwfloHflwflfiwwfifioflfiflfiowoUUOUUUOUUUBBBOOBBUBOfl UBU¢¢qmHBOmmzmzmflwomflmmmomwmommflwmOZBmmqm324Z%%HUHMBM Hmfimmmzomzwmooomw>0m2mm34>0m0mm%UZmDDDBUOMM mmmmwfi>m mocmsvmm UmmmmUOMQQD 4&3 mHQSHOm mvflummmhaom .2 mUflom mvflom mvflom AwNuOZ nofiumfinomwn .0 SMHB amp; map DH Uflom moqmsvmm OQHEm mHHmu04 ~AMMHSHH®UMMuN®V quEm flufls qflmEOU gflmeow OQHEmV 0mm omfllflHHmuofl m was w gm UmmmmUOMQ om om MO oflmaosz mqflvooqm HmUmmH quSQ moqmsvmm quflEMmu map @mumHmU HMQHEMmu map :ufls Mo Mo Umumamv OMHImN was OHM uOZ wH ma Bmmqm324Z mefifl>om0mD%UZmD dqm%4Q>BQQBm43mm qoqmmqw>qmmmmmmw MZOmBmmHmmmmOBmO UHHZBBHHZOqumfiq >4BQDmMQQ>ZMmMmD qumflmmOmZHflwHQ> >>>m0qmmqmmmOOHm qm>mmm>owflmqm4m4 monmsvmm BmflmmemOm DQBUOMM>QHHBOmmZ mmwfi>mmwwflmmqmfim mQHEHD>Ewwmmmmmm MDqumHM>¢>mDZZQ mOMDmmflfiHQqu>mq mmflHmmmmOmOmUBm> mmflzwmmfiw>owmfimw mmmquwmm>mwmflflm DEDBOHHHB>UQO4QO HmmmMmmqm>ZB>mB> BQmOBQQ4Q4>Bm432 mqmmmomwmo mmzomzwmooomw>0m w23m4QQ>HQmQOOHm O¢M3>memwm¢Mqu ZmOmMm¢m mmmwmmmm>flqwmmflq Omm>QHBQ>QO24wzm mmMQBEDMHBmmZMME qm>qommBBOZ>mmmH OmmZflBmflwomquDOmOmommqwmOZBmmqm324zwwHUHmBmflmOmOm mmqmfimmmzomzwmooomw>0m2mm34>0m0mD%UZmQDQBUOMM>QmHE Hmdfimmmmwgmmwwfi. OmmZflBmflwomquDOmOmommqwmOZBmmqm324zwwHUHmBmflmOmOm mmqmfimmmzomzwmooomw>0m2mm34>0m0mD%UZmQDQBUOMM>QmHE o00030500034000030BooBoo00050oowwfiwwwfiooowowwoflwhd wodflodfiodfio540w304000040¢U¢UBUUU¢UUUUBUUUUUBUHowwo ¢0m2mMB4>UMOMD%UZmDDHBUUMM>QmHE HZHBDMmMmmmqm>mmwwflflmmflmommofimfiwwwfimflfimmmm%B>mmUO¢. zwommmmMHM¢Zm>m>UD>%BZmM>mmDmmm>D>>>UB>mmHMm mmflfiw>0mmmmOUM¢MmHBMHHm>mdflMZm>MommeUZQBDOEQ>BH>m mODmmfl>mmBBM%ZmeOOmeBm>4HDmmwmwm>flofiflm>OZMBZHMMm MOmmamamMOmezmflflmmZ>mOmm>ZOOOBmmMD>BHmeflmm UmmZflBmflwomflmmmomwmommqwmOZBmmqm3242%%Hommfimflmwmwm mmqmfimmmzomzwmooomw>0m2mMB4>UMOMD%UZmDDQBUUMM>HmHE Em>m>>>ofi>mmBMmHZHBDMQMQmmqm>mmwwflqmm4moflmofimfiwwwd.

MO MO nofiumfinomwn ®HQSHOm QHMEOU cm Op ®HQSHOm QHQEOU QflmuOMQ m uwmflv UmmSM QflmuOMQ m QOHmSM mQHmHMQEOU M6H5HH®U®MHN® mHHmp04 APHHOZ QHMEOU QOHmSM mQHmHMQEOU M6H5HH®U$MHX® OHM uOZ ON HN monmsvmm HMOZHBDOEH>BH>m>>M%BmzwommmmMBM¢ZE>m>OD>%BZmM>mmOm QUBflm>OZMBZMMMmmmqfiw>OmmmmOOM¢MmHBMMHm>mfl¢MZm>MUM% OBMmMD>BHmeflmmmODmmfl>mmBBM%ZmeOOme3m>4HDmmwmwm> MOmmamflmMOmezmqflmmZ>mUmm>ZOO >flmHmemzmzmflwomflmmmomwmommflwmOZBmmqm324Z%%HUMMBH mwwflmmHmfimmmzomzwmooomw>0m2mm34>UmOMD%UZmDDDBUOMM mmmwfi>m >flmHBOmmzmzmflwomqmmmomwmommqwmOZBmmqm324Z%%HUHMBH mwwflmmflmfimmmzomzwmooomw>0m2mMBfl>UMOMD%UZmDDDBUOMM Bmmmmwfi>m UmmflUmOZBmmqm324Z%%HUHMBmflflwmm>m>4OUQQQ>UUQUMM24DZ >OmZmHB4>UMOMD%UZmDDDBUOMM>HmHBUmmzmzmflwomflmmmomOm may map DH 0m gufls OQHEm Ommv cm mHQSHOm mvflummmhaom .2 mUflom mUflom mUflom AwNuOZ mHQSHOm .2 mUflom mUflom mUflom AwNuOZ nofiumfinomwn .0 .0 map flufls Op quEm qflmEOU map quEm qflmEOU DH amp; map quEm map ma mvflummmhaom quEm qflmEOU amp; omlmHHmuo< Awmmmwwflmmqmfimmmzomzwmooomw 42m>m>wm>%32mm>mmDmmm>m>>>ofi>mmBMmHZQBDMmMmmem>mm mHBMmHmflmdflMZm>MUmmeOZQBDOEQ>BQ>m>>mwfimzwommmmMBM mOOme3m>flHDmmwmwm>qofiqm>OZMBmemmmeBw>OmmmmOOM¢M meZEQ4mmZ>mUmm>ZOOOBmmMD>BQmeqmmmODmDQ>mmBBM%ZZm *Mwmmqmqmmo M>qmHmemzmzmflwomqmmmomwmommqwmOZBmmqm324zwwHUHmBm >mm0©4mmqmfimmmzomzwmooomw>0m2mm34>0m0mD%UZmDDDBUOM BMmHZQBDMmMmmmqm>mmwwqqmmflmommofimfiwwwfimmmmwfi DOEQ>BQ>m>>mwfimzwommmmMBM¢Zm>m>OQ>%BZmM>mmDmmm>m>> HMmmeBw>OmmmmOOM¢MmHBMHHmflmQ¢MZm>Momwmmwzqz >BQmeqmmmODmDQ>mmBBM%ZmeOOme3m>4HDmmwmwm>qofiqm> *Mwmmamammoewmzqummz>momm>zwoozmmmm Omm243mflwomqmmmomwmommqwmOZBmmqm324zwwHUHmBmflmOmO mmqmfimmmzomzwmooomw>0m2mHB4>UmomD%UZmDDQBOOMM>QmHE Hmdfimmmmwe>mmww4 Omm243mflwomqmmmomwmommqwmOZBmmqm324zwwHUHmBmflmOmO mmHmfimmmzomzwmooomw>0m2mMB4>UHOMD%UZmDDQBUOMM>HmHE QHMEOU mUHUm mflu mvflom AwNuOZ 4&3 mUHUm AwNuOZ .0 mUflom no QHMEOU no mvflom AmHuOZ AmHuOZ DH SHHB OQHEM gufls omlmHHmu04 OQHEM mvflom DH ®HQSHOm ®HQSHOm mUflom nofiumfinomwn om mflu amp; DH map DH om mflu amp; quEm m OQHEM mflu QHMEOU oqflEmv 0mm Una moqmsvmm QflmuOMQ m OQHEM qflmeov 0mm mvflummmhaom 0mm mvflugmghaom 0mm HmQHEMmulz Ufim gm mflu m HmQHEMmulz Ufim m OQHEmV gm quEmv flufls ma om MO om MO OQHEmV MO mHHMHofl MO mHHMHofl MO MO mUHUm Umumamfi mu Qoflumuse mflu :ufls map MO Umumamv :ufls was Ummm®UOMm Umumamfi HMHImN HmUmmH QOHmSM mUHUm Hmfiflfihmu mo U HMHImN was Qoflumuse SMESS ~AMMHSHH®06MMX®V ~AMMHSHH®UMMuN®V Ummmmoomm moqmsvmm wmalom SMESS UmmmmUOMQ moqmsvmm quflEMmu UmumHmU mHHIQN 0mm uoz mm mm hm mmqmeZBmmqm324Z me34>om0mD%UZmD dqm%4Q>quBm4Hmm qoqmmqw>qmmmmmmw MZUmBmmHmmmmOBmO UHMZBBHHZUqumfiq >4BQDmMQQ>ZMmMmD qumflmmOmZHflwmq> >>>m0qmmqmmmOOHm qm>mmm>owflmqm4m4 monmsvmm wwHommBmflmwmwmwm DHBUOMM>QMHBUmmZ mmwfi>mmwwflmmqmfim mammHQ>mwwmmmmmm MmoqmmHM>¢>mDZZq mwmmmmflfiquqm>mq mmflHmmMmUmmeBm> mmdzwmmfiw>owmfimw mm>mwmdflm DEDBUmmHB>UQO4QU HmmmMmmqm>ZB>mB> H4Q4>Bm432 mzmfiwomqmmmomwmo wmooomw>0m wzzm4QQ>ququHm O¢M3>memwm¢Mqu ZmUmMm¢m mmmwmmmm>flqwmmflq omm>quQ>q024wzm mquBEDMHBmmZMMm qm>QUDmBBUZ>mmmH OmmzmzmflwomflmmmomwmommqwmOZBmmflm324Z%%HUHMBmflmOmwm mmflmfimmmzomzwmooomw>0m2mHB4>UHOMD%UZmDDHBUOMM>QmHE Bmflfimmmmwfi>mmwwfl OmmzmzmflwomflmmmomwmommqwmOZBmmflm324Z%%HUHMBmflmOmwm mmflmfimmmzomzwmooomw>0m2mHB4>UHOMD%UZmDDHBUOMM>QmHE OmmzmzmflwomflmmmomwmommflwmOZBmmqm324Z%%HUMMBmflmOMU mmzomzwmooomw>0m2mHB4>UMOMD%UZmDDQBUOMM>QmHE Bmflfimmmmwfi>mmwwfl UmmzmzmflwomflmmmomwmommqwmOZBmmqm324Z%%HUHMBmflmme mmHmfimmmzomzwmooomw>0m2mMB4>UHOMD%UZmDDQBUOMM>HmHE MOmMDUmMQ Awmmv mHQSHOm mvflummmhaom mvflom AwNuOZ .0 mUflom mUflom AwNuOZ mvflom AwNuOZ nomwn monSUmm ~AMMHSHH®UMMuN®V DH mHQSHOm DH m DH mHQSHOm mUHuomo mHHmuofl quEmv 0mm mvflummmhaom map quEm mHHmuo< mHHmu04 ~AMMHSHH®UMMuN®V flufls OQHEmV 0mm mvflummmhaom 0mm ma quEmv HO.

MO mHHmuo< mHHmuo< MO MO Ewes: QflmuOMQ amass UmmmmUOMQ moqmsvmm wmalmfi quSQ UmmmmUOMQ moqmsvmm quflEMmu UmumHmU mfifilmfi amass ~AMMHSHH®UMMuN®V UmmmmUOMQ moqmsvmm wmalom Ewes: ~AMMHSHH®UMMuN®V Ummm®UOMo 0mm uoz mm mm om Hm mm monmsvmm >qmHmemZflBmflwomflmmmomwmommflOmOZBmmflm324Z%%HUMMBH mwwflmmflmfimmmzomzwmooomw>0m2mHBfl>UMOMD%UZmDDDBUUMM Bmmmmwfi>m UmqumOZBmmflm324Z%%HUMMBmflflwmm>m>4OUHQQ>UUQUMM24DZ >OmZmm34>0m0mm%UZmDDDBUOMM>QmHBUmm24Bmflwomflmmmomwm Owflqmmflmommofimfiwwwfimmmmwfi>mmwwflmmflmfimmmzomzwmooomw 42E>M>OD>%BZmM>mmDmmm>m>>>ofi>mmBMmHZHBDMmMmmem>mm mHBMmHmflmHflMZm>MomwMMUZHBDOEQ>BQ>m>>M%BmzwommmmMBM mOUme3m>flHmmmmeM>flUBflm>OZMBZMMMmmmflfiw>OmmmmOOM¢M mezmflflmm2>momm>ZOOOBMmMD>BHMqummmODmDfl>mmBBM%ZZm *MOmmflmflmMO M>flmHmemZflBmflwomflmmmomOmomqumOZBmmqm324Z%%HUMMBM >mm0©4mmHmfimmmzomzwmooomw>0m2mMBfl>UMOMD%UZmDDDBUOM BMmHZHBDMmMmmmflm>mmwwqflmm4mUmmUBEBOOOBmmmm%B H>m>>M%BmzwommmmMBM¢Zm>m>OD>%BZmM>mmDmmm>m>> mUHom map map .0 AwNuOZ mUflom mUflom AmHuOZ mUHom AmHuOZ 4&3 map mUHom mHQSHOm mvflummmhaom .2 mUflom .0 flufls qflmeov .0 qflmeov OQHEm map mUHom nomwn DH flufls ~AMMHSHH®UMMuN®V quEm qflmEOU map quEm qflmEOU DH amp; omlmHHmuo< OQHEm om OQHEm qflmEOU DH may amp; flufls omlmHHmu04 OQHEm om flufls m 0mm ma OQHEmV 0mm mHHmu04 flufls 0mm m m qu m OQHEMV gm map gm Ucm map MO om om MO UmmmmUOMQQD qflmuOMQ Unm m OQHEmV UmmmmUOMQ om MO moqmsvmm qflmuOMQ moqmsvmm HMQHEMmu moqmsvmm quflEMmu quflEMmu :ufls qoflumuse Mo :ufls Mo UmumHmU mHHION quSQ map map Mo UmumHmU Mo UmumHmU HMHImN may was qoflmSM HMQHEMmuIZ mvflom UmumHmU mu Mo UmumHmU HMHImN was Qoflumuse HmUmmH Ummm®UOHm qoflmSM HMQHEMmuIZ mvflom OHM uOZ mm wm mm monmsvmm OZMBZMMMmmmqfiw>OmmmmOOM¢MmHBMmHmflmq¢M2m>MommeOZflB >BquwqmmmODmmq>mmBBM%ZmeOOmeBm>4HDmmwmwm>flofiflm> *MOmmamamMOmezmflflmmZ>mUmm>ZOOOBMmMD OmmzmzmflwomqmmmomwmommqwmOZBmmqm324Z%%HUHMBmflmwmw mmHmfimmmzomzwmooomw>0m2mHB4>UHOMD%UZmDDDBUOMM>HmHE Bmflfimmmmwfi>mmwwfl OmmZflBmflwomqmmmomOmommqwmOZBmmqm324Z%%HUHMBmflmwmw mmHmfimmmzomzwmooomw>0m2mHB4>UHOMD%UZmDDDBUOMM>HmHE Bmflfimmmmwfi>mmwwfl UmmzmzmflwomflmmmomwmommqwmOZBmmqm324Z%%HUHMBmflmme mmflmfimmmzomzwmooomw>0m2mMB4>UHOMD%UZmDDDBUOMM>HmHE quflmmflmUmmUBmBOOOBmflfimmmmwfi>mmwwfl 42$>M>OD>$BZmM>mmDmmm>m>>>ofi>mmBMmHZQBDMmMmmem>mm mHBMMHmflmHflMZm>MUmmeOZHBDOEH>BH>m>>mwfimzwommmmMBM mOOme3m>flHDmmwmwm>qofiflm>OZMBZMMMmmmqfiw>OmmmmOOM¢M mezmflflmm2>momm>ZOOOBMmMD>BHMmwflmmmODme>mmBBM%ZZm *Mwmmflmflmmo mflwomflmmmomOmommqwmOZBmmqm324Z%%HUMMBmflmwmw mmflmfimmmzomzwmooomw>0m2mMB4>UMOMD%UZmDDDBUOMM>QmHE OOHHmmflmommofimfiwwwfimflfimmmmwfi>mmwwfl flzm>m>wm>%32mm>mmDmmm>m>>>ofi>mmBMmHZHBDMmMmmmHm>mm mHBMHHmflmHflMZm>MUmmeOZHBDOEH>BH>m>>mwfimzwommmmMBM mOOmeBm>4HDmmmeM>HUBHm>OZMBZHMMmmmflfiw>OmmmmOOM¢M mvflom mvflom AmHuOZ .0 mHQSHOm mvflummmhaom mvflom AwNuOZ mHQSHOm mvflummmhaom mvflom AmHuOZ mHQSHOm mvflummmhaom mvflom AwNuOZ qflmEOU m mvflummmhaom mvflom AmHuOZ nomwn map OQHEm gflmeow DH amp; DH DH om megflfi was m OQHEmV 0mm gm DH QOHHGHSE DH QOHHGHSE quEmv 0mm QOHHQHSE quEmv 0mm quEmv 0mm quEmv 0mm QOHHGHSE Gm om MO HmQHEMmu :ufls mHHmuo< goflumuse ~AMMHSHH®UMMuN®V < ~AMMHSHH®UMMuN®V UmmmmUOMQ MO mm Doha UmmmmUOMQ MO moqmsvmm Doha mHHmuo< MO Doha www mHHmuo< MO Op Doha @mumHmU map Mo UmumHmU HMHImN m was amass wmalom SHHB amass wmalom SHHB amass ~AMMHSHH®UMMuN®V UmmmmUOMQ moqmsvmm wmalom SHHB UmmSM Sufi; amass ~AMMHSHH®UMMuN®V UmmmmUOMQ moqmsvmm wmalom SHHB OHM uOZ mm hm mm mm monmsvmm mezqummz>momm>zwoozmmmm>HQmeqmmmammmq>mmeemw22m *Mwmmqmqmmo wmozemmqm324zwwHummemdmwmwmdwmm>m>4woqqq>ooqwmmz4mz wmmzmzm¢womqmmmomwmommq mmqmemmmzomzwmooomw>om2mm94>omommw02mmmmzowmm>qmHE wwqqmmdmommoemewwwemdemmmmwe>mmww4 42m>m>wm>w32mm>mmmmmm>m>>>oe>mmemmquemMmMmmmqm>mm mHBMmHmdmq¢mzm>momwmmwzqzmomq>3q>m>>mwemzwommmmmem mOGmezm>4Hmmmwmwm>qoeqm>OZMBmemmmmqew>ommmmowm¢m mezqummz>momm>zwoozmmmm>HQmeqmmmammmq>mmeemw22m *mwmmqmqmmo wmozemmqm324zwwHummemdmwmwmdwmm>m>4woqqq>ooqwmmz4mz wmmz4zm¢womqmmmomwmommq mmqmemmmzomzwmooomw>om2mm94>omommw02mmmmzowmm>qmHE wwqqmmdmommoemewwwemdemmmmwe>mmww4 42m>m>wm>w32mm>mmmmmm>m>>>oe>mmemmquemMmMmmmqm>mm mHBMmHmdmq¢mzm>momwmmwzqzmomq>3q>m>>mwemzwommmmmem m>4Hmmmwmwm>qoeqm>OZMBmemmmmqew>ommmmowm¢m mezqummz>momm>zwoozmmmm>HQmeqmmmammmq>mmeemw22m *mwmmqmqmmo Hammzmzmdwomqmmmomwmommqwmozemmqm324zwwHummemdmwmw 4mmqmemmmzomzwmooomw>om2mm34>omommw02mmquowmm>qmH mmdmwmqoqzqdwmwomw¢¢434mmwwmmHeemdzmwmmww Hammzmzmdwomqmmmomwmommqwmozemmqm324zwwHummemdmwmw 4mmqmemmmzomzwmooomw>om2mm34>omommw02mmmmzowmm>qmH mmflmwmqoflzqflwmwomwflflflfiflmmwwmmHBBmflszmmOO Awm Amfi SH SH cflmeov mHQSHOm mvflugmmhfiog mvflom oz qflmeov vammH m mvflugmmhfiog mvflom oz qflmeov nofiumfinomwn m QH vammH QH mHQSHOm mHQSHOm om ~AHmH5HHmomnuxmv oqflEmv om om 0mm qoflumuse 0mm qoflumuse mvflugmghfiog am am 4me ~AHmH5HHmomnuxmv oqflEmv am 4me ~AmmH5HHmomMuxmv mqfl>6£ HMQHEHmulv UmmoHomHUV mvflummmhaom m 4 mqfl>6£ HMQHEMmuIU UmmoHomHUV omm Mo Mo On On :ufls mHHmu04 moqmsvmm amp; mm Ummmmoomm moqmsvmm amp; On :ufls mHHmu04 mHHmu04 UmmSM amass wmfi-om gufls UmmSM qu amass wmfi-om gufls UmmSM qu mocmsvmm amass ©mmmmoong moqmsvmm ufimflwa/l moqmsvmm Amppmm0\poomoz amass ~AmmH5HHmomMuxmv UmmmmUOMQ mm ucmflpm> mosmsomm 0mm uoz ow aw mw mw 90002030490090000000000900029009032429990009040000 4mm90900020020000099>0020m94>0momm9020000300MM>909 00400090939400000044494000000999043000000 4zm>m>0m>9320m>mmmmmm>m>>>09>mm9mm9299000000999>0m 09900904094020>m0090002930009>99>0>>m9902900000090 00020mzm>49000990M>90990>02092000000999>0000000040 9902094mmz>0000>z00030000>99009990000009>mm99M9ZZm 0090090090 0444000000 4400904400 0440000040 0904400400 0400090090 4000090909 0004000990 0004400000 4000 9044090040 0004444000 9404090040 4409004090 9400 0049004004 9000904004 0004440440 0444000444 0940000009 0090040900 9040090000 mm 9090090900 0000000009 0994490094 9090004400 9009000949 4409 4400400000 9909099949 9004000499 0000004409 0400009000 0009909009 0000 0040440040 9004009000 0440490400 0040090090 0909004400 0090940044 0004049090 4004 0940400040 0099004000009090009 0040404409 9900990904 4049949994 9000000944 0099400900 0090440994 4094990994 0900400009 9000440944 4900409004 4000094040 9000 0909409409 0040900400 0040090049 4004000000 0040900900 9044049040 4404009400 0404004404 4044004094 0094909900 00000909000 4400940094 0040090909 9094400000 0044004000 0044494004 0040000090 0040 4000 9090999440 0000000000 4090440090 4000000900 0004040044 9009009000 0090440990 0044404044 0409009090 0440009440 0000400090 0000004000 0400400000 0444090090 09 0 009>05 0 009000Q>9og 00050 0 0900 0q9>0g 5093 nofiumfinomwn 00505000 00oz09 9099000\9oomoz qoflumuse 0990004 ~30959900050900 059>0g 90095900-0 9099mmo\9oomoz 00900050 090000 000 000000ong 00 905099 0904 Doha 50055 00505000 00005000 00 0099 cm 000990> 00 O0 0009 0909052 00900050 0mm Hoz 00 00 0400404404 3430300330 4000040040 4404003030 4443000000 monmsvmm 3044044040 3300300004 0030040040 0040340034 0303000303 0003 0030 4404003000 0300030034 4040 4400404000 0300003000 4030044004 0303303004 0040430400 0mmZMBm430EflMMDOm0m0MMQ00023MMQmBZ4233HOMM3m4m0m0m mmflm3mmmZ0mZ0m000m3>OmZmm34>0m0mm302mDDHBO0MM>QHH3 HZQ3DMmMmmmHm>mm00flflmm4m0mm03m30003m43mmmm33>mm004. >>m33mZ30mmmmM3M4Zm>m>0D>3BZmM>mmDmmm>D>>>03>mm3Mm mm433>0mmmmO0M4MmH3MmHm>mH4MZm>MOM3mMOZQBDOEQ>3Q>m 00Dmmq>mm33M3ZmeO0meBm>4HDmm3m0¥>fl03flm>OZM3ZMHMm M0mmamamMO33mqu4mmZ>m0mm>Z0OOBMWMD>3flMm3Hmm 0mmZMBm430EflMMDOm0m0MMQ00023MMQmBZ4233HOMM3m4m0m0m mmflm3mmmZ0mZ0m000m3>OmZmm34>0m0mm302mDDHBO0MM>QHH3 >03>mm3MmHZQ3DMmMmmmflm>mm004flmm4m0mm03m30004. HMOZQBDOEQ>3Q>0>>M33mZ%OmmmmM3M4Zm>m>0D>3BZmM>mmOm H03qm>OZM3ZHMMmmmfl33>OmmmmO0M4MmH3MmHm>m44MZm>MOM3 OBMmMD>3flMm3qmm00DmDQ>mm33M3ZmeO0me3m>4HDmm3m0m> M0mmamflmMO33mqu4mmZ>m0mm>Z0O m4QMmmmm00>04444444444444m0m44m0mmmqma4fl4flm0flqflm44q>2 MQQHOM>>MMmHZm4mMQMHMmHHOmMHmMQMHHMmEOMB>0>m00Dmmm4>m mm0D30>4mD3m04ZmH>3m334m3mmmmammmmoq4m00mmmqmflHOqum4 000430m03flmMHMQHOfl3>34mmm>mmq3>BflO4MH>M3mZ>Mmmmmmm00fl HmHOBZmOm0mmBmmfl>OMmDHmOBEOmMmmflmHquMHMHEmm000 Hm3m00Mmmmmmmm0mq0flzmmmMM3Zmfl>MQmmemq0m40m0flm3>4flD30 0m0400mmZ400>HE3EQ3MOZm23m0O0m03Z4M3MMm4HHBDBOm4mmD>3 m000MD>>Z0mHM03HHOOMDZm3QZZHmmZM3m30 030000030030030033000030030030000000000030030034 000000000000000000040000000040000000000000030040 003000040000000030000000000400000000000000000000 030000003000040000040000000030003000000400000004 044034004040430000030040000004040040000003330003 MO MO 0m mflu ww DH 0m nofiumfinomwn ®HQSHOm QHMEOU cm Op ®HQSHOm QHMEOU SHHB OQHEm Ommv mHQ ~.®.H mofimsvmm uoz Op DH QflmuOMQ m MmHSHfimomMuxm «wmmv Awmmv mH UmmSM QflmuOMQ m MmHSHfimomMuxm Umumfimfi UmmSM QH®HOMQ0MQ®MQ ~flqu®HIHH5w Ummm®UOMQQ5 ~HHmD0 Uflom 0mm QOHmSM mQHmHMQEOU mHHmpU4 AmNuOZ QHMEOU QOHmSM mQHmHMQEOU mHHmpU4 HMQHEM®HI0 mUHUm AomuOZ QHmEOU QflmuOMQ HHmD0 Uflmaosz mqflvooqm 0mm uOZ mw 3w ww aw monmsvmm 0040BfloflflooUOUOOflOU¢0>mowmmmmfl>mm4mMmmmmww>wdflflflflflflflflflflflflmwm4 OmmmflmqHOOflmmdeqflOM>>MMmHZmflmMHMQMmQHOmMHmmqmqm mmmmmmooflmmODBO>4mDBm0¢2mH>BMBB¢E$HDHMQmDmmOQ4DO mwwwwwwflfiwmwfiqmmqmqHOflw>34mmm>mmqw>BflO¢Mfl>MBmZ>M mmmflZHmHOBZmOmommBmEQ>OMmDHmOBEOmMmEHMHMflmMHMHEm ZMQ>mqummmflUmflmeqmB>4QDBUm UU04000000UOwUUUUUUUUUUUUUUUUUUUUUUUU00000040000 UUUUBUUUBUUUO00400000UUflUUBUUUUflUUUUUUUOBUUUUUUU UflUUflUUUUUUBBBUOUBUBUUUUOUBUUUUflUUUUUflUUUO UGOUBUdfl

Claims (18)

What we claim is:

1. Use of an ActRII inhibitor in the manufacture of a ment for treating chronic kidney disease-mineral and bone disorder (CKD-MBD) in a subject, wherein said ActRII inhibitor is a polypeptide comprising an amino acid sequence selected from the group ting of: a) at least 90% identical to SEQ ID NO:2; b) at least 95% identical to SEQ ID NO:2; c) at least 98% identical to SEQ ID NO:2; d) SEQ ID NO:2; e) at least 90% identical to SEQ ID NO:3; f) at least 95% identical to SEQ ID NO:3; g) at least 98% identical to SEQ ID NO:3; h) SEQ ID NO:3; m) at least 90% identical to SEQ ID NO:7; n) at least 95% identical to SEQ ID NO:7; o) at least 98% identical to SEQ ID NO:7; p) SEQ ID NO:7; q) at least 90% identical to SEQ ID NO:12; r) at least 95% identical to SEQ ID NO:12; s) at least 98% identical to SEQ ID NO:12; t) SEQ ID NO:12; u) at least 90% identical to SEQ ID NO:17; v) at least 95% identical to SEQ ID NO:17; w) at least 98% cal to SEQ ID NO:17; x) SEQ ID NO:17; y) at least 90% identical to SEQ ID NO:20; z) at least 95% identical to SEQ ID NO:20; aa) at least 98% identical to SEQ ID NO:20; bb) SEQ ID NO:20; cc) at least 90% identical to SEQ ID NO:21; dd) at least 95% identical to SEQ ID NO:21; ee) at least 98% identical to SEQ ID NO:21; ff) SEQ ID NO:21; gg) at least 90% identical to SEQ ID NO:23; hh) at least 95% identical to SEQ ID NO:23; ii) at least 98% identical to SEQ ID NO:23; jj) SEQ ID NO:23; kk) at least 90% identical to SEQ ID NO:25; ll) at least 95% identical to SEQ ID NO:25; mm) at least 98% identical to SEQ ID NO:25; and nn) SEQ ID NO:25.

2. The use of claim 1, wherein said ActRII inhibitor is a polypeptide comprising the amino acid sequence SEQ ID NO: 7.

3. The use of claim 1, wherein said ActRII inhibitor is a polypeptide comprising the amino acid sequence SEQ ID NO: 25.

4. The method of claim 1, n the ActRII inhibitor is a polypeptide comprising: (i) a fragment of the extracellular domain of ActRIIB, wherein the fragment consists of the sequence of amino acid 25 to 131 of SEQ ID NO:28 and wherein the fragment s the L79D amino acid substitution; (ii) a linker; and (iii) an Fc of an IgG1.

5. The use of any one of claims 1 to 4, wherein the CKD-MBD is an adynamic bone disorder form of CKD-MBD.

6. The use of claim 5, wherein the adynamic bone disorder is characterized by absence of tetracycline incorporation into lized bone.

7. The use of any one of claims 1 to 4, wherein the CKD-MBD is a low bone turnover form of CKD-MBD.

8. The use of claim 7, n the low bone turnover form of CKD-MBD is osteomalacia.

9. The use of any one of claims 1 to 4, wherein the CKD-MBD is characterized by hyperphosphatemia.

10. The use of any of claims 1 to 9, wherein the treating comprises eral administration of the ActRII inhibitor.

11. The use of any of claims 1 to 9, wherein the subject is less than 18 years old.

12. The use of any of claims 1 to 9, wherein the treating increases the height of the subject.

13. The use of any of claims 1 to 9, wherein the subject has end stage renal disease.

14. The use of any of claims 1 to 9, wherein the t undergoes dialysis.

15. The use of any of claims 1 to 9, wherein the c kidney disease has reached stage 3, stage 4, stage 5, or stage 5D.

16. The use of any of claims 1 to 9, wherein the chronic kidney disease is end stage kidney disease.

17. The use of any of claims 1 to 9, wherein the subject has renal fibrosis.

18. A use according to claim 1, substantially as herein described and exemplified.